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1.1 Mycale hentscheli and the pelorusides
1.1 Mycale hentscheli and the pelorusides
1.1.1 Peloruside A
Marine sponges of the genus Mycale are known for being a rich source of bioactive secondary
metabolites of diverse structures. In this manner, Perry1,2 discovered the antiviral and
antitumor agents mycalamide A and B (in 1988 and 1990 resp.) on the southeast coast of
the South Island of New Zealand (Otago Harbour) and Northcote3 discovered the cytotoxic
macrolide pateamine (in 1991) on the southwest coast of the South Island (Thompson
Sound). In 2000, Northcote and West4 examined specimens of the same species (Mycale
hentscheli, Fig. 1.1(b)) from Pelorus Sound on the north coast of the South Island and
isolated, next to the already known mycalamide A and pateamine, a novel macrolide and
potent cytotoxin at nanomolar concentrations, peloruside A, named after the place of its
discovery (Fig. 1.1(a)).
(a) (b)
Figure 1.1. (a) New Zealand; (b) Mycale hentschelia
aReprinted with permission from Mike Page of NIWA (The National Institute of Water and Atmospheric
Research) in New Zealand
3
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1.1.2 Structure
The discovery and isolation were soon followed by structure elucidation. The molecular
formula of peloruside A was established as C27H48O11 by HR FAB-MS and the structure
was assigned by spectroscopic methods (IR and NMR). Peloruside A was found to be a
polyoxygenated 16-membered macrolactone, containing a pyranose ring, a gem-dimethyl
moiety, 10 stereogenic centers and a side-chain containing a trisubstituted double bond
with Z geometry. Spectroscopic assignment of the relative stereochemistry was possible
from a combination of NOE and vicinal couplings. Northcote4 proposes the relative stere-
ochemistry of peloruside A as shown in Scheme 1.1 (2). It was however, only until the
first total synthesis of peloruside A by De Brabander5 in 2003, that the absolute stereo-
chemistry could be proven. His synthetic peloruside A had spectroscopic properties (1H
and 13C NMR, IR, HRMS) identical to those of the natural product, but the optical ro-
tation was of opposite sign, concluding he had made (−)-ent-peloruside A. Furthermore,
this (−)-ent-peloruside A did not share the bioactivity of its enantiomer. Based on these
results, the absolute configuration of natural (+)-peloruside A can be assigned as shown
in Scheme 1.1 (1).
O
O
OH
OMe
MeO
OH
OH
OMe
O
HO
HO
(+)-peloruside A (1)
O
O
OH
OMe
MeO
OH
OH
OMe
O
HO
HO
(-)-ent-peloruside A (2)
H H
Scheme 1.1. The natural, isolated (+)-peloruside A (1) and (−)-ent-peloruside A (2), as pro-
posed by Northcote4 and synthesized by De Brabander5
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1.1.3 Peloruside B, C and D
Peloruside B
In 2010, Singh6 discovered a new natural product, named peloruside B (3) (Scheme 1.2),
which was proven to be a natural congener of peloruside A (1). It was isolated in sub-
milligram quantities from a wild Mycale hentscheli specimen, collected from the southwest
coast of the North Island of New Zealand (Kapiti Island) (Fig. 1.1(a), p. 3). The structure
was elucidated based upon extensive 1D and 2D NMR studies, and the relative and absolute
configuration confirmed by total synthesis and comparison of its bioactivity with natural
peloruside B. The structure differs from peloruside A only at C3, possessing a hydroxyl
moiety instead of a methoxy group. Its bioactivity is comparable to that of peloruside A.
Peloruside C and D
In 2011, Northcote7 led a large-scale extraction of wild and aquacultured Mycale hentscheli,
which resulted in the discovery and isolation of two new congeners of peloruside A, named
peloruside C (4) and peloruside D (5) (Scheme 1.2). Their structures were elucidated
based upon extensive 1D and 2D NMR studies, the assignment of the relative stereochem-
istry was attempted using available 1H-1H coupling constants, NOESY correlations and
comparisons with peloruside A, after which they were tentatively assigned as peloruside
A-like structures as shown in Scheme 1.2. While peloruside C was found to be cytotoxic,
albeit approximately 15 times less than peloruside A, peloruside D was found to be only
marginally active.
5
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Scheme 1.2. Peloruside A, B, C and D
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1.2 Activity
1.2.1 Cytotoxicity
Together with its discovery4, peloruside A (peloruside) was found to be highly cytotoxic at
low nanomolar concentrations (P388 murine leukemia cells; IC50 = 18 nm), but the mecha-
nism of cytotoxicity was yet unknown.
Because of structural similarities with bryostatin-1 (bryostatin, 6, Scheme 1.3), it was first
thought that both compounds had similar mechanisms of action8. Bryostatin is a potential
anti-neoplastic compound that causes transient activation of PKC, a serine-threonine ki-
nase involved in intracellular signaling pathways which control proliferation, apoptosis and
tumorigenesis. Both compounds share a pyranose ring adjacent to a gem-dimethyl group
and the anomeric center of this pyranose ring and the carbonyl group of the macrolide ester
have been proposed to be part of the bryostatin pharmacophore. Therefore, the pyranose
ring of peloruside A was chemically reduced with NaBH4 to 7 (Scheme 1.3), leading to a
significant decrease in its growth inhibitory effect. This loss of activity seemed to indicate
that the pyranose ring region was involved in the biological activity of peloruside and thus
suggested that peloruside may be involved in PKC-dependent biological activity, similar to
bryostatin. Although it was found later that peloruside does not act by a PKC-dependent
pathway, it remained however, a potent inducer of a number of biological responses, in-
cluding growth inhibition and induction of apoptosis.
In further efforts to identify the molecular target of peloruside, Hood and coworkers9 have
shown that peloruside alters microtubule dynamics in a manner similar to that reported
for paclitaxel, by inducing tubulin polymerisation in situ and in cell-free systems, causing
cells to arrest in the G2-M phase of the cell cycle, thus inducing apoptosis. Because of
this bioactivity, peloruside could be added to the small but important class of microtubule
stabilizing agents (MSAs).
7
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Scheme 1.3. Bryostatin-1 and the peloruside A reduction product
1.2.2 Microtubule stabilizing agents
There are different types of drugs used in chemotherapeutic treatments, depending on
their structure and mechanism of action. Next to the alkylating agents, the antimetabo-
lites, the topoisomerase inhibitors and the cytotoxic antibiotics, another class of antitumor
compounds are the so-called antimicrotubule agents, which are using tubulin as a target.
Mitosis and the mitotic spindle
Every cell in the human body (normal as well as tumoral) passes the cell cycle (Fig. 1.2),
in which the cell grows and prepares itself for cell division during the interphase, after
which the cell actually divides during mitosis and finally cytokinesis.
Mitosis10 (Fig. 1.3) itself also comprises several steps or phases, in which the microtubules
play a key role.
Interphase: The duplicated chromosomes (sister chromatids) are present in the nucleus
in a decondensed form (chromatin) and can not be distinguished from each other.
The centrosome, on which the microtubules are connected, also duplicates.
8
1.2 Activity
Figure 1.2. The cell cycle
Prophase: The chromosomes condense and become visible, the nuclear membrane starts
to disintegrate and the centrosomes move away from each other.
Prometaphase: The centrosomes are at opposite sides of the cell (poles) and next to
the formation of astral microtubules, also spindle microtubules arise from the centro-
somes, which connect to the chromosomes and move the chromosomes towards the
spindle equator. The nuclear membrane is almost completely gone.
Metaphase: The chromosomes are aligned at the spindle equator by the spindle micro-
tubules, from which their minus ends connect to the centrosomes and their plus ends
to the chromosomes.
Anaphase A: The spindle microtubules start to move towards the poles, pulling the sister
chromatids apart.
Anaphase B: The poles separate further.
Telophase: The spindle microtubules disappear, the nuclear membrane starts to reappear
and the chromosomes decondense again. Cell division/cytokinesis can begin.
Cytokinesis: The cell divides with formation of two daughter cells, each containing their
9
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own centrosome and nucleus with the right amount of chromosomes. The daughter
cells are now back in the interphase and the cell cycle can start again.
Figure 1.3. Mitosisb
Dynamic instability
Microtubules are polymers, which are made up from tubulin heterodimers, which consist in
their way of α- and β-tubulin (Fig. 1.4). Through polymerization and depolymerization,
these tubulin heterodimers can add to or detach from the microtubules, making them grow
and shrink. Both reactions can occur in a state of dynamic instability. This can happen at
both ends, but the plus ends are the most dynamic and are therefore responsible for most
of the action during mitosis.
bReprinted from10, Copyright (2010), with permission from Macmillan Publishers Ltd.
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Figure 1.4. Dynamic instabilityb
Tubulin as a chemotherapeutic target
The strategy of using tubulin as a target for cancer chemotherapy is based on the uncon-
trolled and continuous growth and division of cancer cells and the fact that drugs that
interfere with mitosis have proven effective in the treatment of cancer. There are two ways
in which drugs can interfere with mitosis, either by stabilizing or destabilizing microtubules.
In either way, disruption of the mitotic spindle leads to mitotic arrest and ultimately to
apoptosis or cell death.
The microtubule destabilizing agents (MDAs) are the minor class and the best known ex-
amples are colchicine and the Vinca alkaloids. They interfere with mitosis by shifting the
equilibrium to the depolymerized form of tubulin.
The major class consists of the microtubule stabilizing agents (MSAs) and their
best known representative is one of the most used chemotherapeutic drugs, paclitaxel
(TaxolR©, 8, Scheme 1.4).
Paclitaxel was isolated from the stem bark of the western yew tree, Taxus brevifolia, and
its structure was elucidated by Wani11 in 1971. In 1979, Schiff12 reported its unprece-
dented mechanism of action. Paclitaxel was able to promote tubulin polymerization to
microtubules hence preventing depolymerization, effectively leading to mitotic inhibition
and cell death. The revelation of this unique mechanism of action stimulated a quest
11
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to find new MSAs as potential antitumor drugs. Nowadays, paclitaxel (TaxolR©) and its
semisynthetic analogue docetaxel (TaxotereR©) are, among others, used for the treatment
of breast, ovarian, lung, neck and head cancer and Kaposi’s sarcoma.
12
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Next to the taxane compounds (including paclitaxel and docetaxel), there are other com-
pound families within the group of MSAs that exhibit interesting properties (Scheme 1.4):
• discodermolide (9) and its analogues
• epothilone B (10) and other epothilones
• laulimalide (11) and its analogues
• peloruside A (1) and B (3) and other pelorusides
Although these compounds share a very similar mechanism of action, they do not all share
the same binding site.
paclitaxel (8)
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H
O
O
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OH O
OH
OH
HO
O
HO O
NH2O
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O
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O
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H
H
Scheme 1.4. Microtubule stabilizing agents
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1.3 Binding site
Although most of the MSAs (paclitaxel, docetaxel, the epothilones, discodermolide) share
the same binding site on β-tubulin (the tax site), it was soon clear that there were two
exceptions to this general rule. Laulimalide13 was unable to inhibit the binding of ei-
ther [3H]-paclitaxel or Flutax-2 (a fluorescent paclitaxel derivative) to polymeric tubulin.
Moreover, when polymeric tubulin was formed in the presence of both laulimalide and pa-
clitaxel, it contained nearly molar equivalents of both drugs relative to the tubulin content.
This suggested that laulimalide binds to tubulin at a different binding site. This proposal
was further confirmed by findings that laulimalide was active against cell lines resistant to
paclitaxel or epothilones A and B on the basis of mutations in the M40 human β-tubulin
gene. Peloruside14 showed similar behavior as laulimalide in the Flutax-2 displacement
test, the binding of peloruside to stabilized microtubules and it retained its cytotoxicity in
β-tubulin mutant cell lines. Moreover, peloruside and laulimalide showed to compete for
each other upon tubulin binding. This was enough proof to conclude that peloruside and
laulimalide share the same or an overlapping binding site on tubulin, distinct from the tax
site.
Pineda15 was the first to propose a peloruside/laulimalide binding site, based on docking
and QSAR-approaches. He showed the virtual capability of peloruside and laulimalide to
bind to the tax site, but also proposed an alternative binding site on α-tubulin, under
the B9-B10 loop, in a location equivalent to the luminal site of paclitaxel on β-tubulin
(Fig. 1.5(a)).
Jime´nez-Barbero16 predicted the bioactive conformation of peloruside bound to micro-
tubules by using NMR experiments and docked this conformation on tubulin, proposing
a model of the binding mode to a binding site on α-tubulin, close to that proposed by
Pineda15 (Fig. 1.5(b)).
As an alternative to electron crystallographic data, Huzil17 used data from hydrogen-
deuterium exchange mass spectrometry (HDX-MS) in a data-driven ligand-docking strat-
egy to propose a new binding site for peloruside on β-tubulin, distinct from the tax site.
14
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tax site colchi site B9-B10 site
(a) (b)
Figure 1.5. (a) The proposed peloruside/laulimalide binding site on α-tubulin, under the B9-
B10 loop (B9-B10 site), in relation to the tax site and the colchi sitec; (b) Tubulin
dimer with taxol (red) bound to β-tubulin (green) and peloruside (orange) bound
to the proposed binding site on α-tubulin (blue)d
This mass shift perturbation technique not only suggested a high-resolution model of the
peloruside binding site, it also proposed a unique mode of microtubule stabilization which
rationalizes this binding site on β-tubulin, and also why the proposed binding sites and
interactions suggested by Pineda15 and Jime´nez-Barbero16 are unlikely.
Using a similar mass perturbation shift method as Huzil17, Bennet18 was able to present
a high-resolution binding mode of laulimalide to tubulin. This proposed binding pocket
can both bind peloruside and laulimalide, as it should be, as peloruside and laulimalide
are expected to share the same or an overlapping binding site.
In order to determine the binding properties of peloruside, derivatives bearing fluorescent,
reactive or radioactive groups would be of great value. This is why Pera19 prepared 24-
O-(chloro)acetyl peloruside as a starting point for his investigations. These derivatives
however, were unable to bind to microtubules or induce microtubule assembly in vitro,
leading to the conclusion that the C24 primary alcohol must be essential for biological
activity. With this in mind, they performed docking simulations with these derivatives
on the two proposed binding sites15–17. Docking them onto the binding site on α-tubulin
cReprinted from15, Copyright (2004), with permission from Elsevier
dReprinted from16, Copyright (2006), with permission from American Chemical Society.
15
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explained the loss of binding ability through the loss of the hydrogen bond and the steric
effect of the acetyl and chloroacetyl group. Docking them onto the binding site on β-tubulin
however, predicted that they should retain their activity. Pera19 also studied the binding
of peloruside to microtubules by using saturation-transfer difference NMR (STD-NMR),
which allowed him to identify two regions of peloruside that appeared to be part of the
tubulin-binding epitope and key protons, which are expected to be involved in direct inter-
action with the binding site. This data favored the α-tubulin binding site because all the
protons with high or medium saturation values are pointing inside the proposed binding
site or are in close contact with the protein, which was not the case for the β-tubulin bind-
ing site. Because of these inconsistent results, pointing to both possible binding sites, it
was speculated that peloruside binding involves a two-step binding mechanism equivalent
to that proposed for the taxanes20,21. This mechanism would involve an initial binding
event, which could be on the β-tubulin binding site, with subsequent transportation of the
ligand to the α-tubulin binding site.
Nguyen22 studied with molecular modeling how peloruside and laulimalide interact with
their shared binding pocket, as proposed by Huzil17 and Bennett18. He found their pro-
posed orientation of peloruside in the binding site not ideal, as that model showed no
hydrogen bonds between peloruside and β-tubulin and oriented key hydrophobic groups
of the ligand toward the solvent. By reorienting peloruside in the binding site, they were
able to introduce hydrogen bonds between ligand and protein and to pack large hydropho-
bic motifs into hydrophobic pockets. Furthermore, this new model is now consistent with
the tubulin-binding epitope of peloruside as proposed by Pera19 (using STD-NMR). This
model is also able to rationalize all of the SAR-data known at that time, including the 24-
O-(chloro)acetyl peloruside derivatives used by Pera19 which favored the α-tubulin binding
site. Furthermore, this model provides a structural basis for the superior activity of lauli-
malide relative to peloruside (Fig. 1.6).
In 2011, similar mutation studies were conducted by Begaye23 and Kanakkanthara24, where
they developed peloruside- and laulimalide-resistant cell lines. These cell lines showed cross-
resistance between peloruside and laulimalide but none of them showed any resistance to
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paclitaxel
peloruside
(a)
parent Ki, 0.25 µM), implying that both compounds bind to
the same site.
Molecular Modeling. We modeled laulimalide and peloru-
side A into the -tubulin region identified by Huzil et al.16
by hydrogen-deuterium exchange mass spectrometry as a
likely binding site for peloruside A. However, the orientation
of peloruside A in the binding site proposed by these workers
is not ideal. The earlier model showed no hydrogen bonds
between peloruside A and -tubulin and oriented key
hydrophobic groups of the ligand toward the solvent. By
reorienting peloruside A in the binding site, we were able
both to introduce hydrogen bonds between ligand and protein
and to pack large hydrophobic motifs, such as the bulky,
aliphatic side chain at C-15, into hydrophobic pockets. Our
binding mode is therefore more consistent with observations
that the hydrophobic effects drives ligand binding.30
Figure 6 provides an overview of peloruside A bound to
-tubulin and shows the relative positions of the laulimalide/
peloruside A site, the taxoid site (with bound paclitaxel),
and the exchangeable nucleotide site with bound GDP. The
paclitaxel and GDP conformations and the locations are
identical to those in the 1JFF structure.20 Figures 7 and 8
provide detailed binding poses on -tubulin of peloruside A
and laulimalide, respectively. Figure 9 presents a series of
laulimalide analogues whose reduced activity was consistent
with the Figure 8 model. Finally, Figure 10 presents a
superimposition of laulimalide and peloruside A, from their
orientations in the binding pocket. This provides insights into
a possible pharmacophore and an additional framework for
interpreting future structure-activity findings with these two
compounds.
As shown in Figure 7, peloruside A forms two hydrogen
bonds to -tubulin. The C-2 hydroxyl is hydrogen bonded
to the Val335 backbone carbonyl oxygen atom. While not
depicted in the static binding model of Figure 7, the natural
solution dynamics of -tubulin should also permit the C-2
hydroxyl to interact with the backbone carbonyl oxygen atom
of Asn339 to form intermittently an alternate hydrogen-
bonding interaction (in the Figure 7 model, the oxygen-
oxygen distance between the C-2 hydroxyl and the Asn339
carbonyl is 3.2 Å). The second hydrogen bond between
peloruside A and -tubulin shown in Figure 7 is between
the C-24 hydroxyl (O-11) of peloruside A and the Tyr312
backbone NH moiety.
Additionally, there is an intramolecular hydrogen bond
within peloruside A formed between the hydroxyl groups at
C-9 and C-11. In our proposed model, this bond helps to
Figure 5. Both (11-R)-peloruside A (A) and laulimalide (B) are
competitive inhibitors of the binding of [3H]peloruside A to
microtubules as determined by Hanes analysis. Reaction mixtures
were prepared and analyzed as described in the text. Samples
contained the indicated concentrations of [3H]peloruside A. (A)
Concentrations of (11-R)-peloruside A were as follows: circles,
none; upright triangles, 5.0 µM; inverted triangles, 10 µM; and
squares, 20 µM. (B) Concentrations of laulimalide were as follows:
circles, none; upright triangles, 0.5 µM; inverted triangles, 1.0 µM;
squares, 1.5 µM; and diamonds, 2.0 µM.
Figure 6. Overview of the peloruside A binding site on -tubulin,
showing its position relative to the taxoid site and the exchangeable
nucleotide site (E-site). The tubulin subunits are rendered as
contoured surfaces, with R-tubulin colored yellow and -tubulin
colored transparent purple. Peloruside A, GDP, and paclitaxel are
drawn in CPK and colored cyan, green, and red, respectively.
Figure 7. Detailed pose of peloruside A bound to -tubulin,
highlighting the binding interactions. Peloruside A and the specific
amino acid residues with which it interacts (see text) are shown as
stick diagrams, with polar hydrogen atoms colored white and
oxygen and nitrogen atoms colored red and blue, respectively. The
carbon atoms of peloruside A and the amino acid residues are
colored cyan and green, respectively. Hydrogen bonds are repre-
sented by dashed black lines. To illustrate the contours of the
binding pocket, -tubulin is rendered as a transparent purple surface.
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(b)
Figure 1.6. (a) The proposed peloruside/laulimalide bindin site (pelo usi e) on β-tubulin
(pink), close to the intradimer interface with α-tubulin (yellow), in relation to the
tax site (pacli axel)e; ( ) Detailed pose of peloruside bound to β-tubulin, highlight-
ing the binding interactionse
paclitaxel or other MSAs that bind to the tax site, or to any MDAs tested. Moreover, all of
the mutations were found β-tubulin, in the bin ing sit propos d by Huzil17. Further-
more, the mutations all cluster in a cleft in the bin g site that appea s to accommodate
the drug side chain, and thereby highlights the importance of side chain binding to drug
action. These studies can be seen as the first cell-based evidence to support a β-tubulin
binding site for peloruside and laulimalide.
To summarize on the peloruside binding site: peloruside and laulimalide share the same
(or an overlapping) binding site on tubulin, which is distinct from the binding site of
paclitaxel (tax site). Although early computational docking results15,16 and STD-NMR
analysis19 favored a binding site on α-tubulin, there is a growing consensus for a binding
site on β-tubulin, based on HDX-MS/mass shift perturbation data-directed docking17,18,
modeling22 and mutation studies23,24. This does not mean however, that a secondary
eReprinted from22, Copyright (2010), with permission from American Chemical Society.
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binding site (on α-tubulin or the tax site) can be completely excluded as part of the actual
mechanism of action.
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1.4 Peloruside as a chemotherapeutic drug
1.4.1 Synergy and combination therapy
The use of combinaton therapy in cancer treatment is an approach with great potential for
improving the efficacy of anticancer drugs. Combining two drugs that act synergistically
would allow treatment with lower doses of each drug, yet deliver greater effects of the drugs
at these reduced concentrations.
One of the earliest proposals that peloruside and laulimalide interact with the same binding
site, distinct from the tax site14, was soon confirmed by Hamel25 by his findings on the
apparent synergy. He found no evidence for any synergistic effects on tubulin assembly
when either peloruside and laulimalide were combined, or with multiple combinations of
tax site drugs. He was in contrast able to show that peloruside and laulimalide synergisti-
cally enhanced tubulin assembly when combined with any of the examined tax site drugs,
suggesting two distinct binding sites.
Although different binding sites seem to adequately explain the synergistic interactions
in the polymerization of purified tubilin, interactions in cultured cells appear to be more
complex. Similar synergy in cultured cancer cell lines was indeed found for combinations
of peloruside/laulimalide and tax site drugs26–28, but there has also been found evidence
for synergy in certain tax site drugs combinations29,30 and also a lack of synergy in certain
combinations where synergy was expected based on tubulin assembly13,27. This indicates
that different binding sites are not sufficient for MSAs to synergize. There is also evidence
that the tax site drugs have distinctly different effects on tubulin polymerization and may
interact with different β-tubulin isoforms31. Also other factors presumably play a role in
synergy, including differences in drug effects on microtubule-associated proteins or poten-
tial unique secondary target profiles or downstream effects of the drugs32. Even drug eﬄux
pump activity has been linked to synergistic effects30. Thus, each MSA could have its own
synergy profile with other drugs and in different cell lines, which could determine whether
synergistic interactions can occur or not.
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1.4.2 Multidrug Resistance (MDR)
Paclitaxel is currently one of the most used drugs in the treatment of breast, ovary and
lung cancer. But because of its lipophilic nature, paclitaxel has two major disadvantages as
an anticancer drug. First, it must be delivered in a vehicle, a castor oil-based formulation
(e.g. Cremophor), that causes major undesirable side effects33. Second, it is very sensitive
to multidrug resistance (MDR). Multidrug resistance for MSAs can occur in two ways.
Either by activation of the P-gp eﬄux pump34, which literally pumps the drug out off the
cell, or by mutations in the tubulin gene which affect the binding site35.
Most of the MSAs have been examined for their susceptibility to MDR, and the quest to
find drugs that are effective in paclitaxel-resistant cancer cells looks very promising. It
was found that peloruside14, but also epothilone36, discodermolide37 and laulimalide13, are
not as good a substrate for the P-gp eﬄux pump as paclitaxel. Thus, peloruside remains
cytotoxic at low concentrations in P-gp overexpressing cells that are resistant to paclitaxel.
This is an important property in the development of peloruside as an anticancer drug,
as tumor cells that become resistant to paclitaxel because of the P-gp eﬄux pump over
prolonged treatment periods, would still be sensitive to peloruside.
Tumor cells can also become resistant to tax site drugs as a result of mutations in the
β-tubulin gene that alter the tax site. In this regard, peloruside and laulimalide have an
advantage over tax site MSAs such as paclitaxel, epothilone and discodermolide, because
peloruside and laulimalide share a different binding site. Indeed, it was shown that cancer
cells with mutations affecting the toxicity of paclitaxel and epothilone, were not resistant
to peloruside14 or laulimalide13. This again indicates the possible advantage of peloruside
over paclitaxel-resistant cancer cells.
The mutation studies by Begaye23 and Kanakkanthara24, which previously provided cell-
based evidence to support a β-tubulin binding site, also showed that resistance to peloruside
may arise from altered drug-tubulin interactions. These were affected not only by mutations
in the β-tubulin gene, but also by increased expression of certain β-tubulin isoforms and
posttranslational modifications.
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1.4.3 Specificity
At least eight β-tubulin isoforms are found in varying levels of expression throughout
healthy cells in the human body and the expression of each isoform may change when
tissue turns cancerous38. While this changed expression can lead to drug resistance39, it is
also possible to exploit this property to more effectively eliminate cancer cells while sparing
the normal tissue. If the isoform distribution of the cancerous tissue is known, along with
the effectiveness of many drugs against those isoforms, then the optimum drug for each
patient could be determined. In this manner, Gajewski40 calculated the binding energies
of a whole array of known and de novo peloruside and laulimalide derivatives against the
known β-tubulin binding site17,18 and he found several peloruside derivatives that could be
promising new drugs for several types of cancer.
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1.5 Peloruside and analogues
Natural products, like peloruside and paclitaxel, are the most reliable source for new and
effective anticancer drugs: 63 % of all anticancer drugs of the last 25 years are either natu-
ral products or derivatives of natural products41. The most important class of anticancer
drugs are the antimicrotubule agents, which between 2005 and 2007, accounted for 25 % of
the new clinical candidates42.
The important clinical activity of the taxanes (paclitaxel, docetaxel), coupled with the de-
sire for improved drugs, stimulated the search for new MSAs with therapeutic advantages
like improved ADMET (absorption/administration, distribution, metabolism, excretion
and toxicity), selectivity and activity against resistant tumors. As shown in section 1.4
(p. 19), peloruside (and analogues) have a high potential for the use as an anticancer drug
in combination therapy, against tax site drugs resistant cancer cells and as a β-tubulin
isoform oriented specific drug.
Unfortunately, there is little knowledge on the pharmacophore of peloruside and the
structure-activity relationship (SAR). To undertake a SAR study, a broad variety of ana-
logues is needed. The design, synthesis and pharmacological evaluation of these analogues
then gives the possibility to assign structural elements to possible biological activity and
also shows which elements are necessary or have to be avoided with the design of new ana-
logues. Eventually, this could lead to the development of structurally simplified compounds
which could allow for shorter syntheses.
Exploring the SAR
Before making efforts in elucidating the SAR of peloruside, a look at the literature is
necessary to gain knowledge on the already available information. Since its discovery4
and the determination of the absolute stereochemistry by synthesis of (−)-ent-peloruside
A5, five total syntheses of (+)-peloruside A have been reported43–47. Next to this, also
some analogues have been reported6,7,9,19,48–53. Looking at the structure of peloruside
(Scheme 1.5), four different regions of interest can be discerned, where making changes
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could yield some interesting SAR information: the northern hemisphere (red), the pyranose
ring (green), the southern hemisphere (purple) and the side-chain (blue). A number of
analogues with different changes to one or more of these regions are already known and
provide some SAR information.
13
12
11
9
8
7
5
2
O 3
O
OH
OMe
MeO
OH
OH
OMe
O
HO
18
24
HO H
2
OMe
OH
9
8
7
OH
OMe
HO OH
3
OH
OH
7
OH
5
9
8
7
OH
OH
OH
O
H
13
12
11
9
8
7
O
H
H
13 9
8 7
2
3
HO
OH O
H
H
18
HO
24
O
OR
1
12 3
4
71314, 7R
15, 7S16
17, Z 
18, E
21
19, R = H 
20, R = Cl
O
O
HO
Scheme 1.5. Peloruside and the four regions of interest: the northern hemisphere (red), the
pyranose ring (green), the southern hemisphere (purple) and the side-chain (blue);
also shown, the different analogues known to date
In 2008, Smith48 made an effort for the total synthesis of peloruside, but because of an
unexpected epimerization, he made the (−)-2-epi -peloruside (12) instead. Unfortunately,
nothing is reported on the bioactivity of this epimer.
In 2010, Singh6 reported the isolation, structure, total synthesis and bioactivity of peloru-
side B (3), which only differs from peloruside A at C3, possessing a hydroxyl moiety instead
of a methoxy group. Its bioactivity is also comparable to peloruside A, being only slightly
less active, meaning the methyl is not crucial, but the oxygen probably is (suggesting a
possible hydrogen bond acceptor).
In 2011, Singh7 further explored the SAR by investigating the bioactivity of some newly
found peloruside congeners (peloruside C and D) and some semi-synthetic analogues. The
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most interesting compound was peloruside C (4), which showed a 15-fold decrease in cyto-
toxicity (compared to peloruside A) and for which they suggest four possible contributors:
the direct loss of key target interactions mediated by the C8 and C9 hydroxyl groups and
the methyl from the methoxy at C7; the conformational changes or solvation effects arising
from the loss of intramolecular hydrogen bonds, for example between the hydroxyl groups
of C9 and C11 in 1; the loss of the hemiacetal of 1, which has the potential to open and
subsequently interact covalently with the target; and the acquisition of a new target whose
inhibition is less detrimental to cellular survival.
One of the first synthetic analogues reported was the reduction product (7) by Hood9 in
2002, which was obtained by the reduction of peloruside with NaBH4. This compound,
where the pyranose ring is irreversibly opened, showed a 26-fold decrease in cytotoxicity.
This loss of activity presumably results from the markedly changed relative positioning of
key tubulin-interacting functionalities across the peloruside derived macrocycle, as a result
of the loss of the pyranose ring. It however retained significant antiproliferative activity,
which suggests that even major structural changes in the macrolactone scaffold of 1 do not
completely abolish the ability to interact with microtubules and to inhibit the growth of
human cancer cells.
In light of these findings, Wullschleger49,51 investigated the importance of the pyranose
ring in the bicyclic core structure. He synthesized two monocyclic analogues (14, 15),
completely lacking the pyranose ring, but retaining the C7 hydroxyl (C9 in 1), and also
a bicyclic tetrahydropyran analogue (13), which lacks the C7, C8, C9 oxygen substituents.
While the monocyclic analogues (14, 15) showed to be respectively several 100-fold and
several 1000-fold less active than peloruside A, the bicyclic tetrahydropyran analogue (13)
showed only to be 10-fold less active, which makes it comparable to peloruside C (4). These
findings clearly suggest a defining character of the bicyclic core structure of peloruside A
for potent cellular activity. At the same time however, it is clear that the bicyclic system
by itself is not sufficient for peloruside A-like antiproliferative activity. The relative impor-
tance of the individual oxygen substituents on the pyranose ring remains to be established;
given the activity of 13, however, it is well conceivable that not all of these groups are
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required for full activity.
In 2013, Zimmerman52 made a very restricted analogue (16), containing the tetrahydropy-
ran ring of Wullschleger’s bicyclic analogue (13), lacking the C2, C3 oxygen substituents,
possessing a hydroxyl moiety instead of a methoxy group at C13 and having a disubstituted
double bond in the side-chain. Unsurprisingly, these multiple modifications led to a signifi-
cant decrease in activity, comparable to the monocyclic analogues (14,15) of Wullschleger.
In 2012, Zhao50 envisioned the simplification of the peloruside skeleton by replacement of
two stereogenic centers, C11 and C13, with a set of olefinic isomers, Z -17 and E -18. Un-
fortunately, the instability of these analogues precluded their biological evaluation. This
instability was ascribed to the lack of a potential stabilizing intramolecular hydrogen bond
array through C9-lactol, C11-hydroxyl and C13-methoxy.
In 2010, Pera19 synthesized two side-chain analogues in the context of a modeling study
to find the binding site. They found that their 24-O-acetyl (19) and 24-O-chloroacetyl
(20) analogues lost their microtubule-stabilizing activity completely. This was assigned to
the loss of the presumed hydrogen bond between the C24 hydroxyl and tubulin and the
increase of steric hindrance because of the (chloro)acetyl group.
In 2013, also Trost53 conducted a total synthesis of peloruside, but because of the mis-
assignment of the absolute stereochemistry of one of their building blocks, he made the
(−)-18-epi -peloruside (21) instead. Unfortunately, nothing is reported on the bioactivity
of this epimer.
To conclude on the analogues: although some peloruside analogues have already been iso-
lated and prepared, the useful SAR information is still limited. It seems that not all oxygen
substituents are necessary for activity, but some (like the C24 hydroxyl) are. Furthermore,
making changes that influence the macrocyclic conformation could have huge consequences
as this can disturb multiple interactions at once. Therefore, the careful design and synthe-
sis of new analogues is necessary to further explore the structure-activity relationship of
this promising compound.
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2.1 Strategy
Before starting this PhD thesis, the only analogues known were the (−)-2-epi -peloruside
(12) and the reduction product (7) (Scheme 1.5, p. 23), providing only a minimal amount
of useful SAR information. Therefore, a strategy was envisioned to explore the SAR by
focusing on only one region, which is the side-chain, and leaving the rest of the macrocycle
unchanged. Furthermore, to completely explore the SAR of the side-chain, it was envi-
sioned to make not just one side-chain analogue, but a whole array of side-chain analogues,
introducing multiple variations of the sterical and electronic properties of the natural side-
chain. Because making these analogues would require a long and laborious synthesis, the
design of a strategic precursor was necessary, which allowed to differentiate to these ana-
logues as late in the synthesis as possible, in order to be as efficient as possible by avoiding
the repetition of the same synthetic steps after the side-chain modifications.
Therefore, the design and synthesis of a vinyl iodide precursor (Scheme 2.1, 22) was pro-
posed. This precursor still contains all the complexity (the stereocenters and functional
groups) which is present in the macrocycle of the original peloruside. Therefore, if ana-
logues are obtained and screened for activity, the activity should only be affected by the
changes that are introduced in the side-chain, leading to unambiguous SAR information.
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Scheme 2.1. Peloruside A (1) and the proposed vinyl iodide precursor (22)
Furthermore, the vinyl iodide moiety is a very powerful and versatile group, which allows
the introduction of the different variations in the side-chain. This will be done by two
possible strategies, leading to two different sets of analogues.
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Stille coupling strategy
R1 X + R2 Sn(alkyl)3 R1 R2 + XSn(alkyl)3
LnPd0
R1, R2 = alkenyl, aryl ; X = I, Br, Cl, OTf ; alkyl = Me, Bu
The Stille coupling54 is known as a versatile palladium-catalyzed C−C bond forming
reaction and has been used numerously in the field of organic synthesis. It consists of
the coupling of an organotin compound (a stannane) with a suited electrophile, which is
typically a halide (I, Br, Cl) or pseudohalide (OTf).
While there are few limitations for the R-groups, the most mild and reliable coupling
reactions are between R-groups where the α-carbon is sp2 hybridized. In our case, the
electrophile will be our vinyl iodide precursor (22) and the stannanes which will introduce
the modified side-chains are all proposed to have alkenyl or (hetero)aryl groups. These
stannanes are either commercially available, or can be synthesized according to or based
on known literature procedures.
One of the key benefits of conducting the Stille coupling with stannanes is the tolerance
towards most functional groups. This should allow us to couple the different side-chains
after the final deprotection, thus in the very last step of the synthesis, being as late as
possible, and leading to a first set of side-chain analogues (Scheme 2.2).
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This strategy was based on the work of Nicolaou on the synthesis of epothilone ana-
logues55–61. Starting from vinyl iodide compounds with similar complexity as our vinyl
iodide precursor (22), he successfully made multiple analog libraries.
Suzuki coupling strategy
R1 X + R2 B(OH)2 R1 R2
LnPd0
R1, R2 = alkenyl, aryl ; X = halogen or triflate
base
The Suzuki coupling is similar to the Stille coupling, in being a versatile palladium-
catalyzed C−C bond forming reaction, but using organoboronic acids and halides instead.
Another difference is that the organoboronic acid must be activated, for example with a
base.
What made the Suzuki coupling of our interest, is the practical application of the
C(sp2)−C(sp3) coupling, which is not that common with the Stille coupling.
More in particular, we were very interested in the work of Burke and his MIDA (N -methyl-
iminodiacetic acid) boronates. While he originally developed these boronates for the use in
a very powerful Iterative Cross-Coupling (ICC) strategy for small-molecule synthesis62–65,
his work also led to the development of chiral PIDA (pinene-derived iminodiacetic acid)
boronates66.
This chiral PIDA boronate chemistry could be used for the synthesis and coupling of the
original peloruside side-chain to the vinyl iodide precursor (22)63,66,67 (Scheme 2.3).
In this case a mono-deprotected precursor (23) is obtained, which is a fully protected
peloruside analogue, except for the unprotected primary alcohol of the side-chain, which
could in turn lead to a new set of side-chain analogues, next to peloruside A.
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2.2 Retrosynthetic approach
2.2.1 Disconnections and building blocks
Both strategies for synthesizing the side-chain analogues first require the synthesis of the
same vinyl iodide precursor 22 (Scheme 2.4).
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Scheme 2.4. Retrosynthetic approach: disconnections and building blocks
The first logical retrosynthetic step is the opening of the macrolactone, resulting in the
acyclic C1−C17 seco-acid 24. For further disconnections, a highly convergent asymmet-
ric aldol coupling strategy was envisioned. Led by the potentially very helpful 1,5-anti
relationship between the oxygen substituted C11−C15 and C3−C7, the first retro-aldol dis-
connection can be made between C11 and C12, leading to Building Block C (the C12−C17
fragment) and Building Block D (the C1−C11 fragment). Building Block D can be further
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disconnected between C6 and C7, affording Building Block A (the C1−C6 fragment) and
Building Block B (the C7−C11 fragment). Building Block A, B and C can be synthe-
sized resp. from the commercially available L-ascorbic acid, neopentylglycol and propargyl
alcohol.
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2.2.2 Protecting groups
As the required seco-acid 24 is a poly-oxygenated acyclic compound, a carefully planned
protecting group strategy is necessary (Scheme 2.5), containing two types of protecting
groups: acetal type protecting groups (Pa), which can remain in position until the final
deprotection, and other protecting groups, which can be selectively deprotected during
the synthesis, releasing the corresponding alcohol for further transformation to the desired
functional group.
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The C1 carboxylic acid group can be generated from a terminal acetonide. The latter will
act as a latent carboxylic acid group: the acetonide can be deprotected under mild acid
conditions, yielding a vicinal diol, which can be oxidatively transformed to the carboxylic
acid, prior to macrolactonization.
The C9 hydroxyl group is protected as a SEM ether. This is a robust protecting group which
can be selectively deprotected with fluoride reagents (e.g. TBAF), yielding an alcohol,
which can be oxidized to the required ketone.
At C11 a benzyl ether will be used. This can be selectively removed by hydrogenolysis,
yielding a primary alcohol, which can be oxidized to the aldehyde, prior to aldol coupling.
The C15 hydroxyl group can be protected as a PMB ether. This can be selectively removed
by single electron oxidants (e.g. DDQ or CAN), yielding the seco-acid alcohol (24), prior
to macrolactonization.
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2.3 Total syntheses of peloruside
The synthetic route to vinyl iodide precursor 22 retains all the complexity that can be
found in other total syntheses of peloruside, including the five total syntheses of the natural
peloruside43–47, the (−)-ent-peloruside (2) of De Brabander5 and the (−)-2-epi -peloruside
(12) of Smith48.
To be able to compare our synthesis to what is already known in literature, a brief overview
of these total syntheses is given, including their main disconnections, longest linear sequence
and overall yield.
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Synthesis of (−)-ent-peloruside by De Brabander et al.5
The key steps to build the backbone include two aldol couplings, macrolactonization pro-
ceeded under Mitsunobu conditions with a remarkable retention of configuration.
(−)-ent-peloruside was obtained in 31 linear steps, with an overall yield of 1.8 % (88 % per
step).
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Scheme 2.6. Synthesis of (−)-ent-peloruside by De Brabander et al.5
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Synthesis of peloruside by Taylor et al.43
The key step to build the backbone is the late stage aldol coupling of two advanced building
blocks, macrolactonization proceeded under Yamaguchi conditions.
Peloruside was obtained in 30 linear steps, with an overall yield of 0.24 % (81 % per step).
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Scheme 2.7. Synthesis of peloruside by Taylor et al.43
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Synthesis of peloruside by Ghosh et al.44
The key step to build the backbone is the aldol coupling of two advanced building blocks,
macrolactonization proceeded under Yamaguchi conditions.
Peloruside was obtained in 29 linear steps, with an overall yield of 0.96 % (85 % per step).
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Scheme 2.8. Synthesis of peloruside by Ghosh et al.44
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Synthesis of (−)-2-epi-peloruside by Smith et al.48
The key step to build the backbone is the coupling of a dithiane building block with an
aldehyde, the former being constructed from an aldol coupling, the latter being formed
by making use of multi-component type I anion relay chemistry. Unfortunately, macrolac-
tonization under Yamaguchi conditions led to epimerization at C2.
(−)-2-epi -peloruside was obtained in 27 linear steps, with an overall yield of 1.6 % (85 %
per step).
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Scheme 2.9. Synthesis of (−)-2-epi -peloruside by Smith et al.48
41
2. Aim and strategy
Synthesis of peloruside by Evans et al.45
The key steps to build the backbone include two aldol couplings, macrolactonization pro-
ceeded under Yamaguchi conditions.
Peloruside was obtained in only 22 linear steps, with an overall yield of 5.7 % (87 % per
step).
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Scheme 2.10. Synthesis of peloruside by Evans et al.45
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Synthesis of peloruside by Jacobsen et al.46
The key steps to build the backbone include an aldol coupling and a hetero-Diels-Alder
cycloaddition, macrolactonization proceeded under Yamaguchi conditions.
Peloruside was obtained in only 20 linear steps, with an overall yield of 0.51 % (76 % per
step).
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Scheme 2.11. Synthesis of peloruside by Jacobsen et al.46
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Synthesis of peloruside by Hoye et al.47
The key step to build the backbone is the late stage aldol coupling of two advanced building
blocks, macrolactonization proceeded under Yamaguchi conditions.
Peloruside was obtained in 36 linear steps, with an overall yield of 0.3 % (85 % per step).
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Scheme 2.12. Synthesis of peloruside by Hoye et al.47
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2.4 Preliminary Results
Although the synthesis of the desired vinyl iodide precursor 22 will be carried out from the
proposed starting materials, a great amount of pioneering research on the synthesis of the
required building blocks has already been done during the PhD thesis of Gert Smans68.
Some of these results will form the basis of this new synthesis, and therefore it is needed to
outline these results to better understand the strategic decisions made in this new synthesis
along with its possible shortcomings. In the Results and Discussion chapter, references to
these preliminary results will be made where needed.
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Scheme 2.13. Synthesis of Building Block A (A - 31) by Smans68
The synthesis of Building Block A as provided by Smans68 is already quite solid so no
major changes will be proposed for the synthesis as a whole. As A - 31 will be needed on a
large scale (preferably tens of grams), efforts will be made to improve the individual yield
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of each step and to increase the practical upscalability. In particular the synthesis of 29
(low yield) and 30 (low d.r.) will receive extra attention.
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Scheme 2.14. Synthesis of Building Block B (B - 39) by Smans68
The synthesis of Building Block B as elaborated by Smans68 already delivers the desired
compound, albeit with a long procedure (8 steps) and introducing the expensive SEM
protecting group in the very first step.
A new, shorter and practically easy synthetic route will be investigated as also Building
Block B will be needed in the same magnitude as Building Block A.
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Scheme 2.15. Synthesis of Building Block C (C - 43) by Smans68
The synthesis of Building Block C as conducted by Smans68 contains some practical hur-
dles, as the only 4 steps are often hard to reproduce. Special attention will be given to the
asymmetric step (from 40 to 42) in order to avoid a very cumbersome and low yielding
recrystallization.
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Scheme 2.16. Synthesis of Building Block D (D - 50) by Smans68
The synthesis of Building Block D as executed by Smans68 does not leave a lot to de-
sire. The main concern to address will be upscalability and troublesome chromatographic
purifications.
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Although the synthesis routes shown above allow for the synthesis of the required building
blocks, each route has its shortcomings and/or practical limitations, as will be highlighted
in the Results and Discussion chapter. As the last part of the synthesis, which is the
coupling of Building Block C and D and the further elaboration towards seco-acid 24 and
vinyl iodide precursor 22 (Scheme 2.4, p. 33), poses some significant challenges and loss
of product as a consequence, a sufficient amount of Building Block C and D is necessary
in order to complete the total synthesis.
Therefore, our aim is three-fold:
• optimization of the known syntheses of Building Block A, B, C and D, tackling
the shortcomings, and in doing so, providing a practical and upscalable multigram
procedure and a sufficient amount of Building Block C and D
• aldol coupling of Building Block C and D, and further synthesis towards a sufficient
amount of vinyl iodide precursor 22
• design and synthesis of peloruside A and side-chain analogues, according to the Stille
and Suzuki coupling strategy
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3.1 Synthesis of Building Block A
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Scheme 3.1. Retrosynthesis of Building Block A
For the synthesis of Building Block A, a chiral pool starting material and an asymmetric
aldol coupling are proposed to introduce the desired stereochemistry (Scheme 3.1). Efforts
will be made to improve each step where possible.
3.1.1 Synthesis of the C1−C6 fragment (A - 31)
Protection of the starting material
The synthesis started with the very cheap and commercially available L-ascorbic acid, or
vitamin C. The first step in the synthesis was the protection of the terminal vicinal diol as
an acetonide, which will act as a latent carboxylic acid during the rest of the synthesis.
O O
O
O
HO OH
H
O OH
OH
O
HO OH
H
acetone, AcCl, rt
79%
L-ascorbic acid 25
Scheme 3.2. Synthesis of protected L-ascorbic acid 25
Being the first step in the synthesis, this reaction needed to be done on a very large scale.
Furthermore, because of the polar nature of the compounds, a procedure was sought which
allowed for an experimentally simple setup and a work-up which avoided extraction and
flash chromatography. Several procedures were found in the literature69–76 (on L-ascorbic
acid and the similar D-isoascorbic acid) including acetone as a solvent and either CuSO4
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as a water scavenger, or AlCl3, AcCl, HCl or CSA as a (Lewis) acid. In our findings, the
best combination of ease of setup, work-up, upscalability and yield was the use of 0.25 eq.
AcCl in acetone, at room temperature overnight, followed by a simple filtration with cold
acetone. This provided a reproducible yield of 79 % on a 100 g scale.
Oxidative cleavage and protection
After protection of the diol as an acetonide, the synthesis was continued with the oxidative
cleavage71–73,76–78 affording potassium 3,4-O-isopropylidene-L-threonate (51), followed by
ethylation to the corresponding ethyl ester (26).
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Scheme 3.3. Synthesis of ester 26
The oxidative cleavage of 25 takes place in two stages77(Scheme 3.4). The first stage is
the oxidation to the protected dehydro-L-ascorbic acid 51.1. The second stage involves
the addition of hydrogen peroxide at C3 (or C4) and a hydroxyl anion at C4 (or C3)
to intermediate 51.2 (or equivalent), followed by elimination of a hydroxyl anion from
the hydroperoxide moiety, with cleavage of the C3−C4 bond, resulting in intermediate
51.3. Basic hydrolysis of 51.3 then provides the protected potassium L-threonate 51 and
potassium oxalate 51.4. Separation of 51 from potassium oxalate 51.4 can occur through
filtration with boiling EtOH, in which the oxalate does not dissolve.
After separation of the oxalate, crude 51 was obtained almost quantitatively, after which it
was concentrated and redissolved in ACN, followed by ethylation72 to ethyl ester 26 with
EtBr. Different carbonates (K2CO3
72,76, Na2CO3, CaCO3
71,73,78) were tested as a base,
but the best results were obtained with K2CO3, providing a yield of 90 % over 2 steps.
The next step towards A - 31 was protection of the alcohol with an acetal type protecting
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Scheme 3.4. Oxidative cleavage of 25 to carboxylate 51 and dioxalate 51.4
group. At that stage in the synthesis, a MEM (2-methoxy-ethoxymethyl) ether was cho-
sen, as in the synthesis of Smans68 (Scheme 2.13, p. 45). This reaction proceeded under
standard conditions (MEM-Cl and DIPEA in CH2Cl2, reflux overnight) with 98 % yield.
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98%
26 27
Scheme 3.5. Synthesis of MEM ether 27
Reduction towards the aldehyde
Subsequently, the reduction of ester 27 to aldehyde 28 was investigated. This aldehyde is
sensitive to epimerization, so caution is needed during reaction, work-up and purification.
In theory, it is possible to reduce an ester to an aldehyde with modified aluminium hydride
reagents, e.g. DIBAL-H (diisobutylaluminium hydride), at low temperatures (−78 ◦C),
in toluene, hexane or CH2Cl2 (Scheme 3.6). Elimination of the ethoxy group in the
tetrahedral intermediate 29.1 to aldehyde 29 does not occur until hydrolytic work-up,
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but if the aluminium-oxygen bond gets cleaved before work-up, the resulting aldehyde
can be further reduced to the corresponding alcohol 28 if DIBAL-H is still present. This
overreduction is favored by certain conditions, e.g. high temperature or solvents with donor
heteroatoms. In our case, even at −78 ◦C in different suited apolar solvents, each time a
considerable amount of overreduced alcohol 28 was found. This could be attributed to
the presence of the five oxygens in our substrate (next to the ester moiety), which can
participate in complexation to aluminium and the resulting premature cleavage of the
aluminium-oxygen bond in 29.1, yielding aldehyde 29 in presence of DIBAL-H, resulting
in alcohol 28.
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Scheme 3.6. Reduction of ester 27 to aldehyde 29 / alcohol 28
Therefore, to avoid a mixture of aldehyde 29 and alcohol 28, and taking into account the
possible epimerization, a two-step reduction-oxidation protocol79,80 was proposed, where
first alcohol 28 can be obtained by a smooth reduction, followed by a controlled and
epimerization-free oxidation.
While the reduction to the alcohol by Smans68 was performed with the very reactive LiAlH4
in Et2O with a moderate yield of 81 %, we proposed the use of DIBAL-H, but now with
conditions that favor the overreduction. Conducting the reaction with 2.5 eq. DIBAL-H in
Et2O at room temperature, followed by work-up with a sat. Rochelle salt solution, provided
alcohol 28 with an increased yield of 93 %.
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Scheme 3.7. Two-step synthesis of aldehyde 29
Optimizing the subsequent oxidation seemed to be more rewarding, as the Swern oxidation
by Smans68 delivered only a yield of 64 %, but also more challenging, concerning the
sensitivity to epimerization. The Swern oxidation is known to be a mild and robust reaction,
but the presence of Et3N can lead to epimerization. Therefore several other oxidative
procedures were tested, but only with minor success. The use of Dess-Martin periodinane
(with and without pyridine), the Parikh-Doering oxidation and the use of TEMPO (with
NaOCl or DAIB as a co-oxidant) were investigated. Not only were the reactions themselves
unsuccessful, a clean and fast work-up was often not possible, compromising the outcome
of the subsequent aldol coupling. Therefore, we returned to the Swern oxidation in order
to optimize the reaction conditions and work-up. Our first efforts included reaction times
from 30 to 80 min (after addition of Et3N) and work-up was done by extraction (H2O
and CH2Cl2) and washing
79,80 (0.1m HCl; sat. NaHCO3 sol.). These conditions provided
already satisfying yields of 87-96 %, along however with 5-20 % epimerization. As the
yield and epimerization seemed unrelated to the reaction time, but mostly depending on
the pace and the conditions of the work-up, shorter reaction times and different work-up
conditions to remove the residual reagents and by-products (Et3N, Et3N·HCl and DMSO)
were envisioned. Work-up by addition of toluene to the reaction mixture and filtration of
the salts over a silica plug provided a significant decrease in epimerization (< 2 %) but
low yields of the pure product (and still containing a significant amount of DMSO). In a
new test, performing the extraction with CH2Cl2 and either a sat. NH4Cl sol. or a 0.1m
HCl sol. was not efficient in removing the Et3N and/or DMSO. In a new and last effort,
after a reaction time of 15 min, we first conducted the extraction with CH2Cl2 and H2O in
order to remove most of the DMSO, followed by a double washing with a 1m CuSO4 sol. in
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order to remove the Et3N in a neutral way. CuSO4 can complex amines and thereby pull
them into the water phase, without the use of acid or base, thus avoiding epimerization.
This last procedure seemed very effective, providing a high yield of 96 %, a low level of
epimerization (< 3 %) and a low amount of residual DMSO (< 3 %).
Aldol coupling and methylation
The next step was the asymmetric aldol coupling of aldehyde 29 with acetone as the
nucleophile. One possible strategy is the use of a direct asymmetric aldol reaction, in
particular in an organocatalytic way, with the use of the natural amino acid proline as a
chiral catalyst.
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94% total yield
d.r. 16:1
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29 30
Scheme 3.8. Synthesis of hydroxy ketone 30
The first use of proline as catalyst for an enantioselective transformation dates back from
the early 1970s81,82. It was however only since the reports of List in 2000, where the use
of proline was shown in the direct asymmetric aldol coupling83 and the direct asymmetric
Mannich reaction84, that proline attracted the attention it deserved. For the direct asym-
metric aldol coupling, a catalytic enamine mechanism was proposed83,85–87 (Scheme 3.9),
were proline functions as a “micro-aldolase” that provides both the nucleophilic amino
group and an acid/base co-catalyst in the form of the carboxylate. This co-catalyst may
facilitate each individual step of the mechanism, including the nucleophilic attack of the
amino group (a), the dehydration of the carbinol amine intermediate (b), the deprotona-
tion of the iminium species (c), the carbon-carbon bond forming step (d), and both steps
of the hydrolysis of the iminium-aldol intermediate (e and f). The enantioselectivity can
be explained with a metal free version of a Zimmerman-Traxler type transition state. The
tricyclic hydrogen bonded framework provides for enantiofacial selectivity. In the case of
58
3.1 Synthesis of Building Block A
L-proline, a re-facial attack on aldehyde 29 in the transition state leads to the desired
(R)-diastereomer 30.
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Scheme 3.9. Organocatalytic mechanism of the proline-catalyzed aldol coupling
The use of proline as an asymmetric catalyst has some distinct advantages. Next to good
yields and diastereoselectivities, proline is also non-toxic, inexpensive and readily available
in both enantiomeric forms. The reactions do not require inert conditions, they can be run
at room temperature and as proline is water soluble, it can be readily removed by aqueous
extraction. Also important is that no prior modification of the carbonyl substrates such
as deprotonation or silylation is required. A general limitation however is the scope of
the ketone component, as a large excess of the ketone is often required. In our case, the
required ketone was acetone, offering the advantage that it can be used as a (co-)solvent.
This reaction was tested by Smans68 with different solvents (CH2Cl2, CH3Cl, ACN, pen-
tane, Et2O, THF, toluene and acetone) but only acetone itself seemed to deliver a good
yield. Moreover, with acetone as a solvent, a quantitative yield was achieved, although
with a rather disappointing d.r. of 3.4:1. In early studies, acetone itself was proved to be
a suitable solvent. However, the solubility of L-proline in acetone is poor, so DMSO was
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employed as the co-solvent to improve its solubility. Therefore, to start our experiments,
we returned to the literature and applied the standard conditions (DMSO, 20 % v/v ace-
tone, 30 mol % L-proline) and compared these to the Smans conditions (acetone, 100 mol %
L-proline). Surprisingly, both conditions gave a similar d.r. (resp. 10.1:1 and 8.5:1) that
was much higher than the one of Smans (3.4:1). Probably the d.r. he observed was com-
promised by epimerized starting material, as no values were mentioned of this. From this
experiment, we could also conclude that the use of DMSO as a solvent increased the reac-
tion rate (by increasing the solubility of L-proline), but at the same time also led to some
side-reactions which compromised the total yield. Therefore, although a small increase in
d.r. was observed with the use of DMSO, the disadvantages outweighed this, and further
tests were performed with only acetone as a solvent. In subsequent tests, we could also ob-
serve a remarkable dependence of the results on how the starting material was obtained, as
conducting the reaction under the same conditions did not lead to reproducible d.r. values.
Therefore, reliable conclusions could only be drawn when results were compared between
reactions with the same batch of starting material. Furthermore, still not pleased by these
results, we looked to improve the conversion, yield and enantioselectivity by the use of
additives. In 2006, Zhou and Shan88,89 reported the use of chiral Brønsted acids like (R)-
and (S )-BINOL as additives in the L-proline catalyzed direct aldol reaction. Both (R)- and
(S )-BINOL seemed to enhance the inductive ability of L-proline by the formation of a chi-
ral supramolecular system through hydrogen-bonding interactions (Scheme 3.10), which
not only activated the carbonyl group of the aldehyde, but also stabilized the transition
state, resulting in considerably improved yields and enantioselectivities.
Therefore, we used the best literature conditions (1 mol % (S )-BINOL) in a comparative
experiment and noted a significant increase from d.r. 6.7:1 to d.r. 11.5:1 when (S )-BINOL
was added (using the same batch of aldehyde 29). These results could be further optimized
(longer reaction times, total conversion), so we finally succeeded in obtaining a total yield
(both diastereomers) of 94 % and a d.r. of 16:1. The effective isolated yield of 30 was 89 %.
The last step towards the synthesis of A - 31 was the methylation of hydroxy ketone 30.
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Scheme 3.10. Supramolecular transition state using (S )-BINOL as an additive in the proline-
catalyzed aldol coupling
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Scheme 3.11. Synthesis of methyl ether A - 31
For this (and subsequent) methylation(s), we made use of trimethyloxonium tetrafluo-
roborate (Me3OBF4), which is the methyl analog of Meerwein’s reagent (triethyloxonium
tetrafluoroborate; Et3OBF4). These oxonium salts are exceptionally strong alkylating
agents, and therefore react vigorously with water and alcohols, even at low temperatures.
For use in methylations (of sensitive alcohols), Me3OBF4 forms a terrific combination with
a base such as Proton-sponge R© (1,8-bis(dimethylamino)naphthalene), which is a sterically
very hindered, highly selective, non-nucleophilic, strong base. This reaction was carried
out in CH2Cl2 with the addition of molecular sieves (MS 4A˚) and a yield of 89 % could be
obtained.
With this last step, we can conclude the synthesis of Building Block A (A - 31) in 7 steps
from L-ascorbic acid (Scheme 3.12). We were able to improve the original synthesis68 in
a significant way, increasing the total (isolated) yield from 21 % (80 % average yield per
step) to 49 % (90 % average yield per step), in the same number of linear steps. Moreover,
this synthesis allows for a large-scale preparation of A - 31.
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Scheme 3.12. Synthesis of Building Block A (A - 31)
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3.1.2 Proof of stereochemistry
3 2
1
O
O
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Building Block A (A - 31) contains three stereocenters of which the configuration had to
be confirmed. C1 and C2 originate from the chiral pool starting material L-ascorbic acid
and were assumed to have the configuration as represented. C3 was introduced in the
organocatalytic aldol coupling with L-proline and its absolute configuration was confirmed
by the Mosher protocol90–92(Scheme 3.13). Therefore, hydroxy ketone 30 was derivatized
to its corresponding (S )- and (R)-MTPA (α-methoxy-α-trifluoromethylphenylacetate) es-
ters (52 and 53), where the two carbinyl substituents are represented as the L1 and L2
groups. Both MTPA esters will adopt a conformation where the hydrogen on the carbinyl
is quasi-eclipsed by the carbonyl oxygen and the trifluoromethyl group is aligned syn-
periplanar with the carbonyl group92. This leads to different interactions between the
α-phenyl group of the MTPA moiety and the L1/L2 groups in both (S )- and (R)-MTPA
esters. The anisotropic diamagnetic field, caused by the pi-electron cloud of the aromatic
phenyl group, causes an average time weighted selective shielding of the L2 group of the
(S )-MTPA ester and the L1 group of the (R)-MTPA ester. This shielding results in a lower
chemical shift of the L2 protons of the (S )-MTPA ester relative to the L2 protons of the
(R)-MTPA ester and the other way around for the chemical shift of the L1 protons. By
comparing the chemical shift differences (∆δ = δS − δR) of the L1 and L2 group protons,
represented in Table 3.1, the L1 and L2 groups could be unambiguously assigned, thus
confirming the expected absolute configuration of C3.
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Scheme 3.13. Mosher protocol to determine the absolute stereochemistry at C3
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Table 3.1. 1H NMR shifts (Hz) of MTPA esters 52 and 53 (300 MHz; CDCl3)
4 5
6
7
O
8
O
9
10
O
OMTPA
3
2
O
1
11
O
12
13
O
14
OMTPA
L1
∆δ>0
L2
∆δ<0
∆δ = δS - δR
H (S)-MTPA (52) (R)-MTPA (53) ∆δ = δS − δR
1 648.52 629.55 18.97
3a 913.88 900.30 13.58
3b 851.66 851.01 0.65
5 1101.48 1114.65 −13.18
6 1161.22 1229.93 −68.71
7a 1143.65 1197.79 −54.15
7b 1065.61 1134.01 −68.40
11a 1440.65 1460.85 −20.20
11b 1428.20 1448.82 −20.62
12 1115.01 1127.43 −12.42
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Scheme 3.14. Retrosynthesis of Building Block B
For the synthesis of Building Block B, a high yielding (90 % average yield per step)
yet long procedure (8 steps), starting from (R)-pantolactone was available from Smans68
(Scheme 2.14, p. 46). This time, only minor improvements could be proposed for the avail-
able synthesis as such. Therefore, a new, shorter and more efficient route was suggested
as depicted in Scheme 3.14. This new route relies on an asymmetric alkoxyallylboration
reaction for the simultaneous introduction of the two desired stereocenters. Furthermore,
the number of steps can be lowered from 8 to 5 and introduction of the expensive SEM
protecting group can occur now in the penultimate step instead of the first step.
3.2.1 Synthesis of the C7−C11 fragment (B - 39)
Monobenzylation and oxidation
Our synthesis of Building Block B (B - 39) started from the cheap and commercially avail-
able neopentylglycol, from which the first step was the monobenzylation of the 1,3-diol.
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Ph
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-10°C -> reflux 
quant.
OHOH
PhCH(OMe)2 
CSA, CH2Cl2, rt 
quant.
55
54
neopentylglycol
Scheme 3.15. Synthesis of benzyl ether 55
Our first attempt was the use of classic reaction conditions (1.1 eq. NaH; 1 eq. BnBr; 1
eq. TBAI; THF), but this seemed too reactive and not selective at all as only dibenzylated
product was obtained.
Our next attempt was the use of Ag2O
93 (Table 3.2). In our first experiment (entry
1), the neopentylglycol starting material (SM) was used in large excess, but formation
of dibenzylated product could not be avoided. When using stoichiometric amounts of SM
(entries 2 and 3) and even with very slow addition of BnBr, a large amount of dibenzylated
product was obtained, rendering this strategy useless.
Table 3.2. Monobenzylation with Ag2O
a
nr SM Ag2O BnBr add. t 55
b
1 5 2 1 5 min 83 %
2 1 1.2 1 1 h 64 %
3 1 1.2 1 5 h 61 %
a all reactions were carried out in CH2Cl2 at rt, until TLC showed total
consumption of BnBr
b isolated yield after flash chromatography
Our third strategy for the monobenzylation of neopentylglycol was the use of dibutyltin
oxide (Bu2SnO) (Scheme 3.16), a strategy which is used very often in carbohydrate chem-
istry94. In a first step, the dibutylstannylene acetal is prepared in toluene, with azeotropic
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removal of water using a Dean-Stark apparatus. The second step involves the formation of
a single oxygen-electrophile bond per organotin unit, which gives with the use of benzyl-
bromide the monobenzylated product 55. Normally for the alkylation of these stannylene
acetals, vigorous conditions are needed, but it was found that the addition of tetrabutylam-
monium halides (e.g. TBAI) accelerates the reactions so that they can occur at a reasonable
speed at reflux. Indeed, when conducting the reaction, starting material was already con-
sumed after 1 hour at reflux and no dibenzylated product or degradation products were
noticed. Surprisingly, only 58 % of 55 could be isolated.
OHOBnOHOH OO
Sn
BuBu
Bu2SnO
H2O
BnBr
TBAI
55stannylene acetalneopentylglycol
Scheme 3.16. Monobenzylation with Bu2SnO
As our one-step monobenzylation strategy did not turn out as expected, a new strategy
was proposed95, which involved the synthesis of the symmetrical benzylidene acetal 54,
followed by a reductive cleavage (Scheme 3.17). Therefore, we first conducted the acid
catalyzed transacetalization of neopentylglycol with benzaldehyde dimethyl acetal. After
work-up by washing with a sat. NaHCO3 sol., crude acetal 54 was redissolved in Et2O and
CH2Cl2 (1:1), followed by addition of LiAlH4 and AlCl3 (1:1) at −10 ◦C. AlCl3 acts as a
Lewis acid and coordinates with one of the acetal oxygens, making the acetal carbon more
reactive towards hydride attack of LiAlH4, which results in cleavage of one of the acetal
carbon-oxygen bonds. After hydrolytic work-up, crude 55 was obtained in a quantitative
yield. This benzyl ether could subsequently be oxidized to the aldehyde, using Swern
conditions. Purification by flash chromatography after this third step provided 56, starting
from neopentylglycol, with an overall yield of 98 % over three steps.
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Scheme 3.17. Two-step monobenzylation, followed by Swern oxidation to aldehyde 56
Asymmetric alkoxyallylboration
The next reaction is an asymmetric alkoxyallylboration, which can introduce both desired
stereocenters of Building Block B (B - 39) in a diastereoselective and enantioselective way
in one step, making use of chiral [B -(Z )-γ-alkoxyallyl]-diisopinocampheylboranes96–100
(Scheme 3.18). In this step, also the acetal type protected alcohol at C9 was introduced,
where we chose again to use a MEM ether, as in the synthesis of Smans68 (Scheme 2.14,
p. 46).
OHOBn
OMEM
OOBn sec-BuLi, BF3·OEt2, THF, -78°C
ii)
 NaOH, H2O2, rt
i)
 (-)-Ipc2BOMe, 
MEMO
63%
d.r. 199:1; 78% e.e.
57
57
56 58
Scheme 3.18. Synthesis of alcohol 58
With a prochiral aldehyde, four possible diastereomers can be obtained with this approach
and this in a completely reagent controlled way (Scheme 3.19). The asymmetric induction
can be represented by a Zimmerman-Traxler type transition state where both the configu-
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ration of the double bond and the pinene ligands at boron are responsible for the outcome
of the reaction. While the Z - or E -configuration defines the syn or resp. anti relationship
of both new stereocenters, the choice of Ipc (isopinocampheyl) boron ligands (derived from
(+)- or (−)-α-pinene) defines the absolute configuration of the new C9 stereocenter. To
obtain the correct stereochemistry, the (−)-[B -(Z )-γ-(2-methoxy-ethoxymethoxy)-allyl]-
diisopinocampheylborane derived from (+)-α-pinene is needed, which can be synthesized
from commercially available reagents.
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Scheme 3.19. Reagent-controlled induction of the asymmetric alkoxyallylboration
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First, (−)-Ipc2BOMe was synthesized, in which the first step was the addition of BH3·SMe2
to a solution of (+)-α-pinene in THF, after which crystalline (−)-Ipc2BH was obtained.
Although the (+)-α-pinene used only had an e.e. of 91 %, the (−)-Ipc2BH was enantiomer-
ically pure, through the process of enantiomeric enrichment. Ipc2BH is in an equilibrium
with IpcBH2 and as Ipc2BH with two (+)-isopinocampheyl groups has a higher crystallinity
than Ipc2BH with both a (+)- and (−)-isopinocampheyl group, using a slight excess of (+)-
α-pinene thrives the equilibrium and the enrichment. After enantiopure (−)-Ipc2BH was
obtained, (−)-Ipc2BOMe could be obtained by methanolysis.
BH3·SMe2
THF, rt
BH B
OMe
MeOH
THF, rt
(+)-α-pinene (−)-Ipc2BH (−)-Ipc2BOMe
Scheme 3.20. Synthesis of (−)-Ipc2BOMe
Next, we prepared MEM-protected allyl alcohol (57) using standard conditions
(Scheme 3.21). With this in hand, addition of sec-BuLi first abstracts an allylic proton,
with formation of the lithium-coordinated Z -enol ether (58.1). The latter attacks the
freshly prepared (−)-Ipc2BOMe, after which the electron deficient BF3 eliminates the
methoxy group of 58.2, with formation of the desired chiral boron reagent (58.3). After
addition of aldehyde 56 and coordination with boron, two diastereomeric Zimmerman-
Traxler chair-like transition states (TS) are possible for the asymmetric addition. While
the aldehyde prefers to approach from the less hindered back face (si -face of the boron
reagent; disfavored TS), once it is coordinated, severe sterical hindrance would occur
between an allylic CH2 proton and the two Ipc methyl groups. This leads to the approach
of the aldehyde from the front face (re-face of the boron reagent; favored TS) and a
si -facial attack (referring to the carbonyl group), resulting in the desired stereochemistry.
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After hydroboration of 58.4 and purification, 58 was obtained in a moderate yield of 64 %,
with d.r. 199:1 and 78 % e.e.
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Scheme 3.21. Mechanism of the asymmetric alkoxyallylboration
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Protection and oxidative cleavage
The next step in the synthesis was the protection of the alcohol moiety of 58 as a SEM
(2-trimethylsilyl-ethoxymethyl) ether. This SEM ether can be selectively deprotected with
fluoride reagents later on in the synthesis. Standard conditions could be used and 38 was
obtained in 92 % yield.
OSEMOBn
OMEM
OHOBn
OMEM
SEM-Cl, DIPEA 
CH2Cl2, reflux
92%
58 38
Scheme 3.22. Synthesis of SEM ether 38
The final step to obtain B - 39 was the oxidative cleavage of the terminal alkene moiety to
aldehyde B - 39, where we again had to be aware of possible epimerization at the aldehyde
α-carbon.
OSEMOBn
OMEM
OOSEMOBn
OMEM
i)
 OsO4, NMMO 
acetone, H2O, rt
ii)
 NaIO4, rt
95%
38 B - 39
Scheme 3.23. Synthesis of aldehyde B - 39
This reaction can be done by ozonolysis, but as we wanted complete control of the aldehyde
forming step, we preferred to conduct this reaction in a one-pot two-step protocol, where
first the alkene is dihydroxylated to the vicinal diol intermediate, followed by cleavage of the
latter to aldehyde B - 39. For the first step, the dihydroxylation, the use of KMnO4, RuO4
and OsO4 is known, but in general, OsO4 is used most often, as it is very mild, reliable
and efficient for the synthesis of 1,2-diols. OsO4 is a volatile and very toxic compound, but
fortunately, it is available as a solution in water and can be used catalytically (1 mol%)
with the use of many co-oxidants. Especially the use of NMMO (N -methylmorpholine
N -oxide) as a co-oxidant, known as the Upjohn dihydroxylation101, has broadened the
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Scheme 3.24. Mechanism of the oxidative cleavage of the terminal alkene moiety of 38
synthetic application of OsO4. In the reaction mechanism (Scheme 3.24), the alkene first
adds to OsO4 in a [ 3 + 2 ] cycloaddition with formation of a cyclic osmate ester, which
rapidly hydrolyzes to the vicinal diol and an Os(VI) species, which gets reoxidized by
NMMO to the Os(VIII) species and repeats the catalytic cycle. The vicinal diol obtained
can now be cleaved. This can be achieved by either the use of KMnO4, Pb(OAc)4, HIO4
or NaIO4, but obviously the mildest and safest way is the use of NaIO4, in the periodate
cleavage. Both vicinal alcohol moieties will add to the periodate with formation of a cyclic
periodate ester, which will subsequently break down to NaIO3, water, formaldehyde and
the desired aldehyde B - 39. The reaction rate of the different steps will determine when
to add NaIO4 to the reaction, as NaIO4 can also be used as the co-oxidant of the catalytic
OsO4 dihydroxylation, next to or instead of NMMO. Using NaIO4 instead of NMMO as
the co-oxidant and to in situ cleave the vicinal diol formed, is known as the Lemieux-
Johnson oxidation102. It was found however, that the periodate cleavage happened much
faster than the dihydroxylation, and epimerization occurred when the periodate cleavage
or the reductive Na2S2O3 work-up was left standing for too long (i.e.> 1-2h). Therefore, to
avoid epimerization, the Lemieux-Johnson oxidation protocol was found inappropriate and
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first the Upjohn dihydroxylation protocol (cat. OsO4; NMMO) was followed until total
consumption (26 h) of alkene 38, followed by addition of NaIO4, fast consumption (35 min)
of the vicinal diol and reductive Na2S2O3 work-up. In this way, epimerization was kept
to an absolute minimum, and after purification, aldehyde B - 39 was obtained with 95 %
yield.
With this last step, we can conclude the synthesis of Building Block B (B - 39) in 6 steps
from neopentylglycol (Scheme 3.25). In comparison with the original route by Smans68, a
new and more convergent approach was applied, which improved the synthesis from 8 steps
(49 % total (isolated) yield; 91 % average yield per step) to 6 steps (54 % total (isolated)
yield; 90 % average yield per step; 78 % e.e.), in a way that allowed for the large-scale
preparation of B - 39 in a minimal amount of time.
OHOH OHOBnOO
Ph
OOBn OHOBn
OMEM
OSEMOBn
OMEM
OSEMOBn
OMEM
O
PhCH(OMe)2
CSA, CH2Cl2, rt
LiAlH4, AlCl3
Et2O, CH2Cl2
-10°C -> reflux
(COCl)2, DMSO
Et3N, CH2Cl2, -78°C
SEM-Cl, DIPEA
CH2Cl2, reflux
i)
 OsO4, NMMO
acetone, H2O, rt
ii)
 NaIO4, rt
98%
(3 steps)
63%
d.r. 199:1; 78% e.e.
92% 95%
sec-BuLi, BF3·OEt2, THF, -78°C
ii)
 NaOH, H2O2, rt
i)
 (-)-Ipc2BOMe, 
neopentylglycol 54 55
56
57
58
38 B - 39
Scheme 3.25. Synthesis of Building Block B (B - 39)
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3.2.2 Proof of stereochemistry
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Building Block B (B - 39) contains two stereocenters, C8 and C9, of which the configuration
had to be confirmed. As B - 39 was already synthesized by Smans68 via a different synthetic
route (Scheme 3.14), we confirmed the relative stereochemistry by comparing the spectral
data of 38 and B - 39 with those prepared by Smans68, which allowed us to confirm that
our compounds are diastereomerically identical with those obtained by Smans68.
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Scheme 3.26. Proof of stereochemistry at C8
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Smans68 proved the stereochemistry by correlating the C8 stereocenter to the C9 stere-
ocenter, which can be derived from the natural (R)-pantolactone he used as the start-
ing material. 37 was obtained in 6 steps from (R)-pantolactone (Scheme 2.14, p. 46)
and led to 38 and the desired aldehyde B - 39. After cleavage of the SEM ether of
37, syn-diol 59 was obtained, which could be protected as trans-acetonide 60. The
stereochemistry of the latter was determined by the 3JH,H NMR coupling constant of the
hydrogen atoms at C8 and C9. These are related to the dihedral torsion angles via the
Karplus equation103,104. Via molecular modeling, a dihedral angle of 169◦ was predicted for
trans-acetonide 60, which translates with the Karplus equation to a coupling constant
of 8-9 Hz. For cis-acetonide 61, a dihedral angle of 39◦ was predicted, which translates
to a coupling constant of 4-6 Hz. For the acetonide derived from 37, a 3JH,H coupling
constant of 8.16 Hz was measured, confirming the trans-relationship in 60 and hence the
syn-stereochemistry in derived diol 59, hence proving the stereochemistry at C8.
Unlike the synthesis of Smans68, in our synthesis the two stereocenters at C8 and C9 were
introduced in a single step, resulting in the formation of two enantiomers (78 % e.e.). To
prove that the major enantiomer is the same and expected enantiomer, we compared the
optical rotation of 38 with the presumed same compound synthesized by Smans68. As we
obtained an optical rotation of [α]D =− 28.6 and [α]365 =− 91.5 and Smans68 obtained an
optical rotation of [α]D =− 31.9 and [α]365 =− 100.4 respectively, we can unambiguously
conclude that the major enantiomer we obtained in our synthesis, is the same and expected
enantiomer.
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Scheme 3.27. Retrosynthesis of Building Block D
Looking back at our initial retrosynthetic approach (Scheme 2.4, p. 33), the next step is
to obtain Building Block D (Scheme 3.27). Therefore we first need to couple Building
Block A and B via an aldol reaction, followed by methylation of the new stereocenter at C7.
Next, the C5 ketone needs to be reduced and the alcohol protected, followed by selective
deprotection of the C11 benzyl ether and oxidation of the alcohol to the aldehyde, affording
Building Block D. Efforts will be made to improve each step where possible.
3.3.1 Aldol coupling of Building Block A and B
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Cy2BCl, Et3N              
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O
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A - 31B - 39 45
Scheme 3.28. Aldol coupling of A - 31 and B - 39
81
3. Results and Discussion
Strategy
The aldol coupling is a powerful carbon-carbon bond forming reaction between two car-
bonyl moieties (most often a ketone and an aldehyde), which is extensively used as a key
methodology in the total synthesis of polyoxygenated natural products. We have used this
approach twice in an organocatalytic direct asymmetric aldol coupling, with acetone as
the ketone and L- or D-proline as the catalyst, in the synthesis of Building Block A and C,
and also in two occasions as the key coupling step between Building Block A and B and
Building Block C and D. Unfortunately, direct aldol couplings often require a large excess
of the ketone, which is not feasible with highly precious Building Block A or C as the ke-
tone. For compounds of this complexity, other methodologies have been developed, which
convert the ketone first quantitatively to an enolate, followed by nucleophilic addition to
the aldehyde. Our strategy includes the use of suitable boron reagents to form the boron
enolate.
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Scheme 3.29. Stereocontrolled aldol addition using boron enolates
When aldehyde 45.2 is added to preformed boron enolate 45.1 (Scheme 3.29), a boron-
coordinated ate-complex 45.3 is formed, which after aldol reaction yields two possible aldol
adducts, 45.4a and 45.4b. After hydrolysis, ideally a single stereoisomer, 45.5a or 45.5b
is obtained, if the nucleophilic attack to the aldehyde is selectively directed to the re- or
si -face respectively. Compared to other metal enolates, the boron-oxygen bond is relatively
short, which leads to a tight six membered ring transition state (chair, boat and twist-boat
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are known to occur), resulting in a highly stereoselective carbon-carbon bond formation.
Multiple factors influence the absolute stereocontrol, including the size and chirality of the
aldehyde, the ketone and the boron ligands, next to some reaction parameters like the
solvent and the reaction temperature. Both aldehyde B - 39 and ketone A - 31 possess
stereocenters nearby the carbonyl and their inducing power can possibly be combined and
reinforced by the use of achiral or chiral boron ligands. Many studies by Evans105–108 and
Paterson109–112 are reported on the single, double and triple stereodifferentiating effects of
boron enolates, lithium enolates and enol silanes. While the inducing power of syn-α,β-
bisalkoxy aldehyde B - 39 is highly dependent on the protecting alkoxy groups used and
also quite moderate with the use of boron enolates (in general more so with lithium eno-
lates and enol silanes), high levels of 1,5-anti stereoinduction are obtained with β-alkoxy
methyl ketones bearing appropriate alkoxy (protecting) groups (e.g. -OMe, -OPMB, PMP
acetal). Furthermore, chiral Ipc-derived boron enolates are known to dominate the in-
duction, hence either reinforcing a synergetic induction, or overruling an (unexpectedly)
opposite induction. We speculated that methyl ketone A - 31 would be stereodominating
and inducing a 1,5-anti relationship between the C3 methoxy group and the newly formed
C7 stereocenter. But of course, matched and mismatched combinations with chiral alde-
hyde B - 39 are possible.
In 2006, Paton and Goodman113 reported a transition state model that offered an explana-
tion for the 1,5-anti induction with β-alkoxy methyl ketones. They modeled the possible
TS (transition state) structures (chair-like and boat-like), calculated their relative energies
and found that at −78 ◦C, only the boat-like TS structures are populated and more specif-
ically one in particular, which leads to the 1,5-anti product (Scheme 3.30). Four different
boat-like TS structures are possible, two of which having the β-alkoxy group oriented away
(OUT), the two others having the β-alkoxy group inward (IN) the cyclic core. The “IN” TS
structures seem to be favored, which is unexpected on steric grounds. However, folding the
alkyl chain inside leads to a stabilizing formyl hydrogen bond (C−H···O) between the alde-
hyde proton and the alkoxy oxygen, which overcompensates for the steric repulsion. The
aldehyde can approach the enolate from two faces, but in the IN-1,5-syn TS, unfavorable
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interactions occur between the R1 alkyl chain and one of the ligands on boron, while in the
IN-1,5-anti TS, these interactions are avoided, making the IN-1,5-anti TS most favorable,
leading to the desired 1,5-anti induction.
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R1
O OMe
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1,5-syn
IN-1,5-anti
IN-1,5-syn
OUT-1,5-anti
OUT-1,5-syn
Scheme 3.30. 1,5-anti induction with β-alkoxy methyl ketones
Results
Smans68 tested this reaction with two boron reagents (Cy2BCl and Bu2BOTf) which are
known to reinforce the 1,5-anti induction with β-alkoxy methyl ketones, but his results
were somewhat surprising. While the use of Cy2BCl gave an excellent yield (98 %) but
a moderate diastereoselectivity (d.r. 2.2:1), the use of Bu2BOTf gave a much improved
diastereoselectivity (d.r. 7.3:1) albeit with a dramatically low yield (13 %). Importantly
both reagents seemed to follow the theoretical TS model and gave the desired diastereomer
as the major compound, yet improvements to the yield and/or diastereoselectivity seemed
feasible.
Results of the tests are given in Table 3.3. The aldehyde was added to the preformed
boron enolate at −78 ◦C (unless otherwise noted), followed by reaction overnight at the
given temperature. To find out if there were any triple stereodifferentiating effects, the
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Table 3.3. Aldol coupling of A - 31 and B - 39a
nr borane Tb ( ◦C) conversionc anti :syn
1 (−)-DIP-Cl −78 very low
2 (+)-DIP-Cl −78 very low
3 Cy2BCl −45 quant. 65:35
4a (−)-DIP-Cl −45 very low
4b (−)-DIP-Cl −20 low 60:40
5 Bu2BOTf −35 very low
6a Cy2BCl −45 90 % 65:35
6b Cy2BCl −78 77 % 67:33
6b Cy2BCl (−96 ◦C)d
−55
70 % 70:30
7e Cy2BCl −45 quant. (94 %)f 65:35
a all reactions were carried out overnight in Et2O, with 1.5 eq. ketone A - 31, 1.8 eq.
Et3N and 1.65 eq. borane
b aldehyde B - 39 was added to the preformed boron enolate at −78 ◦C (unless otherwise
noted), followed by reaction overnight at the given temperature
c based on TLC and/or LC-MS
d addition temperature
e large scale: 7.1 g of aldehyde B - 39
f isolated yield of both diastereomers
reactions were first carried out with the chiral Ipc-derived boron enolates. While (−)-DIP-
Cl should be able to reinforce the induction (matched case), (+)-DIP-Cl is expected to
overrule the inductive effects of ketone and aldehyde (mismatched case). However, when
conducting the reactions overnight at −78 ◦C, only a negligible amount of aldol product was
obtained (entries 1 and 2). Repeating the Smans68-conditions (entry 3; overnight at −45 ◦C
with Cy2BCl), we obtained similar results (quantitative conversion, moderate yield). In
the meantime, it was made clear that fresh reagents and water-free conditions (especially
for long reactions at low temperature) were necessary to obtain good conversions, otherwise
the reaction might stall overnight. The reaction with (−)-DIP-Cl was repeated (−45 ◦C
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overnight) and again a very low conversion was obtained (entry 4a). Therefore, the reaction
was warmed to −20 ◦C and was left reacting for an extra 4 days (entry 4b), which increased
the conversion only a little. After work-up, the diastereoselectivity seemed similar (even
slightly lower) and so the bulky Ipc-ligands were found inappropriate to secure good yields
or diastereoselectivities with our substrates. Also the use of Bu2BOTf led to a very low
conversion (entry 5) and was found inappropriate. Next, a series (entries 6a-c) of temper-
ature controlled reactions were tried. Here, lowering the addition temperature and/or the
overnight reaction temperature only had a minor positive effect on the diastereoselectivity,
but in contrast had a very negative impact on the conversion. So unfortunately, we had to
conclude our tests with no meaningful improvements to the original conditions, but were
left satisfied with a protocol that allowed the large-scale aldol coupling (entry 7) of A - 31
and B - 39. Fortunately, flash chromatography allowed for the (laborious) separation of
both diastereomers and the 1,5-anti aldol product 45 was obtained with a total yield of
61 %.
3.3.2 Synthesis of the C1−C11 fragment (D - 64)
Methylation of the hydroxy ketone
After aldol coupling of A - 31 and B - 39, hydroxy ketone 45 was methylated using
Me3OBF4 as the alkylating agent and Proton-sponge
R© as a suitable base to prevent retro-
aldol cleavage, in extra dry (MS 4A˚) CH2Cl2, affording 46 in 91 % yield after purification.
Me3OBF4
Proton-sponge®
MS 4Å, CH2Cl2, rt
OBn OSEM
OMEM
OMe O OMe
OMEM
O
OOSEMOBn
OMEM
OH O OMe
OMEM
O
O
91%
45 46
Scheme 3.31. Synthesis of methyl ether 46
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Reduction of the C5 carbonyl group and protection
The next step in the synthesis of D - 64 was the diastereoselective reduction of the C5
ketone (46) with formation of the last stereocenter of this building block, followed by
protection of this secondary alcohol (47) with an acetal type protecting group (62).
OBn OSEM
OMEM
5
OMe OR OMe
OMEM
O
OOBn OSEM
OMEM
5
OMe O OMe
OMEM
O
O
NaEt3BH 
CH2Cl2, -78°C
quant. 
d.r. 49:1
MOM-Cl, DIPEA
TBAI, CH2Cl2, reflux
R = H
R = MOM
96%
46 47
62
Scheme 3.32. Synthesis of MOM ether 62
Smans68 was already able to reach high levels of diastereoselectivity (d.r. 32:1) on a test
scale, with NaEt3BH in CH2Cl2 at 0
◦C. Scaling up however, seemed to be problematic
(non-reproducible d.r.’s, low conversion/yield, side-products). By lowering the concentra-
tion (0.010-0.015m in CH2Cl2) and temperature (−78 ◦C) and working carefully under very
inert conditions, we were able to overcome these problems, providing a large-scale (5.5 g)
diastereoselective reduction in quantitative yield with excellent diastereoselectivity (d.r.
49:1), using NaEt3BH in CH2Cl2 at −78 ◦C.
Because of some practical problems which are inherent to the MEM protecting group,
like increased tailing upon flash chromatography or the presence of disturbing signals in
NMR spectra, we decided to replace the MEM groups, which were originally planned
later on in the synthesis, with other suitable acetal type protecting groups. In this way,
our initial protecting group strategy (Scheme 2.5, p. 35) stayed valid, while upcoming
practical problems are (partially) avoided. Therefore, the C5 alcohol was protected as a
MOM (methoxymethyl) ether. As this alcohol moiety was quite sterically hindered by the
neighboring methoxy groups, the addition of TBAI, the use of 4 eq. of MOM-Cl and long
reaction times (28 h) under reflux conditions were needed to obtain complete conversion,
providing 62 in 96 % yield after purification.
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Debenzylation and oxidation of C11
All stereocenters of D - 64 being installed, the only thing left to prepare D - 64 for the next
coupling, was the selective cleavage of the benzyl ether at C11 (62), followed by oxidation
of the primary alcohol (63) to the aldehyde (D - 64).
11
O OSEM
OMEM
OMe OMOM OMe
OMEM
O
O
11
OR OSEM
OMEM
OMe OMOM OMe
OMEM
O
O
Pd/C, H2
EtOH, rt
R = Bn
R = H
(COCl)2, DMSO 
Et3N, CH2Cl2, -78°C
97%
98%
62
63
D - 64
Scheme 3.33. Synthesis of aldehyde D - 64
First, benzyl ether 62 underwent hydrogenolysis with a catalytic amount of palladium
on carbon, under bubbling of hydrogen gas in EtOH, giving 63 in 98 % yield. This was
followed by a Swern oxidation, giving aldehyde D - 64 in 97 % yield.
With this last step, we can conclude the synthesis of Building Block D (D - 64) in 6
steps from Building Block A (A - 31) and Building Block B (B - 39) (Scheme 3.34). In
comparison with the original route by Smans68, a MEM protecting group was replaced
with a MOM protecting group and several individual steps were further optimized. This
improved the synthesis, starting from A - 31 and B - 39, in a significant way, increasing
the total (isolated) yield from 31 % (82 % average yield per step) to 50 % (89 % average
yield per step), in the same number of linear steps. Furthermore, this route allowed for the
large-scale preparation of D - 64, ready for the coupling with C - 43 and further synthesis
towards vinyl iodide precursor 22.
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Me3OBF4
Proton-sponge®
MS 4Å, CH2Cl2, rt
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Cy2BCl, Et3N
Et2O, -78°C -> -45°C
94% total yield
d.r. 1.9:1
61% isolated yield
+
NaEt3BH
CH2Cl2, -78°C
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d.r. 49:1
(COCl)2, DMSO
Et3N, CH2Cl2, -78°C
96%
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A - 31B - 39
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Scheme 3.34. Synthesis of Building Block D (D - 64)
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3.3.3 Proof of stereochemistry
9
O OSEM
8 7
OMEM
5
OMe OMOM
3
OMe
2
OMEM
1 O
O
D - 64
Building Block D (D - 64) contains seven stereocenters, five of which are derived from the
chiral pool starting materials or are already proven, and also two new stereocenters, C5
and C7, which we correlated with already known stereocenters. Therefore, first the relative
stereorelationship between C5 and C7 was determined, followed by the relationship between
C7 and the known C9 stereocenter. In order to do this, the oxygenated stereocenters were
converted to conformationally rigid cyclic acetonides, from which their stereorelationship
was confirmed by using 13C NMR spectroscopy.
Starting from aldol product 45 (Scheme 3.35), the ketone was first reduced in a non-
diastereoselective way with NaBH4 in MeOH, which yielded two diols: 5,7-anti-diol 66
and 5,7-syn-diol 65 (yet to confirm). These diols were next converted with CSA in DMP
(2,2-dimethoxypropane) to the corresponding cyclic acetonides, 68 and 67 respectively. By
looking at the 13C chemical shifts of the acetonide methyl signals, both the trans- and cis-
configuration114–116 could be discerned. The 5,7-cis-acetonide 67 adopts a well-defined
chair conformation, resulting in equatorial R1 and R2 substituents, and also both an axial
and an equatorial acetal methyl substituent, which have 13C chemical shifts at 21.2 ppm
(axial methyl, expected ˜19 ppm) and at 31.2 ppm (equatorial methyl, expected ˜30 ppm).
The 5,7-trans-acetonide 68 on the other hand adopts a twist-boat conformation, in
order to avoid the 1,3-diaxial interactions that would arise in both possible chair confor-
mations, resulting in two acetal methyl substituents with similar chemical environments
and thus similar 13C chemical shifts, both at 26.3 ppm (expected both ˜25 ppm). Com-
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paring the obtained 13C chemical shifts of the acetal methyls, the configuration of both
5,7-diols could be confirmed.
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5,7-syn-diol 65 5,7-anti-diol 66
5,7-cis-acetonide 67 5,7-trans-acetonide 68
Scheme 3.35. Proof of the relative stereochemistry at C5 and C7 via cyclic acetonides
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The stereochemically confirmed 5,7-diols were next permethylated to the corresponding 5,7-
dimethoxy compounds and also reduced compound 47 was methylated to 5-O-methyl-47.
Comparison of the NMR spectra showed unambiguously that 5,7-anti-dimethoxy 70
and 5-O-methyl-47 were identical, which confirmed the 5,7-anti -relationship of 47.
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CH2Cl2
5,7-syn-diol 65 5,7-anti-diol 66
5,7-syn-dimethoxy 69 5,7-anti-dimethoxy 70
47 5-O-methyl-47
Scheme 3.36. Proof of the relative stereochemistry at C5 and C7
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To define the absolute stereochemistry of C5 and C7, the relationship between C7 and
the known stereocenter C9 was determined. This time we started from 5,7-anti-diol 66.
After cleavage of the SEM ether, 5,7-anti-7,9-anti-triol 71 was converted to
7,9-trans-acetonide 72. The 13C chemical shifts of the acetal methyl substituents
were again very similar, at 23.6 ppm and 24.3 ppm (expected both ˜25 ppm), which meant
that the cyclic acetonide adopted a twist-boat conformation, confirming the 7,9-anti -
relationship of 5,7-anti-7,9-anti-triol 71. As the configuration of C9 is known to be
(R), correlating C5 to C7 and C7 to C9 unambiguously reveals the absolute stereochemistry
of C5 and C7.
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Scheme 3.37. Proof of the absolute stereochemistry at C5 and C7 via correlation to C9
93

3.4 Synthesis of Building Block C
3.4 Synthesis of Building Block C
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1617 15
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C propargyl alcohol
Scheme 3.38. Retrosynthesis of Building Block C
The synthesis of Building Block C starts from propargyl alcohol (Scheme 3.38). A car-
bometalation reaction and an asymmetric aldol coupling are proposed to introduce the
desired stereochemistry. Efforts will be made to improve each step where possible.
3.4.1 Synthesis of the C12−C17 fragment (C - 43)
Anti -carbometalation
The first step in the synthesis towards C - 43 was the highly regioselective and stereose-
lective anti -carbometalation of propargyl alcohol to (Z )-iodomethylpropenol 40.
OH
OH
i)
 CuI, MeMgBr 
THF, Et2O
-20°C -> -10°C
ii)
 I2, rt
I
72%
propargyl alcohol 40
Scheme 3.39. Synthesis of propenol 40
While most of the synthetically useful carbometalation reactions involve syn-additions,
the carbomagnesiation reaction of propargylic alcohols with Grignard reagents seems to be
a useful exception on this general rule, enabling anti -additions in a highly regioselective
and stereoselective way117,118 (Scheme 3.40). In the first step, propargyl alcohol will
react with a first equivalent of the Grignard reagent MeMgBr. The resulting magnesium
alkoxide group will act as an intramolecular electrophile and coordinate the attack of a
second equivalent of MeMgBr, where the methyl group will regioselectively attack at the
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alkyne carbon near to the hydroxyl group, forming a magnesium chelated endocyclic five-
membered ring. The net result is the Grignard carbomagnesiation anti -addition. This
sensitive alkenyl magnesium intermediate is replaced by an iodine as electrophile119, by
the addition of I2 or ICl.
OH O
MgBrMe
Mg
Br
O
Mg
OH
MeMgBr I+
I
propargyl alcohol 40
Scheme 3.40. Mechanism of the carbomagnesiation/iodination of propargyl alcohol
It was found that the yield and reaction rate of these Grignard additions could be greatly
enhanced by the addition of a catalytic amount of cuprous halides118 (e.g. CuI). While
this initially suggested the presence of an organocopper intermediate, this hypothesis was
rejected and replaced by the suggestion that Cu0 was the catalyst metal. The exact inter-
mediate copper entities however are still not clarified.
The resulting vinyl iodide propenol moiety 40 has already been synthesized by many
groups120–122 and we were able to obtain 40 from propargyl alcohol in 72 % yield.
Oxidation and aldol coupling
The next step was the oxidation of primary allyl alcohol 40 to enal 41. As 41 turned out
to be a very sensitive and volatile compound, it was not isolated but immediately reacted
in the asymmetric aldol coupling with acetone to yield hydroxy ketone 42.
OH OOH O
D-proline, DMSO 
acetone, rt
77% (2 steps)
99% e.e.
MnO2, DMSO 
CH2Cl2, rt
I I I
40 41 42
Scheme 3.41. Synthesis of (S )-hydroxy ketone 42
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This posed some synthetic and practical challenges, as we needed an oxidation procedure
with a very simple and effective work-up, where aldehyde 41 could be separated from its
oxidation reagent without too much hassle, followed by an operationally simple setup for
the aldol coupling. It should be noted that a one-pot procedure is not feasible, as this would
lead to overoxidation to the diketone. For the first step, the oxidation of the allyl alcohol,
the use of MnO2 was proposed. This black powdered reagent, which is especially suitable for
the oxidation of allyl alcohols, is often needed in a large excess to obtain total conversion,
but the work-up is as simple as a filtration over a fritted funnel. For the asymmetric
aldol coupling, as the nucleophile is again derived from acetone, the use of D-proline was
proposed. In comparison with A - 31, where L-proline was used in a diastereoselective
step to obtain separable diastereomers (d.r. 16:1), it was now very important to obtain
a very high enantioselectivity, as it is not feasible to separate these enantiomers on a
large preparative scale over a chiral column. Therefore, our quest was to find a suitable
solvent system for the oxidation, which also allowed for a high enantioselectivity in the
aldol coupling reaction with D-proline.
Preliminary results have shown that DMSO as a solvent, for both oxidation with MnO2
and aldol coupling with D-proline and acetone, delivered 42 in 61 % yield and 97 % e.e.
on a small scale (up to 1 g of 40). Scaling up however seemed problematic, as the fritted
funnel clogged due to the viscous MnO2-DMSO slurry. The MnO2 could be removed by
centrifugation, but this was cumbersome and led to a further decrease in yield to only
48 %. Furthermore, to obtain enantiopure (> 99 % e.e.) 42, a laborious and low yielding
recrystallization was needed. Our efforts thus also included the quest for a clogging-free
filtration protocol with higher enantioselectivity to avoid the recrystallization.
Therefore, a series of tests on a 1 mmol scale were performed (Table 3.4). When con-
ducting both the oxidation and aldol coupling in DMSO (entry 1), both reactions gave
fast and total conversions, with an already very high enantioselectivity (97.9 % e.e.) and a
moderate isolated yield (60 %). When changing the oxidation solvent to acetone (entry 2),
enantioselectivity and yield dropped dramatically; when using both DMSO and acetone
for the oxidation (entry 3), enantioselectivity and yield were less diminished. This drop
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in enantioselectivity could mean that aldehyde 41 already reacted with acetone without
D-proline, in a non-enantioselective way. Because of the clogging problems with DMSO,
other solvents were tried to (partially) replace DMSO in the oxidation. Acetone clearly
was a bad choice, so our next attempt was Et2O (entry 4). This however, gave very low
reaction rates in both the oxidation and aldol coupling and it was necessary to add DMSO
during the aldol coupling to obtain a meaningful conversion. The enantioselectivity was
quite good (94.7 % e.e.) but the yield unsurprisingly low. Our next attempts (entries 5-8)
were with CH2Cl2. This seemed to considerably slow down both the oxidation and the
aldol coupling, leading to moderate yields (49-51 %) when the oxidation was not allowed
to reach complete conversion (entries 5 & 7), but improved yields (72-73 %) when the oxi-
dation was left standing for 2-3 days (entries 6 & 8). Without the addition of any DMSO
(entries 5 & 6), the aldol coupling was very slow, but without affecting the yield and with a
high enantioselectivity. The addition of DMSO in the aldol coupling step (entry 7) consid-
erably improved the reaction rate with a small increase in enantioselectivity. Changing the
oxidation solvent from solely CH2Cl2 to a 1:1 CH2Cl2:DMSO mixture (entry 8) seemed to
further improve the enantioselectivity. These were also the final conditions that were ap-
plied in the large-scale reaction (entry 9). After 62 h of oxidation at rt, with 20 eq. of MnO2
in a 1:1 CH2Cl2:DMSO mixture, the reaction mixture was filtrated without any clogging
problems, into a flask containing DMSO and 1 eq. of D-proline and the filter was rinsed
with acetone. After total consumption of intermediate aldehyde 41, work-up followed and
42 was obtained in 77 % yield with a very high enantioselectivity (98.6 % e.e.) which was
judged good enough to avoid the laborious and low yielding recrystallization protocol.
99
3. Results and Discussion
Protection of the alcohol
The last step in the synthesis of C - 43 was protection of the secondary alcohol (42) as
a PMB (p-methoxybenzyl) ether (C - 43). This PMB protecting group can later on in
the synthesis be selectively deprotected with reagents like DDQ or CAN, prior to the
macrolactonization.
OPMB OOH O
, Ph3CBF4
96%
I I
O
O NH
CCl3
THF, rt
42
44
44 C - 43
Scheme 3.42. Synthesis of PMB ether C - 43
OOH OI I
acid/base
elimination
42 73
Scheme 3.43. Unwanted elimination of 42
Although protecting an alcohol should be straightforward, the alcohol moiety of 42 exhib-
ited a high sensitivity towards base- and acid-induced elimination reactions, as this leads
to the very stable and highly conjugated vinyl iodide dienone product 73 (Scheme 3.43).
Williamson ether synthesis conditions (strong base + PMB-Cl/PMB-Br) turned out to be
too harsh and therefore the use of PMB-trichloroacetimidate 44 in combination with a
mild acid activator was proposed. Preliminary results68 with different acid activators
(PTSA, CSA, TfOH, PPTS and Ph3CBF4) have shown that only the use of Ph3CBF4
afforded good results, although these were often hard to reproduce. It was found very
important to synthesize PMB-trichloroacetimidate 44 ourselves, instead of using the com-
mercially available reagent and also to prepare it freshly, prior to the protection reaction.
Even with the freshly prepared reagent, TLC analysis showed a complex reaction mixture
with a lot of side-products which complicated the purification. As an excess of PMB-
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trichloroacetimidate 44 was needed for complete conversion, tests were done to figure out
how low this excess could be and if the reaction was upscalable (Table 3.5). Lowering the
number of equivalents of 44 from 3 to 2.5 to 2 (entries 1-3), led to longer reaction times,
which resulted in lower yields. Therefore the use of 3 equivalents of 44 was maintained.
Unfortunately, scaling up had a much bigger influence on the yield (entries 4 & 5), as going
from 2.0 mmol to 4.8 mmol to 13.4 mmol led to a dramatic decrease in yield from 96 %
to a mere 67 %. As time was limited and in the meantime a sufficient amount of C - 43
was obtained, no further investigation was performed to optimize the upscalibility of this
reaction.
Table 3.5. PMB protection of 42a
nr 42 (mmol) 44 (eq.) t (h) C - 43b
1 2.0 3 3.5 96 %
2 2.0 2.5 4.7 95 %
3 2.0 2 5.5 90 %
4 4.8 3 4.2 81 %
5 13.4 3 3.5 67 %
a 42 and Ph3CBF4 (0.1 eq.) were added to 44 in THF at 0
◦C,
followed by reaction at rt, until TLC showed complete conversion
b isolated yield after flash chromatography
With this last step, we can conclude the synthesis of Building Block C (C - 43) in 4
steps from propargyl alcohol (Scheme 3.44). Here we were able to improve the original
synthesis68 in a significant way, increasing the total (isolated) yield from 36 % (78 % average
yield per step; 97 % e.e.) to 53 % (85 % average yield per step; 99 % e.e.), in the same number
of linear steps. Moreover, this synthesis allowed the large-scale preparation of C - 43.
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THF, Et2O
-20°C -> -10°C
ii)
 I2, rt
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44C - 43
Scheme 3.44. Synthesis of Building Block C (C - 43)
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3.4.2 Proof of stereochemistry
16
15
OPMB O
17
I
C - 43
Building Block C (C - 43) contains a single stereocenter at C15 and a trisubstituted double
bond with Z configuration at C16−C17 that had to be confirmed. Fortunately, crystals could
be obtained from its hydroxy ketone precursor 42, allowing confirmation of the absolute
configuration by single crystal X-ray diffraction. Because of the heavy iodine atom present
in 42, its structure and absolute configuration could be confirmed with 99 % certainty.
Figure 3.1. Structure of 42 as determined by X-ray diffraction
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Scheme 3.45. Retrosynthesis of vinyl iodide precursor 22
With both large amounts of Building Block C and D in hand, we could commence the final
stretch of the synthesis towards vinyl iodide precursor 22 (Scheme 3.45). Therefore, first
Building Block C and D will be coupled via an aldol reaction, followed by protection of the
new C11 alcohol with an acetal type protecting group. The next step is the diastereoselective
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reduction of the C13 ketone followed by methylation. Then all the required stereocenters
will be installed, allowing us to start with some selective deprotections and functional group
transformations. First the selective deprotection of the C9 SEM ether and oxidation to the
ketone will be investigated. The next step is the deprotection of the C15 PMB ether and
the C1 acetonide, followed by oxidative cleavage to the C1 carboxylic acid, yielding the fully
functionalised acyclic seco-acid 24. Finally, this seco-acid can undergo a macrolactonization
to vinyl iodide precursor 22.
3.5.1 Aldol coupling of Building Block C and D
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70% isolated yield
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C - 43 D - 64
74
Scheme 3.46. Aldol coupling of C - 43 and D - 64
Strategy
For the aldol coupling of Building Block C and D, a similar boron enolate strategy was
proposed, as the one depicted for the aldol coupling of Building Block A and B (p. 82).
Using a boron enolate, β-alkoxy aldehyde D - 64 should have only minor 1,3-anti -inducing
effects, while β-alkoxy ketone C - 43 now bears a PMB ether, which should result in a major
1,5-anti -inducing effect105–113. This can be achieved with the use of Cy2BCl or Bu2BOTf
(Scheme 3.47). Also chiral boron ligands will be tested. This time, (+)-DIP-Cl should be
able to reinforce the formation of the desired 1,5-anti -product 74, while (−)-DIP-Cl should
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be able to overrule the inherent inducing effect of both ketone and aldehyde to induce the
undesired 1,5-syn-product 75.
O OHOPMB
O OHOPMB
OPMB OI O OSEM
R
R
OSEM
R
OSEM
I
I
Cy2BCl
or Bu2BOTf
or (+)-DIP-Cl
(-)-DIP-Cl
+
1,5-anti
1,5-syn
C - 43 D - 64
74
75
Scheme 3.47. Expected stereocontrol of the aldol coupling of C - 43 and D - 64
Results
A lot of effort was put in finding the optimal conditions for the asymmetric aldol coupling,
from which the most important results are outlined in Table 3.6.
A first series of tests (entries 1-4) included the use of the four different proposed boron
reagents, in order to see if the obtained products were the expected ones according to our
strategy and the underlying theory (Scheme 3.47). While the use of (−)-DIP-Cl seemed
to completely overrule the facial bias of ketone C - 43 and aldehyde D - 64 to provide 75
(anti :syn 1:99) as expected, (+)-DIP-Cl was not able to reinforce the 1,5-anti induction,
but instead unexpectedly afforded 75 with low diastereoselectivity (anti :syn 35:65). This
led us to believe that the facial bias of ketone C - 43 and aldehyde D - 64 preferentially
induced the undesired 1,5-syn-product 75. Indeed, the use of Cy2BCl also led to the
undesired 75 (anti :syn 45:55) but fortunately, the use of Bu2BOTf gave the desired 1,5-
anti -product 74 with good diastereoselectivity (anti :syn 80:20). An explanation for this
odd behavior can probably be found in the size of the boron ligands (the bulky ligands
of Cy2BCl, (−)-DIP-Cl and (+)-DIP-Cl versus the smaller ligands of Bu2BOTf), but this
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seems contradictory if we take a look at the expected TS structures (Scheme 3.30, p. 84).
This further confirms our thoughts about the undesired and unexpected facial basis of
ketone C - 43 and aldehyde D - 64.
Satisfied about the fact that we found a reagent that yielded the desired diastereomer
against all odds, our next tests focused on other reaction parameters in order to further
optimize the conversion and diastereoselectivity.
First the solvent was addressed (entries 5-7). Unfortunately, changing the solvent from
Et2O to CH2Cl2 or toluene decreased both the conversion and diastereoselectivity. Next
the influence of the temperature was investigated. Thermodynamic conditions (entry 8)
were not beneficial for the diastereoselectivity, while improved kinetic conditions (entry
9) decreased the conversion without improving the diastereoselectivity. As CH2Cl2 was
disadvantageous as a solvent and the Bu2BOTf used was a 1m sol. in CH2Cl2, we tried to
switch to a 1m sol. of Bu2BOTf in Et2O, but this was detrimental for the reaction (entries
10-11). Even adding some CH2Cl2 to the reaction mixture was not enough to revert the
outcome. Until now, 3 eq. of ketone (and the accompanying excess of base and borane) were
used to obtain acceptable conversions. Although the excess of ketone could be recovered
during purification, use of a lower excess of ketone was tried, but the conversion dropped
dramatically (entries 12-13). Finally, we had to return to our original conditions and in the
large-scale reaction, 74 was obtained in 86 % yield (calculated on both diastereomers) and
good diastereoselectivity (anti :syn 82:18), after which the diastereomers were separated by
flash chromatography, affording 74 in 70 % yield.
3.5.2 Synthesis of vinyl iodide precursor 22
Protection of C11, diastereoselective reduction and methylation of C13
The next series of steps towards vinyl iodide precursor 22 included protection of the new
stereocenter at C11 (74) with an acetal type protecting group, diastereoselective reduction
of the C13 ketone (76) with formation of the last stereocenter, followed by methylation of
the new C13 alcohol moiety (77), affording methyl ether 78 (Scheme 3.48).
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Scheme 3.48. Synthesis of methyl ether 78
The C11 alcohol was the last one that needed to be protected with an acetal type protect-
ing group and this time we chose a BOM (benzyloxymethyl) ether. When using LC-MS
analysis to monitor our reactions, the recorded UV spectrum is a very powerful and often
indispensable tool to identify and quantify the reaction products with ease. Once the
PMB ether is removed however, our product would have a very low intrinsic UV activity,
making it almost impossible to monitor the often very complex reaction mixtures. BOM
ethers are the only acetal type protecting group known with a significant UV activity and
therefore fit perfectly in our protecting group strategy. A large excess of BOM-Cl (10 eq.)
and DIPEA (13 eq.) in refluxing CH2Cl2 were needed to obtain 76 in 100 % yield.
For the diastereoselective reduction of a ketone, a plethora of methods and reagents are
available, both chiral and achiral, to induce the desired diastereomer. As our C13 ketone has
two neighboring stereocenters (the C11 BOM ether and the C15 PMB ether), we anticipated
on the chiral and sterical environment of the ketone, in combination with achiral reductive
borohydride reagents with small to large alkyl ligands, in different solvents (Scheme 3.49).
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Scheme 3.49. Diastereoselective reduction of 76
Table 3.7. Diastereoselective reductiona of 76 with different reductive reagents in different sol-
vents; obtained mixtures of 77:79
CH2Cl2 THF Et2O toluene
K(s-Bu)3BH 57:43 70:30 83:17 58:42
Na(s-Bu)3BH 86:14 56:44 87:13 85:15
Li(s-Bu)3BH 77:23 75:25 77:23 82:18
KEt3BH 20:80 42:58 44:56 32:68
NaEt3BH 30:70 41:59 59:41 37:63
LiEt3BH 63:37 61:39 60:40 65:35
Li-9-BBN-H 35:65 46:54 40:60 41:59
LiSia3BH 59:41 63:37 69:31 67:33
a 2 mg of 76 was dissolved in the solvent of choice (0.01m),
followed by addition of 6 eq. of the reductive reagent at 0 ◦C;
after 30 min work-up followed and the diastereomeric ratio
was determined by LC-MS analysis
Therefore, a large series of small-scale tests were conducted, with eight reagents in four
solvents (Table 3.7). The values in orange represent the combinations which provided
the undesired diastereomer 79 as the main compound, while the values in green represent
the combinations with the desired diastereomer 77 as the main compound. The values in
dark green are the most interesting, as they represent the combinations with more than
80 % of the desired diastereomer 77. One can easily notice the strong but unpredictable
influence of both the solvent and counter-ion (K+, Na+ or Li+), but it seemed that the X(s-
Bu)3BH reagents in general returned the best results, from which Na(s-Bu)3BH seemed
least dependent on the solvent. The best overall combination was Na(s-Bu)3BH in Et2O,
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resulting in a d.r. of 87:13 (as shown in bold).
In theory, the borohydride reagent can attack the ketone from two opposite diastereotopic
faces, resulting in two possible C13 alcohol diastereomers, which are either the desired
alcohol 77 or the undesired alcohol 79. The product ratio
[77]
[79]
depends on the reaction
rate (k77, k79) of both reactions according to Eq. 3.1-Eq. 3.3 (assuming perfect kinetic
control). According to Eq. 3.3-Eq. 3.6, both k77/79 and d.e. depend on the difference in
activation energy (∆Ea) between the two possible reaction routes.
k77 = e
−
Ea77
RT (3.1)
k79 = e
−
Ea79
RT (3.2)
[77]
[79]
=
k77
k79
= k77/79 = e
−
∆Ea
RT (3.3)
⇐⇒ ∆Ea = −ln(k77/79)RT
with ∆Ea = Ea77 − Ea79
If x =
[77]
[77] + [79]
, then (3.4)
k77/79 =
x
1− x ⇐⇒ x =
k77/79
1 + k77/79
, and (3.5)
d.e. = x− (1− x) = 2x− 1 ⇐⇒ x = d.e. + 1
2
(3.6)
With the experimental d.e. value of 74.3 % at 0 ◦C, ∆Ea was calculated to be -4.34
kJ/mol. With the above equations, also k77/79 and % d.e. versus temperature were
plotted (Fig. 3.2), where it was noticed that lowering the temperature (leaving all the
other experimental parameters equal) from 0 ◦C to −78 ◦C or −96 ◦C could yield a d.e. of
resp. 87.2 % or 90.1 %.
This plot assumes that the reaction proceeds under perfect kinetic control and that ∆Ea
is nearly constant over the applied temperature range. Testing the theory by conducting
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Figure 3.2. Plot of k77/79 and % d.e. versus T (∆Ea = -4.34 kJ/mol)
the reaction at −78 ◦C yielded 77 with 87.4 % d.e., which was in near perfect accordance
with the plot. Confident with this result, we tried lowering the temperature even further,
to −96 ◦C (CH2Cl2, liq. N2) but this seemed to slow down the reaction dramatically (only
24 % conversion after 1.5 h). This was a problem, as maintaining these conditions for long
reaction times was not feasible. After continuing the reaction at −78 ◦C for 2 h, we were
able to obtain 77 in a moderate yield of 72 % but with a high diastereoselectivity (89 %
d.e.; d.r. 17:1). After purification by flash chromatography, diastereopure 77 was obtained
with an overall yield of 68 %.
The alcohol at C13 needed next to be methylated. This was done under the Meerwein
conditions as applied earlier in the synthesis, affording 78 in 94 % yield.
Deprotection and oxidation of C9
With all stereocenters installed and all alcohol moieties either protected with an acetal type
protecting group or methylated, we could start with the necessary selective deprotections
and functional group transformations. First in line was the deprotection of the SEM ether
(78) to the secondary alcohol (80), followed by the oxidation of this alcohol to the ketone
(81), which after the final deprotection will be part of the pyranose ring as the anomeric
carbon (Scheme 3.50).
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Scheme 3.50. Synthesis of ketone 81
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Scheme 3.51. Deprotection of a SEM ether and the known side-reaction
SEM ethers are being used as alcohol protecting groups because of their easy introduction,
their broad pH stability, their selective cleavage with fluoride ion and their orthogonal
conditions for protection and removal in the presence of other functionalities123. However,
these SEM ethers are sometimes too robust and difficulties may arise with their deprotec-
tion, especially when sterically hindered. Low yields of deprotection often occur when using
standard conditions (TBAF in HMPA) and also a side-reaction is known which only desily-
lates the SEM ether, leaving an EOM (ethoxymethyl) ether instead of the fully deprotected
alcohol (Scheme 3.51). While there seems to be no real explanation why the desilylation
occurs instead of the cascade deprotection, the problem itself can be addressed by adding
molecular sieves (MS 4 A˚)124 to obtain dry HMPA or by switching to DMPU125 (with MS
4 A˚) as the solvent. These dry conditions and the polarity of the solvent can be critical for
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certain substrates. Until now, we only obtained excellent results (>90 % yield and (almost)
none of the EOM side-product) upon using TBAF in HMPA with MS 4 A˚, when depro-
tecting the SEM ether in order to determine the stereochemistry (Scheme 3.58, p. 124).
When trying to deprotect the SEM ether of 78 however, already with the first small-scale
attempt (0.022 mmol), the formation of 82 was observed. Next attempts were even worse,
with low conversion and a high amount of 82 being formed, which led us to believe that
the introduction of water (even by taking TLC samples) was very harmful to obtain a good
deprotection. Unfortunately, switching to DMPU was ineffective as this slowed down the
reaction dramatically and was yet not able to prevent the formation of 82. When scaling
up (0.86 mmol), attempts were made to work as dry as possible, but nonetheless a high
amount of 82 was formed and also another undefined side-product was formed, suggesting
epimerization. This resulted in a very difficult and low-yielding purification by flash chro-
matography, and only 39 % yield of pure 80 was obtained. Although disappointed by this
result, we believe that optimization is still possible (as not every option was explored), but
a lack of time and product prevented further research.
The subsequent oxidation fortunately went very smoothly with DMP (Dess-Martin perio-
dinane) in CH2Cl2 at 0
◦C and 81 was obtained in 87 % yield.
Deprotection of C1 and C15; Transformation to seco-acid 24
With the C9 ketone (81) installed, we could continue with the deprotection of the C15 PMB
ether and the C1 acetonide protecting group, followed by transformation of the vicinal diol
(84) to the aldehyde (85) and subsequently to the carboxylic acid (24) (Scheme 3.52).
In the original synthesis route, we first planned to deprotect the PMB ether oxidatively
(using either DDQ or CAN), followed by acid hydrolysis of the terminal acetonide. As we
experienced CAN (cerium(IV) ammonium nitrate) as a suitable and convenient reagent for
the deprotection of a PMB ether (Scheme 3.60, p. 128), we tested its use on a small scale
(0.01 mmol) and found a clean and complete conversion at 0 ◦C after 4.5 h. Performing
the same conditions on a larger scale (0.13 mmol), we again obtained a clean and complete
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Scheme 3.52. Synthesis of seco-acid 24
conversion, but we now discovered not only the deprotected 83, but also a more than
equal amount of 84, which had lost its acetonide protecting group. Although at that
time unexpected, it was not impossible. CAN has some unique properties126–129, making
it possible to deprotect different protecting groups through different reaction mechanisms
(Scheme 3.53). As a powerful oxidizing agent, it can deprotect PMB ethers via a sequence
of single electron transfers and a hydrogen transfer, yielding an oxonium ion which is
stabilized by resonance with the para-methoxy group. Upon hydrolysis of this oxonium
ion, first the hemi-ketal and finally para-methoxybenzaldehyde and alcohol 83 are obtained.
The Ce(IV)-salt can also function as a catalytic Lewis acid and deprotect the acid sensitive
acetonide protecting group of 83 to yield the vicinal diol 84. Deprotection of acetals and
ketals is also possible in a similar oxidative way as the PMB deprotection, but that would
not yield the vicinal diol and was also not encountered. Finally, CAN is also able to function
as a Brønstedt acid, by the formation of a small amount of HNO3. However, typical
conditions for the use of CAN to deprotect acetals or ketals (like our acetonide), require
high temperatures up to 70 ◦C, while our reactions were performed at 0 ◦C. As we needed
to deprotect the acetonide anyway, this side-reaction could turn out advantageously as it
seemed that we could deprotect both the PMB ether and the acetonide of 81 to triol 84 in
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Scheme 3.53. Double deprotection by CAN
a single step. When similar conditions were applied to a similar substrate (Scheme 3.60),
only a negligible amount of acetonide deprotection was observed, so for reasons unknown,
our substrate (81, 83) is very sensitive towards CAN concerning the acetonide deprotection.
Confident about this one-pot strategy, 81 was reacted with CAN under identical conditions
as before, but overnight, to allow complete conversion of 83 to 84. After work-up however,
a large amount of side-products seemed to have formed. Because of this complex mixture
of side-products, their exact identity could not be unraveled, but the available spectral
data seemed to suggest that not only the acetonide was deprotected, but also one and/or
both of the MEM protecting groups. To the best of our knowledge, this is unprecedented in
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literature or in our own work with similar substrates and conditions, and thus completely
unexpected. As a result, after purification, only 45 % yield of 84 was obtained.
Subsequently, the oxidative cleavage of the vicinal diol of 84 with NaIO4 to aldehyde 85 was
investigated. As this was quite trivial and had been done before (Scheme 3.23, p. 75), no
problems were expected or encountered, except for the purification. Next to the possibility
of epimerization, this aldehyde seemed to be very reactive towards hydration. While both
aldehyde 85 and its hydrate (86) were present as sharp peaks in the LC-MS chromatogram,
on purification by flash chromatography (and on the TLC plate), 85 and 86 seemed to
be in a dynamic equilibrium which led to excessive peak broadening and extreme tailing,
rendering purification on silica gel almost impossible. As LC-MS analysis made clear that
85 (and 86) was very pure, even without purification, a quantitative amount of 85/86 was
obtained after the extractive work-up and was used as such in the subsequent oxidation
step.
The last step towards seco-acid 24 was the oxidation of aldehyde 85, where a Pinnick oxida-
tion was proposed (Scheme 3.54). This very mild oxidation uses NaClO2 as the oxidative
agent, with 2-Me-2-butene as a HOCl scavenger, under buffered (NaH2PO4) conditions,
in t-BuOH/H2O at room temperature, with an excellent functional group tolerance and
leaving aldehyde α-carbon stereocenters unaffected. The reaction went very smoothly, but
the purification by flash chromatography appeared to be cumbersome. As we wanted to
avoid the use of AcOH in the eluent and as LC-MS analysis confirmed that our product
was already very pure after extractive work-up, a quantitative amount of 24 was obtained
and was used as such in the subsequent macrolactonization step.
Macrolactonization
The only step left towards vinyl iodide precursor 22 was the intramolecular ring-closing
of seco-acid 24. For this esterification, the Yamaguchi macrolactonization protocol was
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Scheme 3.54. Pinnick oxidation of 85 to seco-acid 24
proposed, which has been used with success in numerous syntheses, including most of the
total syntheses of peloruside A43–47 and its analogues6,48,51,53.
This reaction relies on the activation of the carboxylic acid, making it more susceptible to
nucleophilic attack of the C15 alcohol (Scheme 3.56). Therefore, seco-acid 24 first gets
converted to mixed anhydride 22.2, by reaction with 2,4,6-trichlorobenzoyl chloride (22.1)
and DIPEA in THF, releasing the DIPEA·HCl salt. Next, 22.2 is diluted in toluene and
added very slowly to a (heated) solution of DMAP in toluene. DMAP, which is a known
nucleophilic catalyst for acyl transfer reactions, will then attack 22.2 regioselectively at
the carboxyl carbon furthest from the sterically hindered trichlorobenzoyl group, with for-
mation of acyl pyridinium salt 22.4 and elimination of aromatic carboxylate anion 22.3.
Intermediate 22.4 will then undergo an intramolecular attack of the alcohol moiety, with
formation of the ring-closed macrolactone 22. To avoid intermolecular coupling, the reac-
tion is conducted under high-dilution conditions (∼ 0.001m). When conducting the reac-
tion, the formation of the mixed anhydride was impossible to follow by TLC analysis, but
after the assumed consumption of 24, dilution with toluene and slow addition to a high-
diluted solution of DMAP in toluene, TLC analysis showed the immediate formation of
macrolactone 22 (even at room temperature) and no signs of seco-acid 24. After reaction
overnight at elevated temperature to ensure total conversion, extractive work-up followed
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and after purification by flash chromatography, not only 22 was isolated in 56 % yield (over
3 steps), but also 22 % yield of the undesired diolide 87 was recovered. In early attempts
to perform the macrolactonization, the formation of 87 was passed by unnoticed, as in the
LC-MS analysis of the reaction mixture, diolide 87 had a significantly lower UV activity
compared to macrolide 22 and was very hard to ionize, making it almost undetectable.
Only after isolation of the different products of the large-scale macrolactonization, diolide
87 could be identified. Under the high-dilution conditions applied, formation of this cyclic
dimer is quite unexpected. Concerning the total syntheses of peloruside A and some ana-
logues (vide supra), only Wullschleger51 seemed to have encountered a similar diolide. As
an explanation for this behavior, maybe the mixed anhydride 22.2 was already activated
enough, without the need for the DMAP acyl transfer catalyst, and was therefore able to
react intermolecularly while being more concentrated in THF. If so, this problem could be
overcome by synthesizing the mixed anhydride 22.2 in a diluted toluene solution, as per-
formed in the total synthesis of peloruside A by Ghosh44 and Hoye47. If the intermolecular
coupling could be suppressed, than this could turn the already good yield (in comparison
with the other total syntheses) to an excellent yield.
With this last step, we can conclude the synthesis of vinyl iodide precursor 22 in 10 steps
from Building Block C (C - 43) and Building Block D (D - 64) (Scheme 3.57). While
most of these steps deliver satisfying yields, improvements still need to be made and are
most certainly possible for the SEM, PMB and acetonide deprotection, and also for the
macrolactonization, where formation of diolide 87 should be avoided. Starting from C - 43
and D - 64, vinyl iodide precursor 22 could be obtained in 10 steps (3.8 % total (isolated)
yield; 72 % average yield per step). The longest linear sequence to obtain 22 (starting from
L-ascorbic acid) comprises 23 steps (0.93 % total (isolated) yield; 82 % average yield per
step).
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3.5.3 Proof of stereochemistry
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Vinyl iodide precursor 22 contains a trisubstituted double bond with Z configuration at
C16−C17 that was proven by single crystal X-ray diffraction, and also eight stereocenters,
six of which are derived from the chiral pool starting materials or are already proven.
It also contains two newly formed stereocenters, C11 and C13, which we correlated to
already known stereocenters. Therefore, the relationship between C11 and the known C9
stereocenter (which is oxidized later on) was determined and also the relationship between
C13 and the known C15 stereocenter. In order to do this, the oxygenated stereocenters were
converted to conformationally rigid cyclic acetonides, from which their relationship was
proven by using 13C NMR spectroscopy, as described before for C5 and C7 (Scheme 3.35,
p. 91 and Scheme 3.37, p. 93).
Stereochemistry of C11
To determine the relationship between the C9 and C11 stereocenters, our strategy was to
start from the aldol product that was obtained from the aldol coupling with (−)-DIP-Cl
(Table 3.6, p. 108), as it was the only reaction that provided us with a significant amount
of aldol product with a diastereoselectivity that was high enough to unambiguously as-
sign the stereochemistry, even though it was suspected to be the undesired diastereomer
75. To proof that it was the undesired 75, we first tried to deprotect the SEM ether
of aldol product 75, to assign the stereochemistry via the acetonide of the obtained diol
(Scheme 3.58). Unfortunately, the reaction conditions applied to deprotect the SEM ether
(TBAF in HMPA) were too basic and led to retro-aldol reaction and elimination of hydroxy
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Scheme 3.58. Proof of the absolute stereochemistry at C11 via correlation with C9
ketone 75. Therefore, we worked around this ketone by first performing a highly diastereos-
elective 1,3-anti -reduction with Me4NBH(OAc)3, followed by a regioselective methylation
to obtain 91 (permethylation could not be avoided, not even at −40 ◦C, but a sufficient
amount of 91 could be isolated). Deprotection of the SEM ether was now without any
problem, and diol 92 was converted to its corresponding acetonide 93 with DMP and
CSA. The 13C chemical shifts of 19.6 ppm (axial methyl, expected ˜19 ppm) and 30.9
ppm (equatorial methyl, expected ˜30 ppm) confirmed that acetonide 93 adopted a chair
conformation, which meant that the C9 and C11 stereocenters were in a syn-relationship.
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This confirmed that the aldol product obtained with the use of (−)-DIP-Cl was indeed
the undesired diastereomer 75, and thus the major compound, obtained with the use of
Bu2BOTf, was the desired diastereomer 74.
Stereochemistry of C13
To determine the relationship between the C13 and C15 stereocenters, ketone 76 was first
reduced in a non-diastereoselective way with DIBAL-H in CH2Cl2, which yielded both
13,15-syn 77 and 13,15-anti 79 (Scheme 3.59). Our initial strategy was similar as the
one used for the determination of the C5 stereocenter (Scheme 3.35, p. 91). Therefore, we
wanted to deprotect the PMB ether in both 77 and 79 to obtain the 13,15-syn-diol 94 and
the 13,15-anti -diol 95. When using DDQ in CH2Cl2 : pH 7 buffer (2:1) however, almost no
94 and 95 were obtained, but instead PMP acetals 96 and 97 were identified. This was
unexpected, as to make these PMP acetals, anhydrous conditions are normally required
to prevent the complete deprotection to 94 and 95. Therefore, the reaction was repeated
with CAN instead of DDQ. CAN also works as a one electron oxidizing agent, but can be
used in a miscible ACN/H2O solvent system, which should favor the deprotection. This
time, it seemed that the 13,15-syn 77 (yet to confirm) predominantly was converted to the
PMP acetal 96, while the 13,15-anti 79 (yet to confirm) seemed to predominantly undergo
deprotection to the 13,15-anti -diol 95. This behavior could be rationalized by looking at
the reaction mechanism (Scheme 3.59; see also Scheme 3.53, p. 117). After losing two
electrons and a proton, the oxonium ion can either be attacked by H2O, which leads to
deprotection, or by a neighboring hydroxyl moiety, which leads to PMP acetal formation.
One could speculate that the hydroxyl moiety of 13,15-syn 77 has a higher probability to
attack the oxonium ion, as the hydroxyl moiety of 77 will be in closer proximity than the
one of 79. Furthermore, this would lead to a stable chair-like cyclic PMP acetal 96, in
comparison to a higher-energy twist-boat-like cyclic PMP acetal 97.
To prove this theory (Scheme 3.60), 76 was reduced with DIBAL-H in CH2Cl2 and
the obtained 77 and 79 were separated. The presumed 77 was converted with DDQ
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Scheme 3.59. Proof of the absolute stereochemistry at C13 via correlation with C15
in CH2Cl2 : pH 7 buffer (10:1) to PMP acetal 96. This cyclic 13,15-cis PMP acetal will
adopt a chair-like conformation, which results in three axial hydrogens which are in close
enough proximity to be determined by a NMR NOESY experiment. The axial acetal hy-
drogen showed strong NOEs with both hydrogens at C13 and C15, which is only possible
with the 13,15-cis PMP acetal, and thus confirms its configuration.
To obtain extra proof, the presumed 79 was deprotected with CAN in ACN/H2O and
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subsequently converted to acetonide 99 with CSA in DMP. The 13C chemical shifts of
the acetal methyl protons were again very similar, at 25.4 ppm and 25.7 ppm (expected
both ˜25 ppm), which meant that the cyclic acetonide adopted a twist-boat-like conforma-
tion, which confirmed the 13,15-anti -relationship of 79. In this way, both desired 77 and
undesired 79 could be stereochemically confirmed.
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4.1 Aim and strategy
The aim of this PhD thesis was to explore the SAR of the side-chain of peloruside A, a
promising macrocyclic lactone with a microtubule stabilizing activity, which can be used in
the fight against cancer. Therefore, the design and synthesis of peloruside A and two sets
of side-chain analogues was proposed, which can be accessed through a Stille and Suzuki
coupling strategy (Scheme 4.1).
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Scheme 4.1. Stille and Suzuki coupling strategy
Both strategies require the synthesis of a sufficient amount of vinyl iodide precursor 22.
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Scheme 4.2. Retrosynthetic approach
The proposed retrosynthetic approach (Scheme 4.2) consists first of the opening of the
macrolactone, resulting in the acyclic C1−C17 seco-acid 24, followed by a highly conver-
gent asymmetric aldol coupling strategy. The first retro-aldol disconnection can be made
between C11 and C12, leading to Building Block C (the C12−C17 fragment), which can be
synthesized from propargyl alcohol, and Building Block D (the C1−C11 fragment). The
latter can be further disconnected between C6 and C7, affording Building Block A (the
C1−C6 fragment) and Building Block B (the C7−C11 fragment), which can be synthesized
from L-ascorbic acid and neopentylglycol respectively. Synthetic routes to obtain each
building block were developed during the PhD thesis of Gert Smans68, but each route had
its shortcomings and/or practical limitations, which impeded their efficient and large-scale
preparation.
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Therefore, during this PhD thesis, three objectives were pursued:
• optimization of the known syntheses68 of Building Block A, B, C and D, tackling
the shortcomings, and in doing so, providing a practical and upscalable multigram
procedure and a sufficient amount of Building Block C and D
• aldol coupling of Building Block C and D and further synthesis towards a sufficient
amount of vinyl iodide precursor 22
• design and synthesis of peloruside A and side-chain analogues, according to the Stille
and Suzuki coupling strategy
133
4. Conclusions and future perspectives
4.2 Synthesis, optimization and scaling up of Building
Block A, B, C and D
Building Block A
O O
O
O
HO OH
H
O OH
OH
O
HO OH
H
acetone, AcCl, rt
EtO
O
O
OH
O
EtO
O
O
OMEM
O O
O
OMEM
OH
O
O
OMEM
O O
O
OMEM
OMeOO
O
OMEM
OHO
79%
i)
 K2CO3,H2O2, H2O, rt
ii)
 EtBr, ACN, reflux
90%
MEM-Cl, DIPEA
CH2Cl2, reflux
98%
DIBAL-H
Et2O, rt
93%
(COCl)2, DMSO, Et3N
CH2Cl2, -78°C
96%
L-proline, (S)-BINOL
acetone, rt
94% total yield
d.r. 16:1
89% isolated yield
Me3OBF4
Proton-sponge®
MS 4Å, CH2Cl2, rt
89%
L-ascorbic acid 25 26
27 28
29 30 A - 31
Scheme 4.3. Synthesis of Building Block A (A - 31)
The synthesis of Building Block A (A - 31) started with L-ascorbic acid. After protection
of the terminal vicinal diol as an acetonide (25), the synthesis was continued with the
oxidative cleavage, followed by ethylation to the corresponding α-hydroxy ester (26), which
was protected as a MEM ether. The next reaction was the two-step reduction-oxidation of
ester 27 to aldehyde 29, which underwent an organocatalytic asymmetric aldol coupling
with L-proline, (S )-BINOL and acetone as the nucleophile. Methylation of hydroxy ketone
30 under Meerwein conditions provided A - 31 in 7 steps. Here we were able to improve
the original synthesis68 in a significant way, increasing the total (isolated) yield from 21 %
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(80 % average yield per step) to 49 % (90 % average yield per step), in the same number of
linear steps. Moreover, this synthesis provided the large-scale preparation of A - 31.
Building Block A (A - 31) contains three stereocenters of which the configuration had to
be confirmed (Scheme 4.4). C1 and C2 originate from the chiral pool starting material
L-ascorbic acid and were assumed to have the configuration as represented. C3 was intro-
duced in the organocatalytic aldol coupling with L-proline and its absolute configuration
was confirmed by the Mosher protocol. Therefore, hydroxy ketone 30 was derivatized to
its corresponding (S )- and (R)-MTPA esters. By comparing the chemical shift differences
(∆δ = δS − δR) of the L1 and L2 group protons, the L1 and L2 groups could be unambigu-
ously assigned, thus confirming the expected absolute configuration at C3.
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Scheme 4.4. Mosher protocol to determine the absolute stereochemistry at C3
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Scheme 4.5. Synthesis of Building Block B (B - 39)
For the synthesis of Building Block B (B - 39), a high yielding (90 % average yield per step)
yet long procedure (8 steps), starting from (R)-pantolactone was available from Smans68.
This time, only minor improvements could be proposed for the available synthesis as such.
Therefore, a new, shorter and more efficient route was suggested, starting from neopentyl-
glycol. After a two-step monobenzylation, alcohol 55 was oxidized under Swern conditions,
providing aldehyde 56 in an almost quantitative yield after 3 steps. The next reaction was
an asymmetric alkoxyallylboration, introducing a MEM monoprotected diol with moderate
enantioselectivity, after which the remaining alcohol (58) was protected as a SEM ether.
Finally, the one-pot two-step oxidative cleavage of the terminal alkene moiety of 38 pro-
vided aldehyde B - 39 in 6 steps. In comparison with the original route by Smans68, a new
and more convergent approach was applied, which improved the synthesis from 8 steps
(49 % total (isolated) yield; 91 % average yield per step) to 6 steps (54 % total (isolated)
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yield; 90 % average yield per step; 78 % e.e.), in a way that allowed for the large-scale
preparation of B - 39 in a minimal amount of time.
Building Block B (B - 39) contains two stereocenters, C8 and C9, of which the configuration
had to be confirmed (Scheme 4.6). As B - 39 was already synthesized by Smans68 via
a different synthetic route, we confirmed the relative stereochemistry by comparing the
spectral data of 38 and B - 39 with those prepared by Smans68, which allowed us to confirm
that our compounds are diastereomerically identical with those obtained by Smans68.
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Scheme 4.6. Proof of stereochemistry at C8
Smans68 proved the stereochemistry by correlating the C8 stereocenter to the C9 stereo-
center, which can be derived from the natural (R)-pantolactone he used as the starting
material. After cleavage of the SEM ether of 37, syn-diol 59 was obtained, which could
be protected as trans-acetonide 60. The stereochemistry of the latter was determined
by the 3JH,H NMR coupling constant of the hydrogen atoms at C8 and C9. These are
related to the dihedral torsion angles via the Karplus equation. Via molecular modeling,
a dihedral angle of 169◦ was predicted for trans-acetonide 60, which translates with the
Karplus equation to a coupling constant of 8-9 Hz. For cis-acetonide 61, a dihedral angle
of 39◦ was predicted, which translates to a coupling constant of 4-6 Hz. For the acetonide
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derived from 37, a 3JH,H coupling constant of 8.16 Hz was measured, confirming the trans-
relationship in 60 and hence the syn-stereochemistry in derived diol 59, hence proving the
stereochemistry at C8.
Unlike the synthesis of Smans68, in our synthesis the two stereocenters at C8 and C9 were
introduced in a single step, resulting in the formation of two enantiomers (78 % e.e.). To
prove that the major enantiomer is the same and expected enantiomer, we compared the
optical rotation of 38 with the presumed same compound synthesized by Smans68. As we
obtained an optical rotation of [α]D =− 28.6 and [α]365 =− 91.5 and Smans68 obtained an
optical rotation of [α]D =− 31.9 and [α]365 =− 100.4 respectively, we can unambiguously
conclude that the major enantiomer we obtained in our synthesis, is the same and expected
enantiomer.
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Scheme 4.7. Synthesis of Building Block D (D - 64)
The synthesis of Building Block D (D - 64) started with the aldol coupling of Building
Block A (A - 31) and Building Block B (B - 39), affording hydroxy ketone 45, followed
by methylation under Meerwein conditions, providing 46. The next reaction was the
diastereoselective reduction of the ketone with NaEt3BH and protection of the secondary
alcohol (47) as a MOM ether (62). Finally, the benzyl ether was removed selectively
by hydrogenolysis, followed by oxidation of the obtained primary alcohol (63), affording
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aldehyde D - 64 in 6 steps. In comparison with the original route by Smans68, a MEM
protecting group was replaced with a MOM protecting group and several individual steps
were further optimized. This improved the synthesis, starting from A - 31 and B - 39, in a
significant way, increasing the total (isolated) yield from 31 % (82 % average yield per step)
to 50 % (89 % average yield per step), in the same number of linear steps. Furthermore,
this route allowed for the large-scale preparation of D - 64, ready for the coupling with
C - 43 and further synthesis towards vinyl iodide precursor 22.
Building Block D (D - 64) contains two new stereocenters, C7 and C5, which were intro-
duced in the asymmetric aldol coupling reaction and the diastereoselective ketone reduction
respectively. First, the relative stereorelationship between C5 and C7 was determined, fol-
lowed by the relationship between C7 and the known C9 stereocenter. In order to do this,
the oxygenated stereocenters were converted to conformationally rigid cyclic acetonides,
from which their relationship was proven by using 13C NMR spectroscopy (Scheme 4.8).
Starting from aldol product 45, the ketone was first reduced in a non-diastereoselective
way to both 5,7-syn-diol 65 and 5,7-anti-diol 66 (yet to confirm), which were converted
to their corresponding cyclic acetonides 5,7-cis/trans-acetonide 67/68. By comparing
the obtained 13C chemical shifts of the acetal methyls, the configuration of both 5,7-diols
could be confirmed.
The stereochemically confirmed 5,7-diols were next permethylated to the corresponding 5,7-
dimethoxy compounds and also reduced compound 47 was methylated to 5-O-methyl-47.
Comparison of the NMR spectra showed unambiguously that 5,7-anti-dimethoxy 70
(from 5,7-anti-diol 66) and 5-O-methyl-47 (from 47) were identical, which confirmed
the 5,7-anti -relationship of 47.
To define the absolute stereochemistry of C5 and C7, the relationship between C7 and
the known stereocenter C9 was determined. This time 5,7-anti-diol 66 was converted
to 7,9-trans-acetonide 72. By measuring the 13C chemical shifts of the acetal methyls,
the 7,9-anti -relationship of 5,7-anti-diol 66 and 7,9-trans-acetonide 72 could be con-
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firmed. As the configuration of C9 is known to be (R), correlating C5 to C7 and C7 to C9
unambiguously revealed the absolute stereochemistry of C5 and C7.
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Scheme 4.8. Proof of stereochemistry at C5 and C7
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Scheme 4.9. Synthesis of Building Block C (C - 43)
The synthesis of Building Block C (C - 43) started from propargyl alcohol. An anti -
carbometalation reaction first provided the regio- and stereoselective introduction of an
iodide and methyl group, to (Z )-iodomethylpropenol 40. The next reaction was the MnO2
oxidation of allyl alcohol 40 to the volatile and reactive allyl aldehyde 41, which immedi-
ately underwent an organocatalytic asymmetric aldol coupling with D-proline and acetone
as the nucleophile. Hydroxy ketone 42 was then protected as a PMB ether with freshly
prepared PMB-trichloroacetimidate 44, yielding C - 43 in 4 steps. Here we were able to
improve the original synthesis68 in a significant way, increasing the total (isolated) yield
from 36 % (78 % average yield per step; 97 % e.e.) to 53 % (85 % average yield per step; 99 %
e.e.), in the same number of linear steps. Moreover, this synthesis allowed the large-scale
preparation of C - 43.
16
15
OPMB O
17
I
C - 43
Building Block C (C - 43) contains a single stereocenter at C15 and a trisubstituted double
bond with Z configuration at C16−C17. The structure and absolute configuration of C - 43
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could be confirmed by X-ray diffraction of a single crystal of its hydroxy ketone precursor
42.
4.3 Further synthesis towards 22
+
OPMB OI O OSEM
OMEM
OMe OMOM OMe
OMEM
O
O
OSEMOR
OMEM
OOPMB
OMEM
OMeOMOMOMe
O
OI
OSEMOBOM
OMEM
OROPMB
OMEM
OMeOMOMOMe
O
OI
BOM-Cl, DIPEA
CH2Cl2, reflux
R = H
R = BOM
Me3OBF4
Proton-sponge®
MS 4Å, CH2Cl2, rt
R = H
R = Me
quant.
94%
Bu2BOTf, Et3N
Et2O, -78°C -> -45°C
86% total yield
d.r. 4.6:1
70% isolated yield
Na(s-Bu)3BH 
Et2O, -96°C
72% total yield
d.r. 17:1
68% isolated yield
C - 43 D - 64
74
76
77
78
Scheme 4.10. Synthesis of vinyl iodide precursor 22 (step 1-4)
The final stretch of the synthesis towards vinyl iodide precursor 22 started with the asym-
metric aldol coupling of Building Block C (C - 43) and Building Block D (D - 64), followed
by protection of the secondary alcohol (74) as a BOM ether (76). The next step was the
diastereoselective reduction of the ketone with Na(s-Bu)3BH, introducing the last stere-
ocenter (77), followed by methylation under Meerwein conditions, affording compound
78.
From here onwards, we could start with the necessary selective deprotections and functional
group transformations (Scheme 4.11). At first was the selective deprotection of SEM
ether 78 to secondary alcohol 80, followed by oxidation with Dess-Martin periodinane
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Scheme 4.11. Synthesis of vinyl iodide precursor 22 (step 6-10)
to ketone 81. The next reaction was the double deprotection of the PMB ether and
the acetonide moiety to triol 84, followed by oxidative cleavage of the vicinal diol to
aldehyde 85 with NaIO4 and further oxidation to seco-acid 24 under Pinnick oxidation
conditions. Finally, this seco-acid underwent macrolactonization using the Yamaguchi
macrolactonization protocol, affording vinyl iodide precursor 22, but also a significant
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amount of diolide 87, in 10 steps from Building Block C (C - 43) and Building Block D
(D - 64). While most of these steps deliver satisfying yields, improvements still need to be
made and are most certainly possible for the SEM, PMB and acetonide deprotection, and
also the macrolactonization, where formation of the diolide should be avoided. Starting
from C - 43 and D - 64, vinyl iodide precursor 22 could be obtained in 10 steps (3.8 %
total (isolated) yield; 72 % average yield per step). The longest linear sequence to obtain
22 (starting from L-ascorbic acid) comprises 23 steps (0.93 % total (isolated) yield; 82 %
average yield per step).
Vinyl iodide precursor 22 contains two new stereocenters, C11 and C13, which were in-
troduced during the asymmetric aldol coupling reaction and the diastereoselective ketone
reduction respectively. These were correlated to already known stereocenters, by convert-
ing them to conformationally rigid cyclic acetonides, from which their relationship was
proven by using 13C NMR spectroscopy.
To determine the relationship between the C9 and C11 stereocenters, we converted the pre-
sumed undesired aldol product 75, which was the only compound that we could initially
obtain as a single diastereomer in a sufficient amount, to its corresponding acetonide 93.
The 13C chemical shifts of the acetal methyls confirmed that the C9 and C11 stereocenters
possess a syn-relationship, which confirmed that 75 indeed was the undesired diastereomer.
To determine the relative stereorelationship between the C13 and C15 stereocenters, ketone
76 was first reduced in a non-diastereoselective way with DIBAL-H in CH2Cl2 and the
obtained 77 and 79 were separated. The presumed desired diastereomer 77 was converted
with DDQ to PMP acetal 96. This cyclic 13,15-cis PMP acetal will adopt a chair-like con-
formation, which results in three axial hydrogens which are in close enough proximity to
be determined by a NMR NOESY measurement. The axial acetal hydrogen showed strong
NOEs with both hydrogens at C13 and C15, which is only possible with the 13,15-cis PMP
acetal and thus confirms its configuration. To obtain extra proof, the presumed undesired
diastereomer 79 was deprotected with CAN in ACN/H2O and subsequently converted to
acetonide 99 with CSA in DMP. The 13C chemical shifts of the acetal methyls confirmed
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Scheme 4.12. Proof of stereochemistry at C11 and C13
the 13,15-anti -relationship of 79. In this way, both desired 77 and undesired 79 could be
stereochemically confirmed.
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4.4 Towards peloruside A and side-chain analogues
Unfortunately, because of some unexpected side-reactions in the last part of the total
synthesis of 22, we were left with unoptimized low yields in the deprotection of the SEM
ether, PMB ether and acetonide moiety. Also the Yamaguchi macrolactonization protocol
needs to be further adapted to avoid the formation of diolide 87. This resulted in only
a very low amount of 22, making it not feasible to further conduct the synthesis towards
both peloruside A and two sets of side-chain analogues, making use of the Stille and Suzuki
coupling strategy. However, large amounts of C - 43 and D - 64 are still available, which
can be used in further research to optimize the last steps of the total synthesis and hereby
provide a sufficient amount of 22. This should enable the synthesis of peloruside A and its
side-chain analogues, as outlined below.
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Scheme 4.13. Proposed side-chain analogues using the Stille coupling strategy
Using the Stille coupling strategy (Scheme 4.13), a first set of side-chain analogues can be
introduced, all bearing alkenyl or (hetero)aryl groups, making use of the according stannane
compounds. These are either commercially available or can be synthesized according to
or based on known literature procedures. The proposed analogues aim at exploring the
influence of the electronic and sterical properties of the side-chain on the biological activity,
by introducing different heteroatoms and sterical environments.
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Using the Suzuki coupling strategy (Scheme 4.14), next to the synthesis of peloruside A,
a second and strategic set of side-chains can be introduced. The proposed analogues mostly
aim at exploring the role of the primary alcohol of the side-chain, which is considered to
be important for the activity of peloruside.
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5.1 General information
5.1 General information
Unless otherwise noted, the following general conditions apply.
All non-aqueous reactions were carried out under an inert argon atmosphere with oven-
dried glassware. Et2O and THF were distilled from sodium/benzophenone, toluene from
sodium and CH2Cl2, Et3N, DIPEA and pyridine from calcium hydride. All other solvents
and reagents were purchased from Sigma-Aldrich, Acros, TCI, Alfa Aesar, Biosolve, Chem-
Lab and Filter Service and were used without further purification.
Reaction progress was monitored by TLC on Macherey-Nagel SIL G-25 UV254 glass plates
and visualized by UV-light (254 nm) and staining with a cerium molybdate solution or
basic permanganate solution. Flash chromatography was performed with silica gel from
Grace (70-200µm) or Rocc (40-63µm), using solvents of technical quality.
1H and 13C (APT) NMR spectra were recorded on a Bruker Avance 300, Bruker Avance
II 500 and Bruker Avance III 500 spectrometer, with chemical shifts (δ) in ppm relative
to the residual solvent signal of the deuterated solvent used. Scalar couplings (J ) are
expressed in Hz as singlet (s), multiplet (m), doublet (d), triplet (t), quartet (q) and
combinations thereof. IR spectra were recorded on a Perkin-Elmer Spectrum 1000 FT-IR
spectrometer with a pike-HATR module. Optical rotations were recorded on a Perkin-
Elmer 241 polarimeter.
EI-MS were recorded on a Hewlett-Packard 5989A mass spectrometer or a Hewlett-Packard
G1800B GCD system. LC-MS and MS analysis were performed on an Agilent 1100 series
HPLC system with a diode array detector and single quad MS detector (G1946C) with
an electrospray ionization source (ESI-MS), using a Phenomenex Luna C18(2) column
(250× 4.6 mm; 5µm) or Phenomenex Kinetex C18 column (150× 4.6 mm; 5µm). HRMS
spectra were recorded with an Agilent 6220A time-of-flight MS detector with a multimode
ionization source. Analytical chiral LC separation was performed with an Agilent 1100
series HPLC system with a diode array detector, using a Chiralcel (OD-H, OJ-H, OB-H)
or Chiralpak (AD-H, AS-H) column.
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5.2 Synthesis of the C1−C6 fragment (A - 31)
5.2.1 Synthesis of protected L-ascorbic acid 25
O O
O
O
HO OH
H
O OH
OH
O
HO OH
H
acetone, AcCl, rt
79%
L-ascorbic acid 25
To a solution of L-ascorbic acid (100 g; 568 mmol) in acetone (400 mL) at rt was added
AcCl (10.1 mL; 142 mmol) and stirring was continued for 16 h. The resulting suspension
was filtered over a fritted funnel and the precipitate was washed with cold, dry acetone
(400 mL). Thereafter the volatiles were removed under reduced pressure and 25 (97.5 g;
79 % yield) was obtained as a white powder.
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Name: 5,6-O-isopropylidene-L-ascorbic acid (25)
Formula: C9H12O6
M.M.: 216.19 g/mol
Rf: 0.28 (CH2Cl2/MeOH 8/2)
IR: ν = 3198, 2985, 2365, 2333, 1763, 1686, 1648, 1560, 1508, 1376, 1323, 1264, 1211,
1141, 1065, 975, 879, 847, 810, 756, 671 cm-1
EI-MS (m/z (%)): 216 (6), 201 (17), 171 (<1), 159 (3), 141 (14), 129 (5), 101 (47), 85
(19), 73 (17), 59 (50), 43 (100)
ESI-MS (m/z): 217.1 [M + H+]
[α]D = + 10.9 (c = 1.2 in CHCl3)
[α]436 = + 9.3
1H NMR (500 MHz, methanol-d4): δ = 4.67 (d, J=3.2 Hz, 1 H), 4.33 (td, J=6.6, 3.2
Hz, 1 H), 4.17 (dd, J=8.4, 7.0 Hz, 1 H), 4.04 (dd, J=8.5, 6.3 Hz, 1 H), 1.34 (s, 3 H),
1.32 (s, 3 H) ppm
APT (126 MHz, methanol-d4): δ = 173.3 (C), 154.4 (C), 120.2 (C), 111.3 (C), 76.7 (CH),
75.6 (CH), 66.6 (CH2), 26.4 (CH3), 25.8 (CH3) ppm
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5.2.2 Synthesis of ester 26
O
O
O
OH
O
O O
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HO OH
H K2CO3, H2O2
H2O, rt
EtO
O
O
OH
O
K
EtBr, ACN, reflux
90%
25 51 26
To a solution of 25 (4.0 g; 18.5 mmol) in H2O (87 mL) at 0
◦C were added K2CO3 (7.42 g;
53.7 mmol) and H2O2 (5.7 mL; 66.6 mmol; 35 wt% in H2O), which resulted in a tempera-
ture rise, but the overall temperature remained below 10 ◦C. After 19 h of stirring at rt,
the reaction mixture was concentrated by rotary evaporation and freeze-drying. Subse-
quently the product was put on a fritted funnel and washed with boiling EtOH, resulting
in a whitish filtrate. This filtrate then was concentrated in vacuo and redissolved in ACN
(87 ml), followed by the addition of EtBr (4.14 mL; 55.5 mmol). Next, the reaction mixture
was heated at reflux temperature for 3 h, followed by removal of the resulting salts by filtra-
tion over a fritted funnel and concentration in vacuo. Purification by flash chromatography
(pentane/acetone 8/2) provided 26 (3.38 g; 90 % yield) as a clear oil.
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Name: ethyl (2R,3S )-2-hydroxy-3,4-O-isopropylidene-butanoate (26)
Formula: C9H16O5
M.M.: 204.22 g/mol
Rf: 0.30 (pentane/acetone 8/2)
IR: ν = 3238, 2990, 2362, 1748, 1663, 1654, 1433, 1374, 1331, 1257, 1213, 1138, 1068, 883,
840, 819, 669, 514 cm-1
EI-MS (m/z (%)): 201 (2), 189 (12), 183 (1), 167 (4), 151 (7), 141 (3), 131 (12), 115 (7),
109 (9), 101 (39), 81 (9), 73 (28), 57 (20), 55 (20), 45 (100), 43 (89)
ESI-MS (m/z): 227.0 [M + Na+]
[α]D = + 21.0 (c = 0.98 in CHCl3)
[α]436 = + 37.2
1H NMR (500 MHz, benzene-d6): δ = 4.23 (td, J=7.0, 2.0 Hz, 1 H), 3.97 (t, J=7.6 Hz,
1 H), 3.90 (q, J=7.2 Hz, 2 H), 3.78 (dd, J=8.2, 2.0 Hz, 1 H), 3.70 (dd, J=7.7, 7.0
Hz, 1 H), 3.06 (d, J=8.2 Hz, 1 H), 1.35 (s, 3 H), 1.25 (s, 3 H), 0.85 (t, J=7.2 Hz, 3
H) ppm
APT (126 MHz, benzene-d6): δ = 172.8 (C), 110.3 (C), 77.3 (CH), 70.3 (CH), 65.9 (CH2),
62.0 (CH2), 26.5 (CH3), 26.1 (CH3), 14.3 (CH3) ppm
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5.2.3 Synthesis of MEM ether 27
EtO
O
O
OMEM
O
EtO
O
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OH
O MEM-Cl, DIPEA 
CH2Cl2, reflux
98%
26 27
To a solution of 26 (31.0 g; 152 mmol) in CH2Cl2 (152 mL) at rt were added DIPEA
(66.1 mL; 379 mmol) and MEM-Cl (34.7 mL; 304 mmol) dropwise, with formation of a white
haze that disappears after a couple of minutes. After stirring for 14 h at reflux tempera-
ture, the reaction mixture was poured into H2O (1 L) and CH2Cl2 (800 mL), the organic
phase separated and the water phase extracted with CH2Cl2 (3× 600 mL). The combined
organic phases were dried over MgSO4 and concentrated in vacuo. Purification by flash
chromatography (pentane/Et2O 3/7) provided 27 (43.7 g; 98 % yield) as a clear oil.
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Name: ethyl (2R,3S )-3,4-O-isopropylidene-2-(2-methoxy-ethoxymethoxy)-butanoate
(27)
Formula: C13H24O7
M.M.: 292.33 g/mol
Rf: 0.31 (pentane/Et2O 3/7)
IR: ν = 2985, 2926, 2356, 1746, 1456, 1371, 1253, 1200, 1178, 1136,1114, 1043, 853 cm-1
HRMS (m/z): calcd: 293.1595, found: 293.1603 [M + H+]
[α]D = + 29.0 (c = 1.28 in CHCl3)
[α]436 = + 55.2
1H NMR (500 MHz, benzene-d6): δ = 4.84 (d, J=6.9 Hz, 1 H), 4.72 (d, J=6.9 Hz, 1 H),
4.48 (q, J=6.3 Hz, 1 H), 4.27 (d, J=5.4 Hz, 1 H), 4.08 (dd, J=8.4, 6.3 Hz, 1 H), 3.93
(q, J=7.4 Hz, 2 H), 3.89 (dd, J=8.5, 6.9 Hz, 1 H), 3.57 - 3.69 (m, 2 H), 3.24 - 3.36
(m, 2 H), 3.08 (s, 3 H), 1.46 (s, 3 H), 1.28 (s, 3 H), 0.91 (t, J=7.2 Hz, 3 H) ppm
APT (126 MHz, benzene-d6): δ = 170.2 (C), 110.3 (C), 95.8 (CH2), 77.0 (CH), 76.7 (CH),
72.4 (CH2), 68.2 (CH2), 66.3 (CH2), 61.2 (CH2), 59.0 (CH3), 26.9 (CH3), 26.0 (CH3),
14.4 (CH3) ppm
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5.2.4 Synthesis of alcohol 28
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O DIBAL-H 
Et2O, rt
93%
27 28
To a solution of 27 (20.0 g; 68.4 mmol) in Et2O (270 mL) at rt was added DIBAL-H (170 mL;
1m in cyclohexane) dropwise. After stirring for 1 h, a sat. Rochelle salt sol. (700 mL) was
added and stirring was continued overnight until two clear phases appeared. Then EtOAc
(500 mL) was added, the organic phase separated and the water phase extracted with
EtOAc (3× 750 mL). The combined organic phases were dried over MgSO4 and concen-
trated in vacuo. Purification by flash chromatography (pentane/acetone 7/3) provided 28
(16.0 g; 93 % yield) as a clear oil.
160
5.2 Synthesis of the C1−C6 fragment (A - 31)
O
O
OMEM
OH
Name: (2S,3S )-3,4-O-isopropylidene-2-(2-methoxy-ethoxymethoxy)-butan-1-ol (28)
Formula: C11H22O6
M.M.: 250.29 g/mol
Rf: 0.25 (pentane/acetone 7/3)
IR: ν = 3433, 2928, 2365, 2333, 1462, 1371, 1253, 1211, 1036, 853, 789 cm-1
HRMS (m/z): calcd: 273.1309, found: 273.1301 [M + Na+]
[α]D = − 60.3 (c = 1.27 in CHCl3)
[α]365 = − 178.7
1H NMR (500 MHz, benzene-d6): δ = 4.69 (d, J=7.3 Hz, 1 H), 4.67 (d, J=7.3 Hz, 1 H),
4.11 (dt, J=7.3, 6.3 Hz, 1 H), 3.75 (dd, J=8.2, 6.5 Hz, 1 H), 3.57 - 3.70 (m, 4 H),
3.54 (td, J=6.0, 3.3 Hz, 1 H), 3.38 (ddd, J=10.9, 5.5, 3.0 Hz, 1 H), 3.13 - 3.24 (m, 3
H), 3.05 (s, 3 H), 1.38 (s, 3 H), 1.28 (s, 3 H) ppm
APT (126 MHz, benzene-d6): δ = 109.6 (C), 96.6 (CH2), 82.3 (CH), 77.2 (CH), 72.3
(CH2), 68.0 (CH2), 66.3 (CH2), 63.2 (CH2), 58.9 (CH3), 27.0 (CH3), 26.0 (CH3) ppm
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5. Experimental
5.2.5 Synthesis of aldehyde 29
O
O
OMEM
OO
O
OMEM
OH (COCl)2, DMSO, Et3N 
CH2Cl2, -78°C
96%
2928
To a solution of (COCl)2 (2.8 mL; 33.1 mmol) in CH2Cl2 (180 mL) at −78 ◦C was added
DMSO (5.1 mL; 72.2 mmol) dropwise. After stirring for 20 min, a precooled solution of 28
(5.02 g; 20.0 mmol) in CH2Cl2 (20 mL) was added via cannula and stirring continued for
20 min, followed by the addition of Et3N (19.5 mL; 140 mmol). After stirring for 15 min,
the reaction mixture was poured into H2O (400 mL) and CH2Cl2 (200 mL), the organic
phase separated and the water phase extracted with CH2Cl2 (2× 400 mL). The combined
organic phases were dried over MgSO4 and washed with a 1mCuSO4 sol. (2× 300 mL). The
organic phase was dried again over MgSO4 and concentrated in vacuo. Because of possible
epimerization, no further purification steps were elaborated. 29 (4.79 g; 96 % yield) was
obtained as a clear oil.
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5.2 Synthesis of the C1−C6 fragment (A - 31)
O
O
OMEM
O
Name: (3S,2R)-3,4-O-isopropylidene-2-(2-methoxy-ethoxymethoxy)-butanal (29)
Formula: C11H20O6
M.M.: 248.27 g/mol
Rf: 0.25 (hexane/EtOAc 3/7)
IR: ν = 2985, 2931, 2895, 2333, 1732, 1691, 1632, 1456, 1372, 1259, 1216, 1152, 1042, 847,
794, 511 cm-1
HRMS (m/z): calcd: 266.1598, found: 266.1600 [M + NH4
+]
[α]D = + 13.8 (c = 0.99 in CHCl3)
[α]365 = + 139.7
1H NMR (500 MHz, benzene-d6): δ = 9.63 (d, J=1.3 Hz, 1 H), 4.61 (d, J=6.9 Hz, 1 H),
4.57 (d, J=6.9 Hz, 1 H), 4.17 (td, J=6.4, 5.2 Hz, 1 H), 3.84 (dd, J=8.7, 6.3 Hz, 1
H), 3.78 (dd, J=8.5, 6.8 Hz, 1 H), 3.74 (dd, J=5.0, 1.3 Hz, 1 H), 3.41 - 3.52 (m, 2
H), 3.18 (t, J=4.7 Hz, 2 H), 3.04 (s, 3 H), 1.38 (s, 3 H), 1.21 (s, 3 H) ppm
APT (126 MHz, benzene-d6): δ = 201.2 (CH), 110.1 (C), 96.5 (CH2), 82.3 (CH), 76.1
(CH), 72.3 (CH2), 68.2 (CH2), 65.9 (CH2), 59.0 (CH3), 26.7 (CH3), 25.7 (CH3) ppm
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5. Experimental
5.2.6 Synthesis of hydroxy ketone 30
O
O
OMEM
OHOO
O
OMEM
O L-proline, (S)-BINOL 
acetone, rt
94% total yield
d.r. 16:1
89% isolated yield
29 30
To a solution of L-proline (2.96 g; 25.7 mmol) and (S )-BINOL (73.6 mg; 257µmol) in ace-
tone (230 mL) at rt was added 29 (6.39 g; 25.7 mmol). After stirring for 64 h, the reaction
mixture was poured into a sat. NH4Cl sol. (500 mL) and EtOAc (500 mL), the organic
phase separated and the water phase extracted with EtOAc (2× 500 mL). The combined
organic phases were dried over MgSO4 and concentrated in vacuo. Purification by flash
chromatography (toluene/Et2O 95/5) provided 30 (6.97 g; 89 % yield) as a clear oil.
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5.2 Synthesis of the C1−C6 fragment (A - 31)
O
O
OMEM
OHO
Name: (4R,5S,6S )-4-hydroxy-6,7-O-isopropylidene-5-(2-methoxy-ethoxymethoxy)-
heptan-2-one (30)
Formula: C14H26O7
M.M.: 306.35 g/mol
Rf: 0.14 (toluene/EtOH 95/5)
IR: ν = 3482, 2986, 2923, 2364, 1718, 1454, 1370, 1248, 1219, 1160,1092, 1031, 844, 772
cm-1
HRMS (m/z): calcd: 324.2017, found: 324.2016 [M + NH4
+]
[α]D = − 21.4 (c = 1.14 in CHCl3)
[α]365 = − 58.5
1H NMR (500 MHz; benzene-d6): δ = 4.84 (d, J=6.8 Hz, 1 H), 4.71 (d, J=6.8 Hz, 1 H),
4.37 (dt, J=7.4, 6.6 Hz, 1 H), 4.20 (dddd, J=8.4, 5.2, 4.3, 3.8 Hz, 1 H), 3.92 (dd,
J=8.4, 6.5 Hz, 1 H), 3.81 (t, J=7.6 Hz, 1 H), 3.58 (ddd, J=10.9, 6.3, 3.6 Hz, 1 H),
3.50 (dd, J=6.0, 3.8 Hz, 1 H), 3.45 (ddd, J=10.9, 5.6, 3.5 Hz, 1 H), 3.20 - 3.30 (m, 2
H), 3.18 (d, J=5.2 Hz, 1 H), 3.07 (s, 3 H), 2.57 (dd, J=17.0, 4.3 Hz, 1 H), 2.49 (dd,
J=16.9, 8.4 Hz, 1 H), 1.75 (s, 3 H), 1.41 (s, 3 H), 1.32 (s, 3 H) ppm
APT (126 MHz; benzene-d6): δ = 207.9 (C), 109.5 (C), 97.2 (CH2), 81.1 (CH), 77.2 (CH),
72.5 (CH2), 68.8 (CH), 68.4 (CH2), 66.7 (CH2), 59.0 (CH3), 46.8 (CH2), 30.7 (CH3),
27.1 (CH3), 26.2 (CH3) ppm
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5. Experimental
5.2.7 Synthesis of methyl ether A - 31
O
O
OMEM
OMeOO
O
OMEM
OHO Me3OBF4, Proton-sponge
® 
MS 4Å, CH2Cl2, rt
89%
A - 3130
To a solution of 30 (5.29 g; 17.3 mmol) in CH2Cl2 (410 mL) at rt were added molecular
sieves (6.9 g; 4 A˚; powdered; activated). After stirring for 1 h, Proton-sponge R© (9.62 g;
44.9 mmol) and Me3OBF4 (6.39 g; 43.2 mmol) were added. After stirring for 20 h, the
yellow-orange suspension was filtered over a fritted funnel and the filtrate was washed
with a 1mCuSO4 sol. (2× 800 mL). The water phases were back-extracted with CH2Cl2
(800 mL), the combined organic phases dried over MgSO4 and concentrated in vacuo. The
resulting yellow sludge was filtered over a silica plug and rinsed with Et2O. Purification by
flash chromatography (pentane/Et2O 2/8) provided A - 31 (4.93 g; 89 % yield) as a clear
oil.
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5.2 Synthesis of the C1−C6 fragment (A - 31)
O
O
OMEM
OMeO
Name: (4R,5S,6S )-6,7-O-isopropylidene-4-methoxy-5-(2-methoxy-ethoxymethoxy)-
heptan-2-one (A - 31)
Formula: C15H28O7
M.M.: 320.38 g/mol
Rf: 0.18 (pentane/Et2O 2/8)
IR: ν = 2985, 2936, 2820, 2363, 2344, 1718, 1685, 1654, 1578, 1543, 1458, 1370, 1247,
1211, 1160, 1093, 1067, 1034, 850, 767, 670 cm-1
HRMS (m/z): calcd: 338.2173, found: 338.2180 [M + NH4
+]
[α]D = − 26.5 (c = 1.05 in CHCl3)
[α]436 = − 50.9
1H NMR (500 MHz; benzene-d6): δ = 4.94 (d, J=6.8 Hz, 1 H), 4.76 (d, J=6.8 Hz, 1 H),
4.30 (dt, J=8.0, 6.3 Hz, 1 H), 4.04 - 4.09 (m, 1 H), 3.97 (dd, J=8.4, 6.2 Hz, 1 H),
3.77 - 3.84 (m, 2 H), 3.64 - 3.70 (m, 1 H), 3.54 - 3.60 (m, 1 H), 3.28 - 3.38 (m, 2 H),
3.13 (s, 3 H), 3.11 (s, 3 H), 2.72 (dd, J=17.0, 3.5 Hz, 1 H), 2.40 (dd, J=16.9, 8.6 Hz,
1 H), 1.76 (s, 3 H), 1.43 (s, 3 H), 1.38 (s, 3 H) ppm
APT (126 MHz; benzene-d6): δ = 205.7 (C), 109.2 (C), 96.7 (CH2), 77.7 (CH), 77.3 (CH),
77.1 (CH), 72.6 (CH2), 68.1 (CH2), 67.0 (CH2), 59.0 (CH3), 58.2 (CH3), 44.4 (CH2),
30.8 (CH3), 27.1 (CH3), 26.6 (CH3) ppm
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5. Experimental
5.2.8 Synthesis of MTPA esters 52 and 5368
O
O
OMEM
OMTPAOO
O
OMEM
OHO MTPA chloride 
pyridine, kt
99%
52/5330
Het startproduct (30) (10 mg; 32.6µmol) wordt opgelost in pyridine (640µl) en hieraan
wordt MTPA chloride (81.6µmol; 20.6 mg; 15.0µL; 2.5 eq.) toegevoegd. De reactie wordt
gedurende 16 uur geroerd bij kamertemperatuur. Na 16 uur wordt het reactiemengsel
afgewerkt met H2O (5 mL) en gee¨xtraheerd met dichloormethaan (5× 5 mL). De gecom-
bineerde organische fasen worden gedroogd op MgSO4 en na filtratie in vacuo geconcen-
treerd, het bekomen residu gezuiverd via kolomchromatografie (tolueen/ethanol 98/2). Het
gewenste product wordt bekomen met een rendement van 99 %.
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5.2 Synthesis of the C1−C6 fragment (A - 31)
O
O
OMEM
OMTPAO
Name: (4R,5S,6S )-6,7-O-isopropylidene-5-(2-methoxy-ethoxymethoxy)-4-O-MTPA-
heptan-2-one (52/53)
Formula: C24H33F3O9
M.M.: 522.51 g/mol
Rf: 0.80 (toluene/EtOH 95/5)
(S)-MTPA (52)
1H NMR (300 MHz; chloroform-d): δ = 7.52 (m, 2 H), 7.40 (m, 3 H), 5.57 (ddd (app.
p), J=3.33 Hz, 1 H), 4.86 (d, J=7.02 Hz, 1 H), 4.82 (d, J=7.02 Hz, 1 H), 4.09 (dd,
J=13.14, 6.61 Hz, 1 H), 3.99 (dd, J=8.50, 6.58 Hz, 1 H), 3.69 (m, 4 H), 3.55 (dd,
(app. t), J=4.50 Hz, 2 H), 3.50 (s, 3 H), 3.37 (s, 3 H), 2.99 (dd, J=17.95, 4.56 Hz, 1
H), 2.83 (dd, J=17.95, 7.77 Hz, 1 H), 2.09 (s, 3 H), 1.38 (s, 3 H), 1.30 (s, 3 H) ppm
APT (75 MHz; chloroform-d): δ = 204.80 (C), 165.75 (C), 131.67 (CF3), 129.72 (CH),
128.50 (CH), 127.56 (CH), 125.15 (CF3), 121.32 (CF3), 109.56 (C), 96.72 (2 CH2),
77.80 (CH), 75.82 (CH), 71.73 (CH2), 71.35 (CH), 67.94 (CH2), 65.98 (CH2), 59.07
(CH3), 55.45 (CH3), 43.70 (CH2), 30.30 (CH3), 26.42 (CH3), 25.35 (CH3) ppm
(R)-MTPA (53)
1H-NMR (300 MHz; chloroform-d): δ = 7.50 (m, 2 H), 7.40 (m, 3 H), 5.54 (ddd (app.
p), J=4.05 Hz, 1 H), 4.79 (d, J=6.97 Hz, 1H), 4.76 (d, J=6.97 Hz, 1H), 3.86 (dd,
J=12.12, 6.63 Hz, 1 H), 3.82 (dd, J=14.55, 6.51 Hz, 1 H), 3.69 (m, 3 H), 3.55 (m,
3H), 3.51 (s, 3 H), 3.28 (s, 3 H), 3.07 (dd, J=18.12, 4.17 Hz, 1H), 2.87 (dd, J=18.09,
8.19 Hz, 1 H), 2.16 (s, 3 H), 1.33 (s, 3 H), 1.24 (s, 3 H) ppm
APT (75 MHz; chloroform-d): δ = 205.14 (C), 165.76 (C), 132.72 (CF3), 129.72 (CH),
128.47 (CH), 127.22 (CH), 125.11 (CF3), 121.29 (CF3), 109.48 (C), 96.48 (CH2), 94.20
(CH2), 76.53 (CH), 75.04 (CH), 71.72 (CH2), 71.16 (CH), 67.89 (CH2), 65.84 (CH2),
59.08 (CH3), 55.66 (CH3), 43.17 (CH2), 30.31 (CH3), 26.31 (CH3), 25.40 (CH3) ppm
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5. Experimental
5.3 Synthesis of the C7−C11 fragment (B - 39)
5.3.1 Synthesis of diprotected neopentylglycol 54
OHOH OO
Ph
PhCH(OMe)2, CSA 
CH2Cl2, rt
quant.
neopentylglycol 54
To a solution of neopentylglycol (9.99 g; 95.9 mmol) in CH2Cl2 (264 mL) at rt were added
PhCH(OMe)2 (14.4 mL; 105.5 mmol) and CSA (2.67 g; 11.5 mmol). After stirring for 1 h,
the reaction mixture was poured into CH2Cl2 (500 mL) and washed with a sat. NaHCO3
sol. (200 mL). The organic phase was dried over MgSO4 and concentrated in vacuo. Crude
54 (95.9 mmol) was obtained quantitatively as colorless-white crystals and was used as
such in subsequent reactions.
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5.3 Synthesis of the C7−C11 fragment (B - 39)
OO
Ph
Name: 5,5-dimethyl-2-phenyl-1,3-dioxane (54)
Formula: C12H16O2
M.M.: 192.25 g/mol
Rf: 0.40 (pentane/Et2O 9/1)
ESI-MS (m/z): 193.1 [M + H+]
1H NMR (500 MHz, chloroform-d): δ = 7.52 (dd, J=8.0, 1.5 Hz, 2 H), 7.32 - 7.41 (m, 3
H), 5.41 (s, 1 H), 3.79 (d, J=11.2 Hz, 2 H), 3.67 (d, J=10.6 Hz, 2 H), 1.32 (s, 3 H),
0.82 (s, 3 H) ppm
APT (126 MHz, chloroform-d): δ = 138.5 (C), 128.9, 128.3, 126.1, 101.8 (CH), 77.7 (2
CH2), 30.2 (C), 23.0 (CH3), 21.9 (CH3) ppm
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5. Experimental
5.3.2 Synthesis of alcohol 55
OHOBnOO
Ph LiAlH4, AlCl3 
Et2O, CH2Cl2      
-10°C -> reflux 
quant.
quant.
5554
To a solution of 54 (crude; 95.9 mmol) in Et2O (192 mL) and CH2Cl2 (192 mL) at
−10 ◦C was added LiAlH4 (3.94 g; 105.5 mmol). Subsequently a solution of AlCl3 (14.1 g;
105.5 mmol) in Et2O (72 mL) was added via cannula and after 10 min at −10 ◦C, the re-
action mixture was heated to reflux temperature. After 1 h, the reaction mixture was
cooled again to −10 ◦C and carefully quenched by the addition of EtOAc (50 mL) and H2O
(300 mL). Next, the reaction mixture was poured into H2O (500 mL) and EtOAc (400 mL),
the organic phase separated and the water phase extracted with EtOAc (2× 800 mL). The
combined organic phases were dried over MgSO4 and concentrated in vacuo. Crude 55
(95.9 mmol) was obtained quantitatively as a clear oil and was used as such in subsequent
reactions.
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5.3 Synthesis of the C7−C11 fragment (B - 39)
OHOBn
Name: 3-benzyloxy-2,2-dimethyl-propan-1-ol (55)
Formula: C12H18O2
M.M.: 194.27 g/mol
Rf: 0.24 (pentane/Et2O 6/4)
1H NMR (500 MHz, chloroform-d): δ = 7.28 - 7.40 (m, 5 H), 4.53 (s, 2 H), 3.48 (d,
J=5.8 Hz, 2 H), 3.34 (s, 2 H), 2.57 (t, J=5.9 Hz, 1 H), 0.94 (s, 6 H) ppm
APT (126 MHz, chloroform-d): δ = 138.1 (C), 128.4, 127.7, 127.4, 79.5 (CH2), 73.5 (CH2),
71.8 (CH2), 36.2 (C), 21.9 (2 CH3) ppm
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5. Experimental
5.3.3 Synthesis of aldehyde 56
OOBnOHOBn (COCl)2, DMSO Et3N, CH2Cl2, -78°C
98% (3 steps)
55 56
To a solution of (COCl)2 (17.9 mL; 211 mmol) in CH2Cl2 (850 mL) at −78 ◦C was added
DMSO (30.0 mL; 422 mmol) dropwise. After stirring for 15 min, a precooled solution of 55
(crude; 95.9 mmol) in CH2Cl2 (100 mL) was added via cannula and stirring continued for
20 min, followed by the addition of Et3N (93.5 mL; 671 mmol). After stirring for 1 h, the
reaction mixture was poured into H2O (1.5 L) and Et2O (500 mL), the organic phase sepa-
rated and the water phase extracted with Et2O (2× 1.5 L). The combined organic phases
were dried over MgSO4 and concentrated in vacuo. Purification by flash chromatography
(pentane/Et2O 85/15) provided 56 (18.11 g; 98 % yield; 3 steps) as a clear oil.
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5.3 Synthesis of the C7−C11 fragment (B - 39)
OOBn
Name: 3-benzyloxy-2,2-dimethyl-propanal (56)
Formula: C12H16O2
M.M.: 192.25 g/mol
Rf: 0.56 (pentane/Et2O 7/3)
ESI-MS (m/z): 193.1 [M + H+]
1H NMR (500 MHz, chloroform-d): δ = 9.58 (s, 1 H), 7.28 - 7.38 (m, 5 H), 4.52 (s, 2 H),
3.47 (s, 2 H), 1.10 (s, 6 H) ppm
APT (126 MHz, chloroform-d): δ = 205.3 (CH), 138.1 (C), 128.4, 127.6, 127.4, 75.1
(CH2), 73.4 (CH2), 47.1 (C), 19.0 (2 CH3) ppm
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5. Experimental
5.3.4 Synthesis of alcohol 58
Synthesis of MEM protected allyl alcohol 57
MEM-Cl, DIPEA 
CH2Cl2, reflux
88%
HO MEMO
allyl alcohol 57
To a solution of allyl alcohol (13.7 mL; 200 mmol) in CH2Cl2 (200 mL) at rt were added
DIPEA (45.3 mL; 260 mmol) and MEM-Cl (25.1 mL; 220 mmol) dropwise, with formation
of a white haze that disappears after a couple of minutes. After stirring for 16 h at re-
flux temperature, the mixture was washed with a 0.1m HCl sol. (2× 100 mL) and a sat.
NaHCO3 sol. (100 mL). Next, the organic phase was dried over MgSO4 and concentrated in
vacuo. Purification by vacuum distillation (19 mmHg; Tb = 70-75
◦C) provided 57 (25.8 g;
88 % yield) as a clear liquid.
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5.3 Synthesis of the C7−C11 fragment (B - 39)
Synthesis of (−)-Ipc2BOMe
BH3·SMe2
THF, rt
BH B
OMe
MeOH
THF, rt
(+)-α-pinene (−)-Ipc2BH (−)-Ipc2BOMe
To a solution of (+)-α-pinene (24.8 mL; 156 mmol) in THF (18.7 mL) at rt was added
BH3·SMe2 (5.92 mL; 62.4 mmol) dropwise over 30 min. Crystallization occurred overnight,
after which it was cooled to 0 ◦C for 2 h. Next, the supernatant liquid was removed via
cannula and the crystals were rinsed with cold Et2O (12.5 mL). Concentration in vacuo
provided (−)-Ipc2BH (14.28 g; 49.9 mmol; 80 % yield) as white crystals.
To a solution of (−)-Ipc2BH (14.28 g; 49.9 mmol) in THF (49.9 mL) at rt was added MeOH
(791µL; 49.9 mmol) dropwise, with the formation of H2. After complete dissolution, the
mixture was precooled for further reaction.
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5. Experimental
Synthesis of alcohol 58
OHOBn
OMEM
OOBn sec-BuLi, BF3·OEt2, THF, -78°C
ii)
 NaOH, H2O2, rt
i)
 (-)-Ipc2BOMe, 
MEMO
63%
d.r. 199:1; 78% e.e.
57
57
5856
To a solution of 57 (7.29 g; 49.9 mmol) in THF (29.9 mL) at −78 ◦C was added sec-BuLi
(38.4 mL; 1.3m in cyclohexane/hexane 92/8) dropwise over 20 min. After stirring for 1 h
at −78 ◦C, a precooled solution of (−)-Ipc2BOMe (49.9 mmol; 1m in THF) was added via
cannula. After again stirring for 1 h at −78 ◦C, BF3·Et2O (7.90 mL; 62.3 mmol) was added
dropwise, followed by the addition of a precooled solution of 56 (7.99 g; 41.6 mmol) in THF
(49.9 mL) via cannula. After stirring for 3 h at −78 ◦C, the reaction mixture was left to
warm to rt overnight. After stirring for 16 h, the reaction mixture was concentrated in
vacuo and redissolved in Et2O. Next, a preformed solution of NaOOH (by adding H2O2
(13.0 mL; 35 wt% in H2O) to a solution of NaOH (4.07 g; 102 mmol) in H2O (34 mL) at 0
◦C)
was added and stirring continued at rt. After 3 h, the reaction mixture was poured into a
sat. NH4Cl sol. (20 mL) and EtOAc (100 mL), the organic phase separated and the water
phase extracted with EtOAc (3× 250 mL). The combined organic phases were dried over
MgSO4 and concentrated in vacuo. Purification by flash chromatography (hexane/EtOAc
7/3) provided 58 (8.85 g; 63 % yield; d.r. 199:1; 78 % e.e.) as a clear oil.
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5.3 Synthesis of the C7−C11 fragment (B - 39)
OHOBn
OMEM
Name: (3R,4R)-1-benzyloxy-4-(2-methoxy-ethoxymethoxy)-2,2-dimethyl-hex-5-en-3-ol (58)
Formula: C19H30O5
M.M.: 338.44 g/mol
Rf: 0.17 (pentane/Et2O 6/4)
IR: ν = 3504, 2925, 2876, 1496, 1473, 1453, 1385, 1363, 1282, 1248, 1201, 1163, 1094,
1021, 930, 902, 851, 799, 737, 698 cm-1
HRMS (m/z): calcd: 361.1986, found: 361.1987 [M + Na+]
[α]D = − 68.0 (c = 1.21 in CHCl3)
[α]365 = − 206.7
1H NMR (500 MHz, benzene-d6): δ = 7.26 - 7.32 (m, 2 H), 7.13 - 7.20 (m, 2 H), 7.05 -
7.12 (m, 1 H), 5.90 (ddd, J=17.3, 10.2, 8.5 Hz, 1 H), 5.09 (dd, J=17.3, 1.7 Hz, 1 H),
5.03 (dd, J=10.2, 1.7 Hz, 1 H), 4.74 (d, J=6.8 Hz, 1 H), 4.50 (d, J=6.8 Hz, 1 H),
4.37 (d, J=12.1 Hz, 1 H), 4.34 (d, J=12.1 Hz, 1 H), 4.31 (dd, J=8.6, 4.2 Hz, 1 H),
3.71 (dd, J=6.4, 4.2 Hz, 1 H), 3.65 (dt, J=11.0, 4.8 Hz, 1 H), 3.53 (d, J=8.5 Hz, 1
H), 3.40 (dt, J=11.0, 4.8 Hz, 1 H), 3.28 (t, J=4.8 Hz, 2 H), 3.27 (d, J=8.5 Hz, 1 H),
3.13 (d, J=6.3 Hz, 1 H), 3.10 (s, 3 H), 1.15 (s, 3 H), 1.11 (s, 3 H) ppm
APT (126 MHz, benzene-d6): δ = 139.7 (C), 137.6 (CH), 128.9, 128.1, 127.9, 118.9 (CH2),
92.9 (CH2), 78.7 (CH2), 78.5 (CH), 78.2 (CH), 73.9 (CH2), 72.6 (CH2), 68.6 (CH2),
59.0 (CH3), 39.5 (C), 23.3 (CH3), 22.1 (CH3) ppm
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5. Experimental
5.3.5 Synthesis of SEM ether 38
OSEMOBn
OMEM
OHOBn
OMEM
SEM-Cl, DIPEA 
CH2Cl2, reflux
92%
58 38
To a solution of 58 (2.01 g; 5.95 mmol) in CH2Cl2 (5.95 mL) at rt were added DIPEA
(2.59 mL; 14.9 mmol) and SEM-Cl (2.11 mL; 11.9 mmol) dropwise, with formation of a white
haze that disappears after a couple of minutes. The reaction mixture was heated at reflux
temperature for 45 min, after which it was poured into a sat. NaHCO3 sol. (200 mL) and
CH2Cl2 (200 mL), the organic phase separated and the water phase extracted with CH2Cl2
(2× 200 mL). The combined organic phases were dried over MgSO4 and concentrated in
vacuo. Purification by flash chromatography (pentane/EtOAc 3/1) provided 38 (2.57 g;
92 % yield) as a clear oil.
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5.3 Synthesis of the C7−C11 fragment (B - 39)
OSEMOBn
OMEM
Name: (3R,4R)-6-benzyloxy-3-(2-methoxy-ethoxymethoxy)-5,5-dimethyl-4-(2-
trimethylsilyl-ethoxymethoxy)-hex-1-ene (38)
Formula: C25H44O6Si
M.M.: 468.70 g/mol
Rf: 0.23 (pentane/Et2O 3/1)
IR: ν = 2952, 2876, 1476, 1454, 1413, 1375, 1362, 1248, 1197, 1102, 1024, 935, 859, 836,
736, 697 cm-1
HRMS (m/z): calcd: 486.3246, found: 486.3249 [M + NH4
+]
[α]D = − 28.6 (c = 2.41 in CHCl3)
[α]365 = − 91.5
1H NMR (500 MHz, benzene-d6): δ = 7.30 - 7.35 (m, 2 H), 7.17 - 7.21 (m, 2 H), 7.06 -
7.12 (m, 1 H), 5.98 (ddd, J=17.3, 10.3, 7.4 Hz, 1 H), 5.20 (d, J=17.3 Hz, 1 H), 5.06
(d, J=10.3 Hz, 1 H), 4.85 (s, 2 H), 4.79 (d, J=6.8 Hz, 1 H), 4.68 (d, J=6.8 Hz, 1 H),
4.49 (dd, J=7.4, 4.1 Hz, 1 H), 4.44 (d, J=12.0 Hz, 1 H), 4.39 (d, J=12.0 Hz, 1 H),
3.68 - 3.83 (m, 4 H), 3.53 - 3.59 (m, 1 H), 3.46 (d, J=8.5 Hz, 1 H), 3.34 - 3.41 (m,
2 H), 3.32 (d, J=8.7 Hz, 1 H), 3.12 (s, 3 H), 1.28 (s, 3 H), 1.26 (s, 3 H), 0.95 - 1.06
(m, 2 H), 0.00 (s, 9 H) ppm
APT (126 MHz, benzene-d6): δ = 139.8 (C), 138.1 (CH), 128.9, 128.7, 128.0, 117.5 (CH2),
98.3 (CH2), 93.6 (CH2), 84.7 (CH), 78.7 (CH), 78.4 (CH2), 73.7 (CH2), 72.6 (CH2),
68.3 (CH2), 66.4 (CH2), 59.0 (CH3), 40.5 (C), 23.0 (CH3), 22.8 (CH3), 18.7 (CH2),
-0.9 (3 CH3) ppm
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5.3.6 Synthesis of aldehyde B - 39
OSEMOBn
OMEM
OOSEMOBn
OMEM
i)
 OsO4, NMMO 
acetone, H2O, rt
ii)
 NaIO4, rt
95%
B - 3938
To a solution of 38 (8.81 g; 18.8 mmol) in acetone (45 mL) and H2O (45 mL) at rt were
added NMMO (4.40 g; 37.6 mmol) and OsO4 (1.19 mL; 188µmol; 4 wt% in H2O), which
resulted in a yellow suspension. After stirring for 26 h, NaIO4 (16.1 g; 75.1 mmol) was
added and stirring continued for 35 min, after which the reaction mixture was poured into
a sat. Na2S2O3 sol. (400 mL) and Et2O (250 mL), which resulted in a gray suspension.
After stirring for 18 min, the reaction mixture was poured into Et2O (250 mL), the organic
phase separated and the water phase extracted with Et2O (2× 500 mL). The combined
organic phases were dried over MgSO4 and concentrated in vacuo. Purification by flash
chromatography (pentane/acetone 9/1) provided B - 39 (8.37 g; 95 % yield) as a clear oil.
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5.3 Synthesis of the C7−C11 fragment (B - 39)
OSEMOBn
OMEM
O
Name: (2S,3R)-5-benzyloxy-2-(2-methoxy-ethoxymethoxy)-4,4-dimethyl-3-(2-
trimethylsilyl-ethoxymethoxy)-pentanal (B - 39)
Formula: C24H42O7Si
M.M.: 470.67 g/mol
Rf: 0.26 (pentane/Et2O 6/4)
IR: ν = 2952, 2879, 1731, 1454, 1365, 1249, 1099, 1069, 1025, 936, 860, 836, 772, 699 cm-1
HRMS (m/z): calcd: 488.3038, found: 488.3039 [M + NH4
+]
[α]D = − 15.2 (c = 1.00 in CHCl3)
[α]365 = − 30.4
1H NMR (500 MHz, benzene-d6): δ = 9.83 (d, J=0.9 Hz, 1 H), 7.25 - 7.30 (m, 2 H),
7.14 - 7.20 (m, 2 H), 7.06 - 7.11 (m, 1 H), 4.73 (d, J=6.8 Hz, 1 H), 4.67 (s, 2 H), 4.64
(d, J=6.8 Hz, 1 H), 4.32 (d, J=11.7 Hz, 1 H), 4.27 (d, J=12.0 Hz, 1 H), 4.19 (dd,
J=2.6, 0.9 Hz, 1 H), 4.09 (d, J=2.7 Hz, 1 H), 3.77 (td, J=9.1, 7.7 Hz, 1 H), 3.62
(ddd, J=10.9, 5.2, 4.3 Hz, 1 H), 3.49 - 3.56 (m, 2 H), 3.31 (d, J=8.8 Hz, 1 H), 3.24
(ddd, J=5.3, 4.3, 0.9 Hz, 2 H), 3.12 (d, J=8.8 Hz, 1 H), 3.07 (s, 3 H), 1.12 (s, 3 H),
1.10 (s, 3 H), 0.94 - 1.01 (m, 2 H), -0.01 (s, 9 H) ppm
APT (126 MHz, benzene-d6): δ = 202.5 (CH), 139.3 (C), 129.0, 128.3, 128.1, 97.5 (CH2),
96.9 (CH2), 83.7 (CH), 81.9 (CH), 77.6 (CH2), 73.7 (CH2), 72.4 (CH2), 68.7 (CH2),
66.3 (CH2), 59.0 (CH3), 40.4 (C), 22.8 (CH3), 22.5 (CH3), 18.5 (CH2), -1.0 (3 CH3)
ppm
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5. Experimental
5.3.7 Synthesis of diol 5968
OHOBn
OH
OSEMOBn
OH
98%
TBAF, HMPA, MS 4Å 
rt -> 50°C -> 75°C
37 59
Het startproduct (37) (100 mg; 263µmol) wordt opgelost in HMPA (526µL). Hieraan
worden moleculaire zeven van 4A˚ (500 mg/g startproduct) bijgevoegd. De reactie wordt
nu 15 minuten geroerd op kamertemperatuur waarna TBAF (526µL; 526µmol; 2.0 eq.;
1.0m in THF) wordt toegevoegd. Na 15 uur roeren bij kamertemperatuur is de reactie
nog niet afgelopen en wordt het reactiemengsel verwarmd tot 50 ◦C. Na 3 uur is de reactie
verder gevorderd maar nog steeds niet afgelopen. Hierna wordt aan het reactiemengsel
nogmaals moleculaire zeven 4A˚ (100 mg) bijgevoegd en wordt de reactie gedurende 5 uur
verder verwarmd tot 75 ◦C. De reactie lijkt via TLC analyse afgelopen en wordt afgewerkt
door toevoeging van NaOH oplossing (15 mL; 3.0 N). Het gequencht reactiemengsel wordt
nu gee¨xtraheerd met die¨thylether (3× 25 mL), de gecombineerde organische fasen worden
gedroogd op MgSO4 en in vacuo geconcentreerd. Het bekomen residu wordt opgezuiverd
via kolomchromatografie (pentaan/die¨thylether 1/1) en het gewenste product (59) wordt
bekomen met een rendement van 98 % (64.0 mg).
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5.3 Synthesis of the C7−C11 fragment (B - 39)
OHOBn
OH
Name: (3R,4R)-6-benzyloxy-5,5-dimethyl-hex-1-ene-3,4-diol (59)
Formula: C15H22O3
M.M.: 250.33 g/mol
Rf: 0.30 (pentane/Et2O 1/1)
IR: ν = 3400, 2963, 2871, 1477, 1453, 1386, 1366, 1206, 1091, 1074, 1014, 991, 921, 865,
737, 698 cm-1
EI-MS (m/z (%)): 262 (<1), 247 (<1), 233 (<1), 214 (<1), 193 (<1), 176 (<1) 159 (<1),
141 (<1), 119 (1), 107 (10), 91 (100), 65 (12), 57 (20)
[α]D = + 30.4 (c = 0.97 in CHCl3)
[α]436 = + 75.4
1H NMR (300 MHz, chloroform-d): δ = 7.35 - 7.19 (m, 5 H), 5.87 (ddd, J=17.2, 10.3,
5.4 Hz, 1 H), 5.27 (ddd (app. dt), J=17.2, 1.5 Hz, 1 H), 5.12 (ddd (app. dt), J=10.3,
1.5 Hz, 1 H), 4.50 (d, J=11.9 Hz; 1 H), 4.45 (d, J=11.90 Hz, 1 H), 4.25 (s, 1 H),
3.70 (s, 1 H), 3.48 (d, J=9.2 Hz, 1 H), 3.24 (s, 1 H), 3.15 (d, J=9.2 Hz, 1H), 3.03 (s,
1 H), 0.98 (s, 3 H), 0.93 (s, 3 H) ppm
APT (75 MHz, chloroform-d): δ = 139.59 (CH), 137.18 (C), 128.59 (CH), 128.04 (CH),
127.80 (CH), 116.26 (CH2), 79.72 (CH), 73.83 (CH2), 70.23 (CH), 38.68 (C), 24.53
(CH3), 21.38 (CH3) ppm
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5. Experimental
5.3.8 Synthesis of acetonide 6068
OBnOHOBn
OH
96%
CSA, DMP, kt O
O
6059
Het in de vorige reactie bekomen diol (59) (25.0 mg; 100µmol) wordt opgelost in DMP
(1.11 mL; 9.07 mmol; 90.0 eq.). Hieraan wordt nu CSA (2.3 mg; 10µmol; 0.1 eq.)
toegevoegd en de reactie wordt gedurende 2 uur geroerd op kamertemperatuur. Het TLC
beeld van deze reactie toont aan dat het eindproduct kwantitatief is gevormd en dat geen
nevenproducten zijn ontstaan. De reactie wordt enkel afgewerkt door filtratie over silica.
Dit levert het gewenste product (60) op met een rendement van 96 % (27.0 mg).
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5.3 Synthesis of the C7−C11 fragment (B - 39)
OBn
O
O
Name: (3R,4R)-6-benzyloxy-3,4-O-isopropylidene-5,5-dimethyl-hex-1-ene (60)
Formula: C18H26O3
M.M.: 290.40 g/mol
Rf: 0.46 (pentane/Et2O 9/1)
IR: ν = 2963, 2932, 2865, 1452, 1378, 1259, 1211, 1168, 1096, 1059, 1024, 923, 879, 809
cm-1
EI-MS (m/z (%)): 290 (<1), 275 (<1), 247 (<1), 232 (<1), 197 (<1), 183 (<1) 162 (<1),
141 (<1), 127 (9), 91 (100), 69 (31), 43 (28)
[α]D = + 104.7 (c = 0.97 in CHCl3)
[α]436 = + 194.8
1H NMR (300 MHz, chloroform-d): δ = 7.30 - 7.20 (m, 5 H), 5.78 (ddd, J=17.3, 10.2,
7.1 Hz, 1 H), 5.28 (ddd (app. dt), J=17.3, 1.30 Hz, 1 H), 5.12 (ddd (app. dt), J=10.2,
0.8 Hz, 1 H), 4.44 (d, J=12.2 Hz, 1 H), 4.39 (d, J=12.2 Hz, 1 H), 4.28 (dd, J=8.0,
7.2 Hz, 1 H), 3.74 (d, J=8.3 Hz, 1 H), 3.23 (d, J=8.9 Hz, 1 H), 3.19 (d, J=8.9 Hz,
1 H), 1.33 (s, 3 H), 1.32 (s, 3 H), 0.94 (s, 3 H), 0.88 (s, 3 H) ppm
APT (75 MHz, chloroform-d): δ = 137.84 (C), 136.73 (CH), 127.24 (CH), 126.32 (CH),
117.00 (CH2), 107.06 (C), 83.40 (CH), 77.19 (CH), 76.24 (CH2), 72.13 (CH2), 35.91
(C), 26.00 (CH3), 25.97 (CH3), 20.51 (CH3), 19.77 (CH3) ppm
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5.4 Coupling of A - 31 and B - 39; Synthesis of the
C1−C11 fragment (D - 64)
5.4.1 Synthesis of hydroxy ketone 45
OSEMOBn
OMEM
OHO
O
OMEM
OMeO O OMe
OMEM
O
OOSEMOBn
OMEM
Cy2BCl, Et3N              
Et2O, -78°C -> -45°C
94% total yield
d.r. 1.9:1
61% isolated yield
O
+
B - 39 A - 31 45
To a solution of A - 31 (7.28 g; 22.7 mmol) in Et2O (227 mL) at 0
◦C was added Et3N
(3.80 mL; 27.3 mmol) and dicyclohexylboron chloride (25.0 mL; 1m in hexanes). After stir-
ring for 30 min the reaction mixture was cooled to −78 ◦C and a solution of B - 39 (7.13 g;
15.2 mmol) in Et2O (75 mL) was added via cannula. After stirring for 3 h at −78 ◦C, the
reaction mixture was left to warm to −45 ◦C overnight. After stirring for 22 h, the reaction
mixture was warmed to 0 ◦C and quenched by the addition of a pH 7 phosphate buffer
(81 mL), MeOH (81 mL) and H2O2 (19.5 mL; 35 wt% in H2O). After stirring for 90 min,
the reaction mixture was poured into H2O (500 mL) and CH2Cl2 (1 L), the organic phase
separated and the water phase extracted with CH2Cl2 (2× 1 L). Purification by sequential
flash chromatography (CH2Cl2/Et2O/MeOH 8.9/1/0.1 and CH2Cl2/acetone 9/1) provided
45 (7.32 g; 61 % yield; d.r. 1.9:1; 94 % yield on both diastereomers; 92 % recovered excess
A - 31) as a clear oil.
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5.4 Coupling of A - 31 and B - 39; Synthesis of the C1−C11 fragment (D - 64)
OSEMOBn
OMEM
OH O OMe
OMEM
O
O
Name: (2S,3S,4R,8R,9R,10R)-12-benzyloxy-8-hydroxy-1,2-O-isopropylidene-4-
methoxy-3,9-di-(2-methoxy-ethoxymethoxy)-11,11-dimethyl-10-(2-trimethylsilyl-
ethoxymethoxy)-dodecan-6-one (45)
Formula: C39H70O14Si
M.M.: 791.05 g/mol
Rf: 0.17 (CH2Cl2/acetone 9/1)
IR: ν = 3473, 2930, 2888, 1713, 1454, 1371, 1250, 1207, 1101, 1034, 857, 745, 695, 666,
615 cm-1
HRMS (m/z): calcd: 808.4873, found: 808.4874 [M + NH4
+]
[α]D = + 14.6 (c = 1.97 in CHCl3)
[α]436 = + 43.2
1H NMR (500 MHz, benzene-d6): δ = 7.31 (d, J=7.1 Hz, 2 H), 7.20 (t, J=7.6 Hz, 2 H),
7.07 - 7.12 (m, 1 H), 4.96 (d, J=6.8 Hz, 1 H), 4.84 - 4.88 (m, 1 H), 4.72 - 4.83 (m,
4 H), 4.49 - 4.57 (m, 1 H), 4.28 - 4.39 (m, 3 H), 4.17 (dt, J=8.3, 4.0 Hz, 1 H), 4.11
(d, J=6.0 Hz, 1 H), 4.00 (dd, J=8.4, 6.1 Hz, 1 H), 3.96 (t, J=4.8 Hz, 1 H), 3.92 (d,
J=4.4 Hz, 1 H), 3.78 - 3.87 (m, 3 H), 3.68 - 3.79 (m, 2 H), 3.58 - 3.68 (m, 2 H), 3.53
(ddd, J=10.9, 5.6, 3.5 Hz, 1 H), 3.39 (t, J=4.7 Hz, 2 H), 3.27 - 3.36 (m, 2 H), 3.25
(d, J=9.0 Hz, 1 H), 3.20 (s, 3 H), 3.16 (s, 3 H), 3.14 - 3.17 (m, 1 H), 3.13 (s, 3 H),
2.98 - 3.07 (m, 2 H), 2.90 (dd, J=16.5, 9.5 Hz, 1 H), 2.72 (dd, J=17.2, 8.4 Hz, 1 H),
1.44 (s, 3 H), 1.37 (s, 3 H), 1.13 (s, 3 H), 1.08 - 1.15 (m, 1 H), 1.06 (s, 3 H), 0.96 -
1.04 (m, 1 H), 0.03 (s, 9 H) ppm
APT (126 MHz, benzene-d6): δ = 209.0 (C), 139.4 (C), 129.0, 128.3, 128.1, 109.1 (C),
97.6 (CH2), 96.9 (CH2), 96.7 (CH2), 81.2 (CH), 80.7 (CH), 77.8 (CH2), 77.6 (2 CH),
77.2 (CH), 73.7 (CH2), 72.6 (CH2), 72.5 (CH2), 69.7 (CH), 68.4 (CH2), 68.2 (CH2),
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67.1 (CH2), 66.9 (CH2), 59.0 (2 CH3), 58.3 (CH3), 47.1 (CH2), 45.2 (CH2), 40.1 (C),
27.2 (CH3), 26.6 (CH3), 22.4 (CH3), 22.0 (CH3), 18.5 (CH2), -0.9 (3 CH3) ppm
5.4.2 Synthesis of methyl ether 46
Me3OBF4
Proton-sponge®
MS 4Å, CH2Cl2, rt
OBn OSEM
OMEM
OMe O OMe
OMEM
O
OOSEMOBn
OMEM
OH O OMe
OMEM
O
O
91%
4645
To a solution of 45 (6.56 g; 8.29 mmol) in CH2Cl2 (199 mL) at rt were added molecular
sieves (3.3 g; 4 A˚; powdered; activated). After stirring for 30 min at 0 ◦C, Proton-sponge R©
(7.11 g; 33.2 mmol) and Me3OBF4 (4.29 g; 29.0 mmol) were added. After stirring for 15 min
at 0 ◦C and 3.5 h at rt, the yellow-orange suspension was filtered over a fritted funnel and
the filtrate (+ 500 mL CH2Cl2) was washed with a 1mCuSO4 sol. (2× 700 mL). The water
phases were back-extracted with CH2Cl2 (3× 700 mL), the combined organic phases dried
over MgSO4 and concentrated in vacuo. The resulting yellow sludge was filtered over a
silica plug and rinsed with Et2O. Purification by flash chromatography (hexane/acetone
9/1 → 8/2) provided 46 (6.06 g; 91 % yield) as a clear oil.
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5.4 Coupling of A - 31 and B - 39; Synthesis of the C1−C11 fragment (D - 64)
OBn OSEM
OMEM
OMe O OMe
OMEM
O
O
Name: (2S,3S,4R,8R,9R,10R)-12-benzyloxy-1,2-O-isopropylidene-4,8-dimethoxy-3,9-di-
(2-methoxy-ethoxymethoxy)-11,11-dimethyl-10-(2-trimethylsilyl-ethoxymethoxy)-
dodecan-6-one (46)
Formula: C40H72O14Si
M.M.: 805.08 g/mol
Rf: 0.26 (CH2Cl2/acetone 9/1)
IR: ν = 2936, 2884, 2366, 2326, 1718, 1458, 1378, 1368, 1248, 1098, 1028, 858, 839 cm-1
HRMS (m/z): calcd: 822.5030, found: 822.5027 [M + NH4
+]
[α]D = + 43.8 (c = 1.01 in CHCl3)
[α]436 = + 130.2
1H NMR (500 MHz, benzene-d6): δ = 7.35 (d, J=7.1 Hz, 2 H), 7.21 (t, J=7.6 Hz, 2 H),
7.08 - 7.13 (m, 1 H), 5.00 (d, J=6.5 Hz, 1 H), 4.96 (d, J=6.8 Hz, 1 H), 4.89 (d, J=6.5
Hz, 1 H), 4.85 (d, J=6.8 Hz, 1 H), 4.77 (d, J=6.8 Hz, 1 H), 4.74 (d, J=6.6 Hz, 1 H),
4.43 (d, J=12.1 Hz, 1 H), 4.36 (d, J=12.3 Hz, 1 H), 4.28 - 4.34 (m, 2 H), 4.14 - 4.19
(m, 1 H), 4.05 - 4.11 (m, 1 H), 3.94 - 4.02 (m, 2 H), 3.80 - 3.86 (m, 2 H), 3.65 - 3.78
(m, 4 H), 3.58 - 3.65 (m, 2 H), 3.40 - 3.49 (m, 2 H), 3.38 (t, J=4.8 Hz, 2 H), 3.32 (s,
3 H), 3.27 (d, J=9.0 Hz, 1 H), 3.27 (d, J=9.0 Hz, 1 H), 3.19 (s, 3 H), 3.16 (s, 3 H),
3.15 (s, 3 H), 2.88 - 3.13 (m, 3 H), 2.68 (dd, J=17.0, 8.7 Hz, 1 H), 1.43 (s, 3 H), 1.37
(s, 3 H), 1.18 (s, 3 H), 1.09 (s, 3 H), 0.93 - 1.06 (m, 2 H), 0.01 (s, 9 H) ppm
APT (126 MHz, benzene-d6): δ = 207.4 (C), 139.5 (C), 128.9, 128.3, 128.1, 109.1 (C),
97.0 (CH2), 96.7 (CH2), 96.0 (CH2), 80.2 (CH), 79.3 (CH), 77.7 (CH), 77.6 (CH2),
77.5 (CH), 77.2 (CH), 73.8 (CH2), 73.5 (CH), 72.7 (CH2), 72.6 (CH2), 68.1 (CH2),
68.1 (CH2), 67.1 (CH2), 66.5 (CH2), 59.1 (CH3), 59.0 (CH3), 58.4 (CH3), 57.6 (CH3),
45.2 (CH2), 44.7 (CH2), 40.3 (C), 27.2 (CH3), 26.6 (CH3), 22.4 (CH3), 22.0 (CH3),
18.7 (CH2), -0.9 (3 CH3) ppm
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5.4.3 Synthesis of alcohol 47
OBn OSEM
OMEM
OMe OH OMe
OMEM
O
OOBn OSEM
OMEM
OMe O OMe
OMEM
O
O NaEt3BH 
CH2Cl2, -78°C
quant.   
d.r. 49:1
46 47
To a solution of 46 (5.52 g; 6.86 mmol) in CH2Cl2 (446 mL) at −78 ◦C was added NaEt3BH
(13.7 mL; 1m in THF) dropwise. After stirring for 40 min, the reaction mixture was poured
into a pH 7 phosphate buffer (400 mL), the organic phase separated and the water phase
extracted with CH2Cl2 (2× 500 mL). The combined organic phases were dried over MgSO4
and concentrated in vacuo. Purification by flash chromatography (CH2Cl2/acetone 9/1→
7/3) provided 47 (5.53 g; 100 % yield; d.r. 49:1) as a clear oil.
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5.4 Coupling of A - 31 and B - 39; Synthesis of the C1−C11 fragment (D - 64)
OBn OSEM
OMEM
OMe OH OMe
OMEM
O
O
Name: (2S,3S,4R,6S,8R,9R,10R)-12-benzyloxy-1,2-O-isopropylidene-4,8-dimethoxy-3,9-
di-(2-methoxy-ethoxymethoxy)-11,11-dimethyl-10-(2-trimethylsilyl-ethoxymethoxy)-
dodecan-6-ol (47)
Formula: C40H74O14Si
M.M.: 807.09 g/mol
Rf: 0.28 (CH2Cl2/Et2O 4/6)
IR: ν = 2927, 2888, 1458, 1378, 1247, 1202, 1098, 1030, 859, 835, 809, 699 cm-1
HRMS (m/z): calcd: 824.5186, found: 824.5178 [M + NH4
+]
[α]D = + 54.4 (c = 0.99 in CHCl3)
[α]365 = + 158.4
1H NMR (500 MHz, benzene-d6): δ = 7.37 (d, J=7.1 Hz, 2 H), 7.21 (t, J=7.6 Hz, 2 H),
7.08 - 7.13 (m, 1 H), 5.05 (d, J=6.6 Hz, 1 H), 5.03 (d, J=6.9 Hz, 1 H), 5.00 (d, J=6.5
Hz, 1 H), 4.94 (d, J=6.6 Hz, 1 H), 4.86 (d, J=6.5 Hz, 1 H), 4.74 (d, J=6.8 Hz, 1 H),
4.44 - 4.46 (m, 1 H), 4.45 (d, J=12.6 Hz, 1 H), 4.40 (d, J=12.3 Hz, 1 H), 4.27 - 4.37
(m, 2 H), 4.06 (ddd, J=10.8, 5.8, 3.9 Hz, 1 H), 4.00 (dd, J=8.5, 6.1 Hz, 1 H), 3.86
(dd, J=7.1, 3.9 Hz, 1 H), 3.79 - 3.85 (m, 4 H), 3.73 (ddd, J=10.4, 6.1, 3.8 Hz, 1 H),
3.64 - 3.70 (m, 3 H), 3.53 (ddd, J=10.8, 5.6, 3.2 Hz, 1 H), 3.44 - 3.50 (m, 2 H), 3.43
(s, 3 H), 3.36 (s, 1 H), 3.32 - 3.38 (m, 2 H), 3.29 (ddd, J=10.7, 5.7, 3.3 Hz, 1 H),
3.26 (d, J=2.7 Hz, 1 H), 3.17 (s, 3 H), 3.12 (s, 3 H), 3.05 (s, 3 H), 1.98 - 2.10 (m, 3
H), 1.68 (dt, J=14.5, 9.0 Hz, 1 H), 1.43 (s, 3 H), 1.34 (s, 3 H), 1.25 (s, 3 H), 1.17 (s,
3 H), 0.93 - 1.06 (m, 2 H), 0.02 (s, 9 H) ppm
APT (126 MHz, benzene-d6): δ = 139.6 (C), 128.9, 128.7, 128.0, 108.9 (C), 96.8 (CH2),
96.8 (CH2), 96.0 (CH2), 82.9 (CH), 81.0 (CH), 78.7 (CH), 77.8 (CH2), 77.6 (CH),
77.5 (CH), 73.8 (CH2), 73.1 (CH), 72.8 (CH2), 72.6 (CH2), 68.5 (CH), 68.0 (CH2),
67.9 (CH2), 66.8 (CH2), 66.5 (CH2), 59.1 (CH3), 59.0 (CH3), 57.7 (CH3), 57.7 (CH3),
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40.3 (C), 38.4 (CH2), 38.3 (CH2), 27.3 (CH3), 26.5 (CH3), 22.4 (CH3), 22.3 (CH3),
18.7 (CH2), -0.9 (3 CH3) ppm
5.4.4 Synthesis of MOM ether 62
OBn OSEM
OMEM
OMe OMOM OMe
OMEM
O
OOBn OSEM
OMEM
OMe OH OMe
OMEM
O
O MOM-Cl, DIPEA 
TBAI, CH2Cl2, reflux
96%
6247
To a solution of 47 (5.53 g; 6.85 mmol) in CH2Cl2 (68.5 mL) at rt were added TBAI (1.27 g;
3.43 mmol), DIPEA (5.25 mL; 30.2 mmol) and MOM-Cl (12.1 mL; 2.27m in CH2Cl2) drop-
wise, with formation of a white haze that disappears after a couple of minutes. Next, the
reaction mixture was heated at reflux temperature for 28 h, after which it was poured into a
sat. NH4Cl sol. (500 mL) and CH2Cl2 (600 mL), the organic phase separated and the water
phase extracted with CH2Cl2 (2× 600 mL). The combined organic phases were dried over
MgSO4 and concentrated in vacuo. Purification by flash chromatography (hexane/acetone
7/1 → 3/1) provided 62 (5.58 g; 96 % yield) as a clear oil.
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5.4 Coupling of A - 31 and B - 39; Synthesis of the C1−C11 fragment (D - 64)
OBn OSEM
OMEM
OMe OMOM OMe
OMEM
O
O
Name: (2S,3S,4R,6S,8R,9R,10R)-12-benzyloxy-1,2-O-isopropylidene-4,8-dimethoxy-
3,9-di-(2-methoxy-ethoxymethoxy)-6-methoxymethoxy-11,11-dimethyl-10-(2-
trimethylsilyl-ethoxymethoxy)-dodecane (62)
Formula: C42H78O15Si
M.M.: 851.15 g/mol
Rf: 0.33 (hexane/acetone 3/1)
IR: ν = 2925, 2888, 2822, 1454, 1380, 1368, 1248, 1207, 1152, 1098, 1022, 936, 919, 858,
836, 752, 698, 665 cm-1
HRMS (m/z): calcd: 868.5448, found: 868.5447 [M + NH4
+]
[α]D = + 67.2 (c = 0.99 in CHCl3)
[α]365 = + 194.7
1H NMR (500 MHz, benzene-d6): δ = 7.35 (d, J=7.3 Hz, 2 H), 7.21 (t, J=7.6 Hz, 2 H),
7.08 - 7.13 (m, 1 H), 5.10 (d, J=6.9 Hz, 1 H), 5.06 (d, J=6.7 Hz, 1 H), 4.98 (d, J=6.4
Hz, 1 H), 4.91 (d, J=6.6 Hz, 1 H), 4.85 (d, J=6.7 Hz, 2 H), 4.72 (d, J=6.6 Hz, 1 H),
4.62 (d, J=6.6 Hz, 1 H), 4.47 (dd, J=6.6, 1.1 Hz, 1 H), 4.43 (d, J=12.2 Hz, 1 H),
4.40 (d, J=11.6 Hz, 1 H), 4.37 (dd, J=13.7, 7.6 Hz, 1 H), 4.22 (tt, J=7.7, 3.7 Hz, 1
H), 4.02 - 4.10 (m, 2 H), 3.94 (dd, J=7.2, 4.2 Hz, 1 H), 3.90 (t, J=8.4 Hz, 1 H), 3.84
(td, J=9.6, 6.4 Hz, 1 H), 3.79 (ddd, J=10.7, 6.0, 4.1 Hz, 1 H), 3.54 - 3.76 (m, 6 H),
3.46 - 3.53 (m, 2 H), 3.41 - 3.46 (m, 2 H), 3.41 (d, J=8.7 Hz, 1 H), 3.37 (s, 3 H), 3.34
(d, J=9.0 Hz, 1 H), 3.26 (s, 3 H), 3.25 (s, 3 H), 3.17 (s, 3 H), 3.17 (s, 3 H), 2.07 -
2.21 (m, 3 H), 1.83 (ddd, J=14.0, 9.3, 4.1 Hz, 1 H), 1.44 (s, 3 H), 1.36 (s, 3 H), 1.23
(s, 3 H), 1.16 (s, 3 H), 0.91 - 1.03 (m, 2 H), 0.01 (s, 9 H) ppm
APT (126 MHz, benzene-d6): δ = 139.7 (C), 128.9, 128.7, 128.0, 108.8 (C), 96.6 (CH2),
96.6 (CH2), 96.6 (CH2), 95.9 (CH2), 81.3 (CH), 79.2 (CH), 78.3 (CH), 77.8 (CH2),
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77.8 (CH), 77.5 (CH), 73.9 (CH), 73.7 (CH2), 72.8 (CH2), 72.7 (CH2), 72.1 (CH),
68.0 (CH2), 67.9 (CH2), 67.0 (CH2), 66.5 (CH2), 59.1 (CH3), 59.0 (CH3), 57.8 (CH3),
57.1 (CH3), 56.0 (CH3), 40.3 (C), 36.4 (CH2), 35.9 (CH2), 27.3 (CH3), 26.5 (CH3),
22.6 (CH3), 21.8 (CH3), 18.7 (CH2), -0.9 (3 CH3) ppm
5.4.5 Synthesis of alcohol 63
OH OSEM
OMEM
OMe OMOM OMe
OMEM
O
OOBn OSEM
OMEM
OMe OMOM OMe
OMEM
O
O Pd/C, H2 
EtOH, rt
98%
62 63
To a solution of 62 (1.75 g; 2.06 mmol) in EtOH (20 mL) at rt was added Pd/C (175 mg;
10 wt% loading) and H2 was bubbled through the reaction mixture. After stirring for 4 h,
an extra addition of Pd/C (175 mg; 10 wt% loading) was needed, and 2 h later, the black
reaction mixture was filtered over a celite R© plug, rinsed with CH2Cl2 (100 mL) and concen-
trated in vacuo. Purification by flash chromatography (hexane/acetone 85/15) provided
63 (1.53 g; 98 % yield) as a clear oil.
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5.4 Coupling of A - 31 and B - 39; Synthesis of the C1−C11 fragment (D - 64)
OH OSEM
OMEM
OMe OMOM OMe
OMEM
O
O
Name: (3R,4R,5R,7R,9R,10S,11S )-11,12-O-isopropylidene-5,9-dimethoxy-4,10-di-(2-
methoxy-ethoxymethoxy)-7-methoxymethoxy-2,2-dimethyl-3-(2-trimethylsilyl-
ethoxymethoxy)-dodecan-1-ol (63)
Formula: C35H72O15Si
M.M.: 761.02 g/mol
Rf: 0.17 (hexane/acetone 3/1)
IR: ν = 3500, 2930, 2887, 2822, 1465, 1453, 1377, 1369, 1248, 1199, 1153, 1098, 1021, 938,
919, 858, 836, 794, 763, 698, 662 cm-1
HRMS (m/z): calcd: 778.4979, found: 778.4977 [M + NH4
+]
[α]D = + 79.5 (c = 1.14 in CHCl3)
[α]365 = + 229.5
1H NMR (500 MHz, benzene-d6): δ = 5.09 (d, J=6.9 Hz, 1 H), 4.99 (d, J=6.6 Hz, 1 H),
4.98 (d, J=6.6 Hz, 1 H), 4.90 (d, J=6.7 Hz, 1 H), 4.83 (d, J=6.7 Hz, 1 H), 4.74 (d,
J=6.7 Hz, 1 H), 4.71 (d, J=6.7 Hz, 1 H), 4.62 (d, J=6.7 Hz, 1 H), 4.32 - 4.39 (m, 2
H), 4.16 - 4.24 (m, 1 H), 4.05 (dd, J=8.5, 6.2 Hz, 1 H), 3.99 (ddd, J=11.0, 5.5, 4.0
Hz, 1 H), 3.93 (dd, J=7.3, 4.3 Hz, 1 H), 3.89 (t, J=8.2 Hz, 1 H), 3.71 - 3.84 (m, 5
H), 3.58 - 3.70 (m, 3 H), 3.40 - 3.51 (m, 5 H), 3.38 (s, 3 H), 3.35 - 3.40 (m, 1 H), 3.28
(s, 3 H), 3.25 (s, 3 H), 3.17 (s, 3 H), 3.16 (s, 3 H), 3.14 - 3.19 (m, 1 H), 2.08 - 2.18
(m, 2 H), 1.97 - 2.06 (m, 1 H), 1.81 (ddd, J=14.3, 9.0, 4.0 Hz, 1 H), 1.44 (s, 3 H),
1.36 (s, 3 H), 1.10 (s, 3 H), 1.03 (s, 3 H), 0.95 (ddd, J=9.9, 6.8, 2.8 Hz, 2 H), -0.03
(s, 9 H) ppm
APT (126 MHz, benzene-d6): δ = 108.9 (C), 96.8 (CH2), 96.6 (CH2), 96.6 (CH2), 96.3
(CH2), 81.2 (CH), 79.2 (CH), 79.2 (CH), 77.7 (CH), 77.4 (CH), 73.8 (CH), 73.3
(CH), 72.7 (CH2), 72.6 (CH2), 70.9 (CH2), 68.1 (CH2), 68.0 (CH2), 67.0 (CH2), 66.7
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(CH2), 59.1 (CH3), 59.0 (CH3), 57.8 (CH3), 57.3 (CH3), 56.0 (CH3), 40.3 (C), 36.3
(CH2), 36.3 (CH2), 27.3 (CH3), 26.5 (CH3), 23.4 (CH3), 20.3 (CH3), 18.6 (CH2), -1.1
(3 CH3) ppm
5.4.6 Synthesis of aldehyde D - 64
O OSEM
OMEM
OMe OMOM OMe
OMEM
O
OOH OSEM
OMEM
OMe OMOM OMe
OMEM
O
O (COCl)2, DMSO 
Et3N, CH2Cl2, -78°C
97%
D - 6463
To a solution of (COCl)2 (379µL; 4.42 mmol) in CH2Cl2 (14.0 mL) at −78 ◦C was added
DMSO (628µL; 8.84 mmol) dropwise. After stirring for 15 min, a precooled solution of 63
(1.53 g; 2.01 mmol) in CH2Cl2 (6.0 mL) was added via cannula and stirring continued for
20 min, followed by the addition of Et3N (1.96 mL; 14.1 mmol). After stirring for 50 min,
the reaction mixture was poured into H2O (100 mL) and CH2Cl2 (100 mL), the organic
phase separated and the water phase extracted with CH2Cl2 (3× 100 mL). The combined
organic phases were dried over MgSO4 and concentrated in vacuo. Purification by flash
chromatography (hexane/acetone 85/15) provided D - 64 (1.48 g; 97 % yield) as a clear oil.
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5.4 Coupling of A - 31 and B - 39; Synthesis of the C1−C11 fragment (D - 64)
O OSEM
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Name: (3R,4R,5R,7R,9R,10S,11S )-11,12-O-isopropylidene-5,9-dimethoxy-4,10-di-(2-
methoxy-ethoxymethoxy)-7-methoxymethoxy-2,2-dimethyl-3-(2-trimethylsilyl-
ethoxymethoxy)-dodecanal (D - 64)
Formula: C35H70O15Si
M.M.: 759.01 g/mol
Rf: 0.27 (hexane/acetone 3/1)
IR: ν = 2977, 2930, 2893, 2822, 1723, 1466, 1377, 1369, 1248, 1202, 1152, 1099, 1060,
1017, 938, 919, 892, 858, 836, 794, 755, 698, 665 cm-1
HRMS (m/z): calcd: 776.4822, found: 776.4821 [M + NH4
+]
[α]D = + 69.1 (c = 1.14 in CHCl3)
[α]365 = + 204.0
1H NMR (500 MHz, benzene-d6): δ = 9.76 (s, 1 H), 5.09 (d, J=6.7 Hz, 1 H), 4.94 (d,
J=6.9 Hz, 1 H), 4.90 (d, J=6.6 Hz, 1 H), 4.87 (d, J=6.7 Hz, 1 H), 4.83 (d, J=6.7 Hz,
1 H), 4.74 (d, J=6.9 Hz, 2 H), 4.61 (d, J=6.6 Hz, 1 H), 4.32 - 4.39 (m, 1 H), 4.14 -
4.23 (m, 2 H), 4.06 (dd, J=8.4, 6.3 Hz, 1 H), 3.86 - 3.95 (m, 3 H), 3.74 - 3.85 (m, 3
H), 3.60 - 3.73 (m, 3 H), 3.51 - 3.57 (m, 1 H), 3.44 - 3.50 (m, 1 H), 3.37 - 3.44 (m, 4
H), 3.30 (s, 3 H), 3.27 (s, 3 H), 3.25 (s, 3 H), 3.16 (s, 3 H), 3.15 (s, 3 H), 2.14 (ddd,
J=14.3, 7.6, 2.7 Hz, 1 H), 1.97 - 2.11 (m, 2 H), 1.82 (ddd, J=14.0, 9.7, 3.8 Hz, 1 H),
1.45 (s, 3 H), 1.36 (s, 3 H), 1.23 (s, 3 H), 1.08 (s, 3 H), 0.91 - 1.00 (m, 2 H), 0.02 (s,
9 H) ppm
APT (126 MHz, benzene-d6): δ = 203.8 (CH), 108.9 (C), 97.0 (CH2), 96.7 (CH2), 96.6
(CH2), 96.4 (CH2), 80.5 (CH), 80.5 (CH), 79.2 (CH), 77.6 (CH), 77.4 (CH), 74.1
(CH), 73.6 (CH), 72.7 (CH2), 72.6 (CH2), 68.5 (CH2), 68.0 (CH2), 67.0 (CH2), 66.7
(CH2), 59.0 (2 CH3), 57.9 (CH3), 57.2 (CH3), 56.0 (CH3), 50.4 (C), 36.5 (CH2), 36.3
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(CH2), 27.3 (CH3), 26.5 (CH3), 20.3 (CH3), 18.6 (CH2), 18.6 (CH3), -1.0 (3 CH3)
ppm
5.4.7 Synthesis of diols 65 and 6668
OBn OSEM
OMEM
OH OH OMe
OMEM
O
OOSEMOBn
OMEM
OH O OMe
OMEM
O
O
(43,8 %)
NaBH4 
MeOH, kt
OBn OSEM
OMEM
OH OH OMe
OMEM
O
O
+
(24.1%)
45
66
65
Het startproduct (45) (592.5 mg; 750µmol) wordt opgelost in MeOH (5 mL) en hieraan
wordt vervolgens NaBH4 (34.7 mg; 940µmol; 1.25 eq.) toegevoegd en de reactie wordt
gedurende 3 uur op kamertemperatuur geroerd. Na afloop van de reactie wordt het re-
actiemengsel afgewerkt met een verzadigde NH4Cl oplossing (20 mL) en gee¨xtraheerd met
EtOAc (5× 20 mL). De gecombineerde organische fasen worden gedroogd op MgSO4 en
geconcentreerd. Het bekomen residu wordt opgezuiverd via HPLC (75→ 100 % acetonitril
in 20 minuten) op een C18 kolom. We bekomen 65 met een rendement van 43.8 % (260 mg)
en 66 met een rendement van 24.1 % (143 mg).
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5.4 Coupling of A - 31 and B - 39; Synthesis of the C1−C11 fragment (D - 64)
OBn OSEM
OMEM
OH OH OMe
OMEM
O
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Name: (3R,4R,5R,7S,9R,10S,11S )-1-benzyloxy-11,12-O-isopropylidene-9-methoxy-4,10-
di-(2-methoxy-ethoxymethoxy)-2,2-dimethyl-3-(2-trimethylsilyl-ethoxymethoxy)-
dodecane-5,7-diol (65)
Formula: C39H72O14Si
M.M.: 793.07 g/mol
Rf: 0.20 (toluene/acetone 8/2)
IR: ν = 3433, 2930, 2892, 1453, 1369, 1248, 1204, 1098, 1031, 938, 858, 840, 739, 699, 665
cm-1
EI-MS (m/z (%)): 793 (<1), 737 (<1), 692 (<1), 254 (<1), 605 (<1), 537 (<1), 481
(<1), 465 (<1), 392 (<1), 363 (<1), 317 (<1), 275 (<1), 201 (4.2), 149 (15.2), 59
(62.7), 45 (100)
[α]D = + 13.1 (c = 1.11 in CHCl3)
[α]365 = + 36.9
1H NMR (300 MHz, benzene-d6): δ = 7.28 (d, J=6.97 Hz, 2 H), 7.20 (dd (app. t),
J=7.15 Hz, 2 H), 7.10 (dd (app. t), J=7.60 Hz, 1 H), 5.08 (d, J=6.97 Hz, 1 H), 4.86
(d, J=6.97 Hz, 1 H), 4.82 (d, J=6.97 Hz, 1 H), 4.79 (d, J=6.40 Hz, 1 H), 4.78 (d,
J=6.78 Hz, 1 H), 4.74 (d, J=6.78 Hz, 1 H), 4.59 (m, 1 H), 4.38 (m, 2 H), 4.30 (s, 2
H), 4.20 (m, 1 H), 4.98 (dd, J=8.48, 6.03 Hz, 1 H), 3.85 - 4.05 (m, 6 H), 3.55 - 3.75
(m, 4 H), 3.47 (m, 1 H), 3.37 (m, 2 H), 3.32 (s, 3 H), 3.15 - 3.30 (m, 4 H), 3.13 (s,
3 H), 3.10 (s, 3 H), 2.14 (ddd, J=13.56, 10.17, 2.26 Hz, 1 H), 2.05 (ddd (app. dt),
J=14.31, 1.90 Hz, 1 H), 1.91 (m, 1 H), 1.68 (ddd, J=13.00, 10.74, 2.82 Hz, 1 H),
1.46 (s, 3 H), 1.37 (s, 3 H), 1.12 (s, 3 H), 1.02 (s, 3 H), 0.97 (ddd, J=9.42, 7.16, 2.64
Hz, 1 H), 0.00 (s, 9 H) ppm
APT (75 MHz, benzene-d6): δ = 140.26 (C), 129.95 (3 CH), 129.19 (2 CH), 109.74 (C),
98.40 (CH2), 97.85 (CH), 97.63 (CH), 82.55 (CH), 80.99 (CH), 79.94 (CH), 79.26
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(CH), 78.68 (CH2), 78.56 (CH), 75.90 (CH), 74.68 (CH2), 73.63 (CH2), 73.42 (CH2),
70.88 (CH), 69.36 (CH2), 68.93 (CH2), 68.01 (CH2), 67.75 (CH2), 59.94 (2 CH3),
59.64(CH3), 41.03 (CH2), 40.67 (CH2), 40.61 (C), 28.31 (CH3), 27.57 (CH3), 23.54
(CH3), 22.83 (CH3), 19.53 (CH2), 0.00 (3 CH3) ppm
OBn OSEM
OMEM
OH OH OMe
OMEM
O
O
Name: (3R,4R,5R,7R,9R,10S,11S )-1-benzyloxy-11,12-O-isopropylidene-9-methoxy-4,10-
di-(2-methoxy-ethoxymethoxy)-2,2-dimethyl-3-(2-trimethylsilyl-ethoxymethoxy)-
dodecane-5,7-diol (66)
Formula: C39H72O14Si
M.M.: 793.07 g/mol
Rf: 0.27 (toluene/acetone 8/2)
IR: ν = 3472, 2923, 2894, 1538, 1452, 1368, 1249, 1203, 1099, 1062, 1028, 859, 837, 753,
696, 665 cm-1
EI-MS (m/z (%)): 793 (<1), 737 (<1), 692 (<1), 254 (<1), 605 (<1), 537 (<1), 481
(<1), 465 (<1), 392 (<1), 363 (<1), 317 (<1), 275 (<1), 201 (4.2), 149 (15.2), 59
(62.7), 45 (100)
[α]D = + 10.4 (c = 1.11 in CHCl3)
[α]365 = + 20.2
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5.4 Coupling of A - 31 and B - 39; Synthesis of the C1−C11 fragment (D - 64)
1H NMR (300 MHz, benzene-d6): δ = 7.30 (d, J=7.34 Hz, 2 H), 7.18 (dd (app. t),
J=7.16 Hz, 2 H), 7.08 (dd (app. t), J=7.15 Hz, 1 H), 5.04 (d, J=6.79 Hz, 1 H), 4.94
(d, J=6.78 Hz, 1 H), 4.75 - 4.82 (m, 4 H), 4.45 (m, 1 H), 4.37 (m, 2 H), 4.34 (s, 2
H), 4.05 (m, 1 H), 3.95 - 4.02 (m, 2 H), 3.75 - 3.90 (m, 2 H), 3.50 - 3.75 (m, 7 H),
3.20 - 3.37 (m, 5 H), 3.10 (s, 6 H), 3.09 (s, 3 H), 3.05 - 3.15 (m, 1 H), 2.05 - 2.20 (m,
2 H), 1.75 - 1.95 (m, 2 H), 1.42 (s, 3 H), 1.33 (s, 3 H), 1.15 (s, 3 H), 1.10 (s, 3 H),
0.85 - 1.10 (m, 2 H), 0.00 (s, 9 H) ppm
APT (75 MHz, benzene-d6): δ = 140.48 (C), 129.91 (2 CH), 129.18 (3 CH), 109.91 (C),
98.69 (CH2), 97.82 (CH2), 97.68 (CH2), 83.25 (CH), 83.14 (CH), 82.00 (CH), 78.89
(CH), 78.90 (CH2), 78.60 (CH), 74.66 (CH2), 73.56 (CH2), 73.54 (CH2), 70.55 (CH),
69.46 (CH), 69.30 (CH2), 69.06 (CH2), 67.82 (CH2), 59.96 (CH3), 59.93 (CH3), 58.64
(CH3), 41.77 (C), 41.16 (CH2), 39.31 (CH), 28.27 (CH3), 27.45 (CH3), 23.36 (CH3),
23.23 (CH3), 19.50 (CH2), 0.00 (3 CH3) ppm
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5.4.8 Synthesis of acetonide 6768
OBn OSEM
OMEM
O O OMe
OMEM
O
OOSEMOBn
OMEM
OH OH OMe
OMEM
O
O
65%
CSA, DMP, 50°C
6765
Het startproduct (65) (39.6 mg; 50µmol) wordt opgelost in DMP (2.5 mL) en hieraan wordt
CSA (1.2 mg; 5µmol; 0.1 eq.) toegevoegd. De reactie wordt nu gedurende 16 uur geroerd
bij 50 ◦C. Na afloop wordt de reactie afgewerkt met pH 7 buffer (10 mL) en gee¨xtraheerd
met dichloormethaan (5× 20 mL). De gecombineerde organische fasen worden gedroogd op
MgSO4 en in vacuo geconcentreerd. Het bekomen residu wordt gezuiverd via kolomchro-
matografie (tolueen/aceton 9/1) en het gewenste product (67) wordt bekomen met een
rendement van 65.0 % (26.3 mg).
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OBn OSEM
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O O OMe
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Name: (3R,4R,5R,7R,9R,10S,11S )-1-benzyloxy-5,7-O :11,12-O-bis(isopropylidene)-
9-methoxy-4,10-di-(2-methoxy-ethoxymethoxy)-2,2-dimethyl-3-(2-trimethylsilyl-
ethoxymethoxy)-dodecane (67)
Formula: C42H76O14Si
M.M.: 833.13 g/mol
Rf: 0.57 (toluene/acetone 8/2)
IR: ν = 2983, 2927, 1456, 1375, 1249, 1206, 1160, 1095, 1039, 864, 738, 696, 666 cm-1
EI-MS (m/z (%)): 831 (<1), 784 (<1), 743 (<1), 674 (<1), 639 (<1), 583 (<1), 520
(<1), 495 (<1), 446 (<1), 391 (<1), 377 (1.7), 333 (8.5), 275 (11.8), 197 (4.2), 153
(9.3), 149 (15.2), 91 (100), 45 (100)
[α]D = + 5.1 (c = 0.99 in CHCl3)
[α]365 = + 8.5
1H NMR (300 MHz, benzene-d6): δ = 7.32 (d, J=7.33 Hz, 2 H), 7.20 (d, J=7.26 Hz, 2
H), 7.02 (dd (app. t), J=7.18 Hz, 1 H), 5.04 (d, J=6.78 Hz, 1 H), 4.96 (d, J=6.48
Hz, 1 H), 4.92 (d, J=8.20 Hz, 1 H), 4.90 (m, 1 H), 4.82 (d, J=6.81 Hz, 1 H), 4.78
(d, J=6.66 Hz, 1 H), 4.38 (d, J=11.35 Hz, 1 H), 4.35 (d, J=11.35 Hz, 1 H), 4.33 (s,
1 H), 4.27 (ddd (app. q), J=6.39 Hz, 1 H), 3.91 - 4.17 (m, 5 H), 3.60 - 3.91 (m, 8
H), 3.30 - 3.50 (m, 6 H), 3.22 (s, 3 H), 3.15 (s, 3 ), 3.13 (s, 3 H), 3.03 (dd, J=12.51,
9.84 Hz, 1 H), 1.71 (dd (app. t), J=5.81 Hz, 1 H), 1.51 (m, 1 H), 1.48 (s, 3 H), 1.45
(s, 3 H), 1.35 (s, 6 H), 1.28 (m, 1 H), 1.20 (s, 3 H), 1.10 (s, 3 H), 1.00 (m, 2 H), 0.00
(s, 9 H) ppm
APT (75 MHz, benzene-d6): δ = 140.50 (C), 129.92 (CH), 129.80 (CH), 129.61
(CH),109.69 (C), 99.97 (C), 97.74 (CH2), 97.70 (CH2), 96.98 (CH2), 79.28 (CH),
79.08 (CH), 78.81 (CH), 78.74 (CH2), 78.28 (CH), 77.47 (CH), 74.57 (CH2), 73.56
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(CH2), 73.36 (CH), 68.86 (CH2), 68.78 (CH2), 67.88 (CH2), 67.31 (CH2), 67.12 (CH),
59.92 (CH3), 59.89 (CH3), 59.71 (CH3), 40.89 (CH2), 39.23 (C) ,31.69 (CH3), 31.43
(CH2), 28.21 (CH3), 27.49 (CH3), 23.19 (CH3), 22.58 (CH3), 21.19 (CH3), 19.64
(CH2), 0.00 (CH3) ppm
5.4.9 Synthesis of acetonide 6868
OBn OSEM
OMEM
O O OMe
OMEM
O
OOSEMOBn
OMEM
OH OH OMe
OMEM
O
O
34%
CSA, DMP, 50°C
6866
Het startproduct (66) (39.6 mg, 50µmol) wordt opgelost in DMP (2.5 mL) en hieraan wordt
CSA (1.2 mg; 5µmol; 0.1 eq.) toegevoegd. De reactie wordt nu gedurende 16 uur geroerd
bij 50 ◦C. Na afloop wordt de reactie afgewerkt met pH 7 buffer (10 mL) en gee¨xtraheerd
met dichloormethaan (5× 20 mL). De gecombineerde organische fasen worden gedroogd op
MgSO4 en in vacuo geconcentreerd. Het bekomen residu wordt gezuiverd via kolomchro-
matografie (tolueen/aceton 9/1) en het gewenste product (68) wordt bekomen met een
rendement van 34.0 % (13.6 mg).
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5.4 Coupling of A - 31 and B - 39; Synthesis of the C1−C11 fragment (D - 64)
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Name: (3R,4R,5R,7S,9R,10S,11S )-1-benzyloxy-5,7-O :11,12-O-bis(isopropylidene)-9-
methoxy-4,10-di-(2-methoxy-ethoxymethoxy)-2,2-dimethyl-3-(2-trimethylsilyl-
ethoxymethoxy)-dodecane (68)
Formula: C42H76O14Si
M.M.: 833.13 g/mol
Rf: 0.55 (toluene/acetone 8/2)
IR: ν = 3449, 2919, 2857, 1640, 1506, 1462, 1373, 1245, 1219, 1103, 1028, 982, 935, 862,
753, 695, 664 cm-1
EI-MS (m/z (%)): 831 (<1), 784 (<1), 743 (<1), 674 (<1), 639 (<1), 583 (<1), 520
(<1), 495 (<1), 446 (<1), 391 (<1), 377 (1.7), 333 (8.5), 275 (11.8), 197 (4.2), 153
(9.3), 149 (15.2), 91 (100), 45 (100)
[α]D = + 7.8 (c = 0.50 in CHCl3)
[α]365 = + 15.0
1H NMR (300 MHz, benzene-d6): δ = 7.33 (d, J=7.16 Hz, 2 H), 7.20 (dd (app. t),
J=7.16 Hz, 2 H), 7.10 (dddd (app. tt), J=7,35, 2.26 Hz, 1 H), 5.12 (d, J=6.78 Hz,
1 H), 5.03 (d, J=6.41 Hz, 1 H), 4.95 (d, J=6.60 Hz, 1 H), 4.89 (d, J=6.78 Hz, 1 H),
4.88 (d, J=6.59, 1 H), 4.81 (d, J=6.60 Hz, 1 H), 4.50 (ddd (app. q), J=6.41 Hz, 1
H), 4.38 (s, 2 H), 4.20 - 4.30 (m, 2 H), 3.90 - 4.15 (m, 7 H), 3.60 - 3.80 (m, 5 H),
3.45 (m, 2 H), 3.41 (dd (app. t), J=4.90 Hz, 2 H), 3.35 (d, J=8.86 Hz, 1 H), 3.21 (d,
J=8.85 Hz, 1 H), 3.16 (s, 6 H), 3.15 (s, 3 H), 2.35 (m, 1 H), 2.04 (m, 1 H), 1.90 (m,
1 H), 1.79 (m, 1 H), 1.46 (s, 3 H), 1.40 (s, 6 H), 1.34 (s, 3 H), 1.17 (s, 3 H), 1.11 (s,
3 H), 0.99 (ddd, J=9.05, 6.97, 1.70 Hz, 2 H), 0.00 (s, 9 H) ppm
APT (75 MHz, benzene-d6): δ = 140.48 (C), 129.84 (5 CH), 110.11 (C), 101.67 (C), 97.95
(CH2), 97.83 (CH2), 96.91 (CH2), 80.29 (CH), 80.19 (CH), 79.06 (CH), 78.76 (CH2),
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78.57 (CH), 76.95 (CH), 74.71 (CH2), 73.59 (CH2), 73.55 (CH2), 70.51 (CH), 69.14
(CH2), 68.89 (CH2), 67.85 (CH2), 67.36 (CH2), 65.71 (CH), 59.96 (CH), 58.54 (CH),
40.85 (C), 37.52 (CH2), 34.65 (CH2), 28.16 (CH3), 27.36 (CH3), 26.37 (CH3), 26.35
(CH3), 22.96 (CH3), 22.84 (CH3), 19.63 (CH2), 0.00 (3 CH3) ppm
5.4.10 Synthesis of trimethyl ether 6968
OBn OSEM
OMEM
OMe OMe OMe
OMEM
O
OOSEMOBn
OMEM
OH OH OMe
OMEM
O
O
90%
NaH, MeI, kt
6965
Het startproduct (65) (25.0 mg; 31.6µmol) wordt opgelost in MeI (1 mL). Hieraan wordt
NaH (9.09 mg; 189µmol; 6.0 eq.) toegevoegd. De reactie wordt gedurende 72 uur op
kamertemperatuur geroerd. Vervolgens wordt het reactiemengsel geconcentreerd en het
bekomen residu gezuiverd via kolomchromatografie (tolueen/aceton 9/1). Het gewenste
product (69) wordt bekomen met een rendement van 90.2 % (23.0 mg).
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5.4 Coupling of A - 31 and B - 39; Synthesis of the C1−C11 fragment (D - 64)
OBn OSEM
OMEM
OMe OMe OMe
OMEM
O
O
Name: (3R,4R,5R,7S,9R,10S,11S )-1-benzyloxy-11,12-O-isopropylidene-5,7,9-
trimethoxy-4,10-di-(2-methoxy-ethoxymethoxy)-2,2-dimethyl-3-(2-trimethylsilyl-
ethoxymethoxy)-dodecane (69)
Formula: C41H76O14Si
M.M.: 821.12 g/mol
Rf: 0.56 (toluene/acetone 8/2)
IR: ν = 3474, 2929, 2894, 1538, 1453, 1370, 1248, 1215, 1155, 1096, 1024, 859, 840, 757,
696, 666, 610 cm-1
EI-MS (m/z (%)): 784 (<1), 740 (<1), 662 (<1), 646 (<1), 594 (<1), 525 (<1), 479
(<1), 441 (3.4), 389 (<1), 349 (1.0), 289 (2.5), 241 (3.8), 201 (9.3), 149 (20.3), 111
(38.9), 59 (100), 45 (47.4)
[α]D = + 46.6 (c = 0.98 in CHCl3)
[α]365 = + 134.4
1H NMR (500 MHz, acetone-d6): δ = 7.35 (d, J=7.16 Hz, 2 H), 7.21 (t, J=7.21 Hz, 2
H), 7.10 (dd (app. t), J=7.35 Hz, 1 H), 5.09 (d, J=6.78 Hz, 1 H), 5.05 (d, J=6.59
Hz, 1 H), 4.97 (d, J=6.40 Hz, 1 H), 4.90 (d, J=6.59 Hz, 1 H), 4.84 (d, J=6.59 Hz,
1 H), 4.83 (d, J=6.41 Hz, 1 H), 4.30 - 4.45 (m, 4 H), 4.02 - 4.10 (m, 2 H), 3.55 -
3.95 (m, 11 H), 3.39 - 3.50 (m, 4 H), 3.36 (s, 3 H), 3.35 (d, J=8.86 Hz, 1 H), 3.33
(d, J=8.86 Hz, 1 H), 3.25 (s, 6 H), 3.16 (s, 6 H), 2.03 - 2.13 (m, 3 H), 1.74 (ddd,
J=13.37, 9.04, 3.58 Hz, 1 H), 1.44 (s, 3 H), 1.35 (s, 3 H), 1.22 (s, 3 H), 1.13 (s, 3 H),
0.85 - 1.00 (m, 2 H), 0.00 (s, 9 H) ppm
APT (126 MHz, acetone-d6): δ = 140.55 (C), 129.80 (2 CH), 128.89 (2 CH), 125.96 (CH),
109.69 (C), 97.55 (CH2), 97.48 (CH2), 96.85 (CH2), 82.28 (CH), 79.95 (CH), 79.26
(CH), 78.56 (CH), 78,24 (CH), 76.93 (CH), 74.65 (CH2), 73.65 (CH2), 73.62 (CH),
73,55 (CH2), 68.88 (CH2), 68.77 (CH2), 67.95 (CH2), 67,39 (CH2), 59.94 (CH3), 59.95
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(CH3), 58.80 (CH3), 58.51 (CH3), 57.18 (CH3), 41.17 (C), 36.40 (CH2), 35.19 (CH2),
28.21 (CH3), 27.45 (CH3), 23.22 (CH3), 22.97 (CH3), 19.56 (CH2), 0.01 (3 CH3) ppm
5.4.11 Synthesis of trimethyl ether 7068
OBn OSEM
OMEM
OMe OMe OMe
OMEM
O
OOSEMOBn
OMEM
OH OH OMe
OMEM
O
O
52%
NaH, MeI, kt
7066
Het startproduct (66) (25.0 mg; 31.6µmol) wordt opgelost in MeI (1 mL). Hieraan wordt
NaH (9.09 mg; 189µmol; 6.0 eq.) toegevoegd. De reactie wordt gedurende 72 uur op
kamertemperatuur geroerd. Vervolgens wordt het reactiemengsel geconcentreerd en het
bekomen residu gezuiverd via kolomchromatografie (tolueen/aceton 9/1). Het gewenste
product (70) wordt bekomen met een rendement van 51.8 % (13.2 mg).
210
5.4 Coupling of A - 31 and B - 39; Synthesis of the C1−C11 fragment (D - 64)
OBn OSEM
OMEM
OMe OMe OMe
OMEM
O
O
Name: (3R,4R,5R,7R,9R,10S,11S )-1-benzyloxy-11,12-O-isopropylidene-5,7,9-
trimethoxy-4,10-di-(2-methoxy-ethoxymethoxy)-2,2-dimethyl-3-(2-trimethylsilyl-
ethoxymethoxy)-dodecane (70)
Formula: C41H76O14Si
M.M.: 821.12 g/mol
Rf: 0.52 (toluene/acetone 8/2)
IR: ν = 3471, 2925, 2854, 1674, 1641, 1462, 1375, 1248, 1204, 1101, 1025, 859, 806, 736,
698, 665, 626 cm-1
EI-MS (m/z (%)): 821 (<1), 789 (<1), 721 (<1), 695 (<1), 633 (<1), 607 (<1), 555
(<1), 516 (<1), 468 (<1), 401 (<1), 374 (<1), 301 (<1), 259 (<1), 223 (<1), 149
(16.9), 111 (11.8), 69 (27.9),45 (100)
[α]D = + 19.8 (c = 1.01 in CHCl3)
[α]365 = + 57.6
1H NMR (500 MHz, acetone-d6): δ = 7.40 (d, J=7.05 Hz, 2 H), 7.36 (dd (app. t), J=7.35
Hz, 2 H), 7.29 (dd (app. t), J=7.02 Hz, 1 H), 4.91 (d, J=6.70 Hz, 1 H), 4.79 (d,
J=6.55 Hz, 1 H), 4.77 (d, J=6.70 Hz, 1 H), 4.75 (d, J=6.25 Hz, 1 H), 4.72 (d, J=6.06
Hz, 1 H), 4.75 (m, 1 H), 4.57 (d, J=12.10 Hz, 1 H), 4.53 (d, J=12.16 Hz, 1 H), 4.21
(m, 2 H), 4.02 (dd, J=6.20 Hz en 8.50 Hz, 1 H), 3.88 (ddd (app. dt), J=9.90, 5.10
Hz, 1 H), 3.67 - 3.82 (m, 6 H), 3.58 - 3.66 (m, 2 H), 3.49 - 3.57 (m, 6 H), 3.45 (m, 1
H), 3.39 (s, 3 H), 3.37 (s, 3 H),3.35 - 3.42 (m, 2 H), 3.32 (s, 3 H), 3.31 (s, 3 H), 3.28
(s, 3 H), 1.85 (ddd, J=10.40, 7.20, 3.20 Hz, 1 H), 1.75 (ddd, J=9.05, 5.45, 2.66 Hz,
2 H), 1.67 (m, 1 H), 1.36 (s, 3 H), 1.31 (s, 3 H), 1.06 (s, 3 H), 1.02 (s, 3 H), 0.92 (m,
2 H), 0.00 (s, 9 H) ppm
APT (126 MHz, acetone-d6): δ = 107.83 (C), 95.68 (CH2), 95.62 (CH2), 94.91 (CH2),
80.38 (CH), 78.26 (CH), 77.37 (CH), 76.93 (CH2), 76.66 (CH), 76.61 (CH), 75.11
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(CH), 72.77 (CH2), 72.03 (CH), 71.73 (CH2), 71.69 (CH2), 67.04 (CH2), 66.71 (CH2),
65.92 (CH2), 65.51 (CH2), 57.96 (CH3), 57.91 (CH3), 57.04 (CH3), 56.61 (CH3), 55.36
(CH3), 39.37 (C), 34.48 (CH2), 33.64 (CH2), 26.07 (CH3), 25.29 (CH3), 21.17 (CH3),
20.86 (CH3), 17.75 (CH2), -2.08 (CH3) ppm
5.4.12 Synthesis of acetonide 7268
OBn O
OMEM
O OH OMe
OMEM
O
OOSEMOBn
OMEM
OH OH OMe
OMEM
O
O
b) DMP, CSA, 50°C
a) TBAF, HMPA
MS 4Å, kt
10%
7266
Het startproduct (66) (39.6 mg; 50µmol) wordt opgelost in HMPA (100µl) en hieraan
wordt achtereenvolgens moleculaire zeven van 4A˚ (20 mg) en 1m TBAF oplossing in THF
(100µl) toegevoegd. De reactie wordt vervolgens gedurende 16 uur geroerd op 70 ◦C. Ver-
volgens wordt de reactie afgewerkt met water (10 ml) en gee¨xtraheerd met dichloormethaan
(6× 15 ml). De gecombineerde organische fasen worden gedroogd op MgSO4 en geconcen-
treerd in vacuo. Het bekomen residu wordt heropgelost in DMP (1 ml) en hieraan wordt
CSA (668µg; 2.5µmol; 0.05 eq) toegevoegd. De reactie wordt vervolgens gedurende 16 uur
geroerd op 50 ◦C. Het bekomen reactiemengsel wordt rechtstreeks geconcentreerd en ver-
volgens opgezuiverd via kolomchromatografie (tolueen/aceton 8/2). Het gewenste product
(72) wordt bekomen met een rendement van 10 % (3.5 mg).
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5.4 Coupling of A - 31 and B - 39; Synthesis of the C1−C11 fragment (D - 64)
OBn O
OMEM
O OH OMe
OMEM
O
O
Name: (2S,3S,4R,6S,8R,9R,10R)-12-benzyloxy-1,2-O :8,10-O-bis(isopropylidene)-4-
methoxy-3,9-di-(2-methoxy-ethoxymethoxy)-11,11-dimethyl-dodecan-6-ol (72)
Formula: C36H62O13
M.M.: 702.87 g/mol
Rf: 0.37 (toluene/acetone 8/2)
1H NMR (500 MHz, acetone-d6): δ = 7.37 (m, 4 H), 7.29 (m, 1 H), 4.91 (d, J=6.70 Hz,
1 H), 4.79 (d, J=6.65 Hz, 1 H), 4.78 (d, J=7.00 Hz, 1 H), 4.63 (d, J=7.00 Hz, 1 H),
4.54 (d, J=12.00 Hz, 1 H), 4.48 (d, J=12.00 Hz, 1 H), 4.26 (ddd (app. q), J=7.20
Hz, 1 H), 4.01 (m, 2 H), 3.82 - 3.90 (m, 2 H), 3.81 (d, J=3.05 Hz, 1 H), 3.68 - 3.78
(m, 4 H), 3.50 - 3.60 (m, 7 H), 3.39 (d, J=8.75 Hz, 1 H), 3.38 (s, 3 H), 3.34 (s, 3
H), 3.31 (s, 3 H), 3.22 (d, J=8.55 Hz, 1 H), 2.00 (ddd, J=14.20, 9.90, 1.75 Hz, 1 H),
1.84 (ddd (app. dt), J=14.06, 4.85 Hz, 1 H), 1.61 (m, 2 H), 1.36 (s, 6 H), 1.31 (s, 3
H), 1.25 (s, 3 H), 1.05 (s, 3 H), 1.04 (s, 3 H) ppm
APT (126 MHz, acetone-d6): δ = 139.07 (C), 128.18 (CH), 127.53 (CH), 127.29 (CH),
108.04 (C), 100.48 (C), 96.18 (CH2), 95.79 (CH2), 82.50 (CH), 79.80 (CH), 77.10
(CH2), 77.09 (CH), 76.80 (CH), 72.03 (CH), 71,80 (CH2), 71.73 (CH2), 71.26 (CH),
67.39 (CH2), 67.13 (CH2), 65.84 (CH2), 65.52 (CH2), 57.97 (CH3), 57.94 (CH3), 56.83
(CH3), 41.57 (C), 37.94 (CH2), 37.41 (CH2), 26.06 (CH3), 25.23 (CH3), 24.61 (CH3),
23.24 (CH3), 21.14 (CH3), 20.69 (CH3) ppm
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5.5 Synthesis of the C12−C17 fragment (C - 43)
5.5.1 Synthesis of alcohol 40
OH
OH
i)
 CuI, MeMgBr 
THF, Et2O
-20°C -> -10°C
ii)
 I2, rt
I
72%
propargyl alcohol 40
To a solution of CuI (850 mg; 4.47 mmol) in THF (45.0 mL) at −20 ◦C was added propar-
gyl alcohol (2.60 mL; 44.7 mmol) and MeMgBr (33.3 mL; 3m in Et2O) dropwise. Next,
the reaction mixture was stirred at −10 ◦C for 1 h, after which a solution of I2 (11.3 g;
44.7 mmol) in Et2O (10 mL) and THF (14 mL) was added via cannula and stirring contin-
ued at rt. After 1.5 h of stirring at rt, the reaction mixture was poured into a sat. NH4Cl
sol. (50 mL), brine (50 mL) and Et2O (25 mL), the organic phase separated and the wa-
ter phase extracted with Et2O (2× 25 mL). The combined organic phases were dried over
MgSO4 and concentrated in vacuo. Purification by flash chromatography (pentane/Et2O
6/4) provided 40 (6.41 g; 72 % yield) as a clear oil.
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5.5 Synthesis of the C12−C17 fragment (C - 43)
OHI
Name: (Z )-3-iodo-2-methyl-prop-2-en-1-ol (40)
Formula: C4H7IO
M.M.: 198.00 g/mol
Rf: 0.23 (hexane/EtOAc 8/2)
IR: ν = 3324, 2942, 2920, 2346, 2320, 1615, 1433, 1370, 1279, 1231, 1130, 1058, 1029,
1012, 942 cm-1
EI-MS (m/z (%)): 198 (27), 184 (<1), 181 (<1), 167 (<1), 157 (<1), 155 (<1), 141 (<1),
129 (<1), 127 (11), 71 (100), 57 (<1), 53 (40), 43 (83)
1H NMR (300 MHz, chloroform-d): δ = 5.97 - 6.01 (m, 1 H), 4.26 (d, J=6.2 Hz, 2 H),
1.99 (d, J=1.5 Hz, 3 H), 1.54 - 1.62 (m, 1 H) ppm
APT (75 MHz, chloroform-d): δ = 146.1 (C), 74.9 (CH), 68.2 (CH2), 21.7 (CH3) ppm
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5.5.2 Synthesis of hydroxy ketone 42
OH OOH O
D-proline, DMSO 
acetone, rt
77% (2 steps)
99% e.e.
MnO2, DMSO 
CH2Cl2, rt
I I I
424140
To a solution of 40 (3.39 g; 17.1 mmol) in DMSO (34.2 mL) and CH2Cl2 (34.2 mL) at rt was
added MnO2 (35.0 g; 342 mmol). After stirring for 62 h, the reaction mixture was filtered
over a celite R© plug under an Ar atmosphere, into a flask containing a solution of D-proline
(1.97 g; 17.1 mmol) in DMSO (34.2 mL), and rinsed with acetone (171 mL). After stirring
for 6 h at rt, the reaction mixture was poured into H2O (680 mL) and Et2O (420 mL),
the organic phase separated and the water phase extracted with Et2O (4× 420 mL). The
combined organic phases were dried over MgSO4 and concentrated in vacuo. Purification
by flash chromatography (pentane/Et2O 55/45) provided 42 (3.33 g; 77 % yield; 99 % e.e.)
as yellow-white crystals.
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5.5 Synthesis of the C12−C17 fragment (C - 43)
OH OI
Name: (4S,5Z )-4-hydroxy-6-iodo-5-methyl-hex-5-en-2-one (42)
Formula: C7H11IO2
M.M.: 254.07 g/mol
Rf: 0.22 (pentane/Et2O 55/45)
IR: ν = 3428 (b), 3060, 2916, 2358, 1710, 1611, 1435, 1360, 1281, 1166, 1133, 1078, 1019,
765, 677, 570 cm-1
EI-MS (m/z (%)): 254 (<1), 236 (<1), 208 (<1), 197 (12), 179 (2), 167 (4), 141 (2), 127
(54), 109 (29), 85 (12), 69 (48), 58 (12), 43 (100)
[α]D = − 45.6 (c = 1.20 in CHCl3)
[α]365 = − 58.2
1H NMR (300 MHz, chloroform-d): δ = 5.92 - 5.97 (m, 1 H), 5.00 (dt, J=9.3, 2.9 Hz, 1
H), 3.15 (d, J=3.0 Hz, 1 H), 2.69 (dd, J=17.3, 9.2 Hz, 1 H), 2.60 (dd, J=17.3, 3.4
Hz, 1 H), 2.23 (s, 3 H), 1.88 (d, J=1.5 Hz, 3 H) ppm
APT (75 MHz, chloroform-d): δ = 209.0 (C), 147.3 (C), 74.1 (CH), 72.3 (CH), 46.9
(CH2), 30.7 (CH3), 19.2 (CH3) ppm
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Crystal data of 4268
VII. Experimenteel gedeelte  
tweede syntheseroute 
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KRISTALLOGRAFISCHE DATA 
 
Crystal Data 
 
 
Formula:        C7H11IO2 
Formula wheight      254.06 
Crystal Size (mm)      0.10 x 0.10 x 0.20 
D (calc) [g/cm³]      1.872 
Flack x        -0.01 
 
 
Formula: C7H11IO2
Formula weight: 254.07
Crystal size (mm): 0.10× 0.10× 0.20
D (calc) (g/cm3): 1.872
Flack x: -0.01
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5.5 Synthesis of the C12−C17 fragment (C - 43)
5.5.3 Synthesis of PMB ether C - 43
Synthesis of trichloroacetimidate 44
NaH, Cl3CCN 
Et2O, rt
O
OH
O
O NH
CCl3
quant.
4-methoxybenzyl alcohol 44
To a suspension of NaH (416 mg; 10.4 mmol; 60 % dispersion in mineral oil) in Et2O (27 mL)
at 0 ◦C was added 4-methoxybenzyl alcohol (5.13 mL; 41.3 mmol) and stirring was continued
at rt for 30 min, resulting in a clear solution. Next, the reaction mixture was cooled to
0 ◦C and Cl3CCN (4.04 mL; 40.3 mmol) was added. Stirring was continued at rt, resulting
in a color shift from colorless, to yellow and orange. After stirring for 1.5 h, the reaction
mixture was poured into a sat. NaHCO3 sol. (100 mL) and Et2O (100 mL), the organic
phase separated and the water phase extracted with Et2O (2× 100 mL). The combined
organic phases were dried over MgSO4, filtered over a celite
R© plug and concentrated in
vacuo. Crude 44 (40.3 mmol) was obtained quantitatively as a clear oil and was used as
such in subsequent reactions.
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Synthesis of PMB ether C - 43
OPMB OOH O
, Ph3CBF4
96%
I I
O
O NH
CCl3
THF, rt
42 C - 43
44
44
To a flask containing 44 (crude; 5.93 mmol) was added a solution of 42 (502 mg; 1.98 mmol)
in THF (19.8 mL) via cannula. The reaction mixture was cooled to 0 ◦C, Ph3CBF4 (65.2 mg;
198µmol) was added and stirring continued at rt. After stirring for 3.5 h, the reaction
mixture was poured into brine (15 mL), H2O (15 mL) and EtOAc (60 mL), the organic phase
separated and the water phase extracted with EtOAc (2× 60 mL). The combined organic
phases were dried over MgSO4 and concentrated in vacuo. Purification by sequential flash
chromatography (hexane/Et2O 7/3 and toluene/Et2O 96/4) provided C - 43 (707 mg; 96 %
yield) as a clear oil.
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5.5 Synthesis of the C12−C17 fragment (C - 43)
OPMB OI
Name: (4S,5Z )-6-iodo-4-(4-methoxy-benzyloxy)-5-methyl-hex-5-en-2-one (C - 43)
Formula: C15H19IO3
M.M.: 374.21 g/mol
Rf: 0.27 (pentane/Et2O 7/3)
IR: ν = 2997, 2946, 2912, 2858, 1713, 1611, 1585, 1512, 1463, 1439, 1421, 1390, 1357,
1336, 1302, 1282, 1245, 1172, 1134, 1073, 1032, 982, 848, 820, 776, 758, 716, 679 cm-1
HRMS (m/z): calcd: 392.0717, found: 392.0716 [M + NH4
+]
[α]D = + 74.7 (c = 1.16 in CHCl3)
[α]436 = + 188.7
1H NMR (500 MHz, chloroform-d): δ = 7.24 (d, J=8.7 Hz, 2 H), 6.88 (d, J=8.7 Hz, 2
H), 6.15 - 6.16 (m, 1 H), 4.84 (dd, J=9.9, 3.5 Hz, 1 H), 4.37 (d, J=11.1 Hz, 1 H),
4.27 (d, J=11.1 Hz, 1 H), 3.81 (s, 3 H), 2.80 (dd, J=15.3, 10.0 Hz, 1 H), 2.37 (dd,
J=15.4, 3.5 Hz, 1 H), 2.14 (s, 3 H), 1.87 (d, J=1.5 Hz, 3 H) ppm
APT (126 MHz, chloroform-d): δ = 205.5 (C), 159.3 (C), 145.5 (C), 129.8 (C), 129.7 (2
CH), 113.7 (2 CH), 78.8 (CH), 77.0 (CH), 70.8 (CH2), 55.3 (CH3), 46.9 (CH2), 30.3
(CH3), 19.0 (CH3) ppm
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5.6 Coupling of C - 43 and D - 64; Synthesis of the
C1−C17 fragment (22)
5.6.1 Synthesis of hydroxy ketone 74
OSEMOH
OMEM
OSEMO
OMEM
OOPMB
O
O
OMEM
OMeOMOMOMe
OMEM
OMeOMOMOMe
O
O
OPMB O
Bu2BOTf, Et3N
Et2O, -78°C -> -45°C
86% total yield
d.r. 4.6:1
70% isolated yield
+
I
I
C - 43 D - 64
74
To a solution of C - 43 (2.96 g; 7.91 mmol) in Et2O (56 mL) at 0
◦C was added Et3N
(2.21 mL; 15.8 mmol) and dibutylboron triflate (10.6 mL; 1m in CH2Cl2). After stirring for
1 h the reaction mixture was cooled to −78 ◦C and a solution of D - 64 (2.00 g; 2.64 mmol)
in Et2O (10 mL) was added via cannula. After stirring for 3 h at −78 ◦C, the reaction mix-
ture was left to warm to −45 ◦C overnight. After stirring for 18 h, the reaction mixture was
cooled again to −78 ◦C and continued stirring for 1 h, after which it was poured into a pH 7
phosphate buffer (200 mL) and Et2O (200 mL), the organic phase separated and the water
phase extracted with Et2O (2× 200 mL). Purification by sequential flash chromatography
(pentane/acetone 8/2→ 6/4 and hexane/EtOAc 4/6) provided 74 (2.10 g; 70 % yield; d.r.
4.6:1; 86 % yield on both diastereomers) as a clear oil.
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5.6 Coupling of C - 43 and D - 64; Synthesis of the C1−C17 fragment (22)
OSEMOH
OMEM
OOPMB
OMEM
OMeOMOMOMe
O
OI
Name: (1Z,3S,7S,9R,10R,11R,13R,15R,16S,17S )-7-hydroxy-1-iodo-17,18-O-
isopropylidene-11,15-dimethoxy-3-(4-methoxy-benzyloxy)-10,16-di-(2-methoxy-
ethoxymethoxy)-13-methoxymethoxy-2,8,8-trimethyl-9-(2-trimethylsilyl-
ethoxymethoxy)-octadec-1-en-5-one (74)
Formula: C50H89IO18Si
M.M.: 1133.22 g/mol
Rf: 0.14 (hexane/acetone 8/2)
IR: ν = 3488, 2935, 2886, 2822, 1717, 1612, 1587, 1514, 1464, 1368, 1285, 1247, 1210,
1176, 1095, 1070, 1022, 936, 918, 857, 836, 765, 694, 665 cm-1
HRMS (m/z): calcd: 1150.5201, found: 1150.5185 [M + NH4
+]
[α]D = + 60.1 (c = 1.49 in CHCl3)
[α]365 = + 209.2
1H NMR (500 MHz, benzene-d6): δ = 7.22 (d, J=8.7 Hz, 2 H), 6.80 (d, J=8.5 Hz, 2 H),
5.71 (d, J=1.5 Hz, 1 H), 5.11 (dd, J=9.8, 3.2 Hz, 1 H), 5.09 (d, J=6.9 Hz, 1 H), 5.01
(d, J=6.6 Hz, 1 H), 5.02 (d, J=6.9 Hz, 1 H), 4.91 (d, J=6.7 Hz, 1 H), 4.82 (d, J=6.7
Hz, 1 H), 4.75 (d, J=6.7 Hz, 1 H), 4.72 (d, J=7.0 Hz, 1 H), 4.62 (d, J=6.7 Hz, 1 H),
4.58 - 4.64 (m, 1 H), 4.28 - 4.37 (m, 4 H), 4.15 - 4.22 (m, 1 H), 3.96 - 4.08 (m, 4 H),
3.90 - 3.96 (m, 2 H), 3.88 (t, J=8.2 Hz, 1 H), 3.77 (ddd, J=11.0, 6.0, 4.0 Hz, 1 H),
3.73 (ddd, J=11.1, 5.8, 4.3 Hz, 1 H), 3.62 - 3.66 (m, 1 H), 3.67 (ddd, J=10.7, 5.6,
3.8 Hz, 1 H), 3.61 (d, J=10.1 Hz, 1 H), 3.50 - 3.55 (m, 1 H), 3.46 - 3.50 (m, 2 H),
3.41 - 3.45 (m, 2 H), 3.40 (s, 3 H), 3.31 (s, 3 H), 3.30 (s, 3 H), 3.25 (s, 3 H), 3.18 (s,
3 H), 3.17 (s, 3 H), 2.75 (dd, J=15.6, 9.8 Hz, 1 H), 2.58 (dd, J=15.9, 10.4 Hz, 1 H),
2.25 - 2.32 (m, 2 H), 2.08 - 2.17 (m, 2 H), 1.97 - 2.05 (m, 1 H), 1.78 (ddd, J=14.0,
9.5, 4.0 Hz, 1 H), 1.57 (d, J=1.4 Hz, 3 H), 1.44 (s, 3 H), 1.35 (s, 3 H), 1.13 (ddd,
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J=13.7, 11.3, 5.5 Hz, 1 H), 1.01 (ddd, J=13.7, 11.4, 5.8 Hz, 1 H), 0.96 (s, 3 H), 0.95
(s, 3 H), 0.08 (s, 9 H) ppm
APT (126 MHz, benzene-d6): δ = 206.8 (C), 160.2 (C), 146.4 (C), 131.1 (C), 130.2 (2
CH), 114.4 (2 CH), 108.8 (C), 97.1 (CH2), 96.6 (2 CH2), 96.1 (CH2), 81.4 (CH), 79.9
(CH), 79.3 (CH), 79.2 (CH), 77.7 (CH), 77.3 (CH), 77.3 (CH), 73.9 (CH), 72.9 (CH),
72.8 (CH2), 72.7 (CH2), 71.7 (CH), 71.6 (CH2), 68.1 (CH2), 68.0 (CH2), 67.6 (CH2),
67.0 (CH2), 59.1 (CH3), 59.1 (CH3), 57.8 (CH3), 57.4 (CH3), 56.1 (CH3), 55.1 (CH3),
48.1 (CH2), 45.8 (CH2), 42.3 (C), 36.4 (CH2), 36.3 (CH2), 27.3 (CH3), 26.5 (CH3),
19.4 (CH3), 19.2 (CH3), 18.7 (CH3), 18.7 (CH2), -0.9 (3 CH3) ppm
OSEMOH
OMEM
OOPMB
OMEM
OMeOMOMOMe
O
OI
Name: (1Z,3S,7R,9R,10R,11R,13R,15R,16S,17S )-7-hydroxy-1-iodo-17,18-O-
isopropylidene-11,15-dimethoxy-3-(4-methoxy-benzyloxy)-10,16-di-(2-methoxy-
ethoxymethoxy)-13-methoxymethoxy-2,8,8-trimethyl-9-(2-trimethylsilyl-
ethoxymethoxy)-octadec-1-en-5-one (75)
Formula: C50H89IO18Si
M.M.: 1133.22 g/mol
Rf: 0.14 (hexane/acetone 8/2)
IR: ν = 3483, 2935, 2887, 2822, 1714, 1612, 1584, 1514, 1465, 1369, 1300, 1248, 1207,
1176, 1150, 1097, 1068, 1023, 936, 918, 858, 836, 700, 664 cm-1
HRMS (m/z): calcd: 1150.5201, found: 1150.5192 [M + NH4
+]
[α]D = + 75.4 (c = 1.19 in CHCl3)
[α]365 = + 267.5
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1H NMR (500 MHz, benzene-d6): δ = 7.22 (d, J=8.5 Hz, 2 H), 6.82 (d, J=8.7 Hz, 2
H), 5.71 (d, J=1.4 Hz, 1 H), 5.08 (d, J=6.9 Hz, 1 H), 5.03 (d, J=6.7 Hz, 1 H), 5.03
(dd, J=9.8, 3.2 Hz, 1 H), 5.01 (d, J=6.7 Hz, 1 H), 4.90 (d, J=6.7 Hz, 1 H), 4.84 (d,
J=6.7 Hz, 1 H), 4.82 (d, J=6.7 Hz, 1 H), 4.75 (d, J=6.6 Hz, 1 H), 4.67 (d, J=6.4
Hz, 1 H), 4.53 (dd, J=6.7, 1.7 Hz, 1 H), 4.38 - 4.44 (m, 1 H), 4.33 - 4.38 (m, 1 H),
4.28 (d, J=11.1 Hz, 1 H), 4.23 (d, J=11.0 Hz, 1 H), 4.20 - 4.26 (m, 1 H), 3.99 - 4.08
(m, 2 H), 3.84 - 3.95 (m, 3 H), 3.63 - 3.81 (m, 6 H), 3.58 (td, J=9.6, 6.4 Hz, 1 H),
3.47 (s, 3 H), 3.39 - 3.50 (m, 4 H), 3.32 (s, 6 H), 3.26 (s, 3 H), 3.18 (s, 3 H), 3.17 (s,
3 H), 2.60 - 2.71 (m, 2 H), 2.52 (dd, J=16.9, 1.7 Hz, 1 H), 2.12 - 2.20 (m, 4 H), 1.83
(ddd, J=13.6, 9.4, 4.5 Hz, 1 H), 1.55 (d, J=1.4 Hz, 3 H), 1.44 (s, 3 H), 1.35 (s, 3 H),
1.26 (s, 3 H), 1.01 (s, 3 H), 0.94 - 1.00 (m, 2 H), 0.03 (s, 9 H) ppm
APT (126 MHz, benzene-d6): δ = 208.6 (C), 160.3 (C), 146.2 (C), 130.7 (C), 130.3 (2
CH), 114.4 (2 CH), 108.8 (C), 96.6 (3 CH2), 96.1 (CH2), 81.2 (CH), 79.7 (CH), 79.2
(2 CH), 77.7 (CH), 77.5 (CH), 77.5 (CH), 74.0 (CH), 72.9 (CH), 72.7 (CH2), 72.7
(CH2), 71.5 (CH), 71.5 (CH2), 68.0 (CH2), 68.0 (CH2), 67.0 (CH2), 66.7 (CH2), 59.1
(CH3), 59.1 (CH3), 57.8 (CH3), 57.3 (CH3), 56.0 (CH3), 55.1 (CH3), 47.5 (CH2), 45.9
(CH2), 42.6 (C), 36.4 (CH2), 36.1 (CH2), 27.3 (CH3), 26.5 (CH3), 20.5 (CH3), 19.8
(CH3), 19.2 (CH3), 18.7 (CH2), -0.9 (3 CH3) ppm
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5.6.2 Synthesis of BOM ether 76
OSEMOR
OMEM
OOPMB
OMEM
OMeOMOMOMe
O
O
R = BOM
R = H
BOM-Cl, DIPEA 
CH2Cl2, reflux
I
quant.
74
76
To a solution of 74 (2.60 g; 2.29 mmol) in CH2Cl2 (13.8 mL) at rt were added DIPEA
(5.19 mL; 29.8 mmol) and BOM-Cl (3.50 mL; 22.9 mmol; 90 %) dropwise, with formation
of a white haze that disappears after a couple of minutes. After stirring for 23 h at re-
flux temperature, the reaction mixture was poured into a sat. NH4Cl sol. (100 mL) and
CH2Cl2 (100 mL), the organic phase separated and the water phase extracted with CH2Cl2
(2× 100 mL). The combined organic phases were dried over MgSO4 and concentrated in
vacuo. Purification by flash chromatography (hexane/EtOAc/acetone 6/3.2/0.8) provided
76 (2.87 g; 100 % yield) as a clear oil.
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OSEMOBOM
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O
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Name: (1Z,3S,7S,9R,10R,11R,13R,15R,16S,17S )-7-benzyloxymethoxy-1-iodo-
17,18-O-isopropylidene-11,15-dimethoxy-3-(4-methoxy-benzyloxy)-10,16-di-(2-
methoxy-ethoxymethoxy)-13-methoxymethoxy-2,8,8-trimethyl-9-(2-trimethylsilyl-
ethoxymethoxy)-octadec-1-en-5-one (76)
Formula: C58H97IO19Si
M.M.: 1253.37 g/mol
Rf: 0.19 (hexane/acetone 8/2)
IR: ν = 2940, 2894, 2822, 1718, 1612, 1584, 1514, 1463, 1454, 1368, 1287, 1248, 1173,
1153, 1097, 1022, 936, 919, 858, 835, 739, 698, 663 cm-1
HRMS (m/z): calcd: 1270.5776, found: 1270.5798 [M + NH4
+]
[α]D = + 41.7 (c = 1.18 in CHCl3)
[α]365 = + 151.7
1H NMR (500 MHz, benzene-d6): δ = 7.34 (d, J=7.2 Hz, 2 H), 7.18 - 7.23 (m, 4 H), 7.08
(t, J=7.3 Hz, 1 H), 6.78 - 6.83 (m, 2 H), 5.70 (d, J=1.1 Hz, 1 H), 5.05 - 5.14 (m, 4
H), 5.02 (d, J=6.7 Hz, 1 H), 4.97 (d, J=6.6 Hz, 1 H), 4.95 (d, J=6.1 Hz, 1 H), 4.94
(d, J=6.3 Hz, 1 H), 4.83 (d, J=6.7 Hz, 1 H), 4.78 (dd, J=6.9, 3.1 Hz, 1 H), 4.75 (d,
J=6.7 Hz, 1 H), 4.65 (d, J=12.2 Hz, 1 H), 4.62 (d, J=6.6 Hz, 1 H), 4.52 (d, J=12.1
Hz, 1 H), 4.42 (dd, J=6.9, 1.1 Hz, 1 H), 4.31 (d, J=10.8 Hz, 1 H), 4.29 - 4.37 (m,
1 H), 4.27 (d, J=11.0 Hz, 1 H), 4.12 - 4.24 (m, 2 H), 4.04 (dd, J=8.5, 6.2 Hz, 1 H),
4.07 (ddd, J=10.8, 5.8, 4.0 Hz, 1 H), 3.96 (d, J=7.0 Hz, 1 H), 3.89 (t, J=8.4 Hz, 1
H), 3.92 (dd, J=7.2, 4.3 Hz, 1 H), 3.61 - 3.80 (m, 5 H), 3.55 - 3.61 (m, 1 H), 3.37 -
3.54 (m, 4 H), 3.42 (s, 3 H), 3.31 (s, 3 H), 3.30 (s, 3 H), 3.26 (s, 3 H), 3.18 (s, 3 H),
3.17 (s, 3 H), 2.74 (dd, J=17.7, 7.0 Hz, 1 H), 2.62 (dd, J=15.7, 9.9 Hz, 1 H), 2.58
(dd, J=17.7, 3.1 Hz, 1 H), 2.06 - 2.22 (m, 4 H), 1.80 (ddd, J=14.0, 9.4, 4.0 Hz, 1 H),
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1.54 (d, J=1.5 Hz, 3 H), 1.44 (s, 3 H), 1.35 (s, 3 H), 1.20 (ddd, J=13.9, 10.5, 5.5 Hz,
1 H), 1.12 (ddd, J=14.0, 10.8, 6.3 Hz, 1 H), 1.06 (s, 6 H), 0.11 (s, 9 H) ppm
APT (126 MHz, benzene-d6): δ = 205.1 (C), 160.2 (C), 146.2 (C), 139.2 (C), 131.0 (C),
130.2 (2 CH), 128.9 (2 CH), 128.3 (2 CH), 128.0 (CH), 114.4 (2 CH), 108.8 (C),
97.4 (CH2), 97.0 (CH2), 96.7 (CH2), 96.6 (CH2), 96.0 (CH2), 81.4 (CH), 80.0 (CH),
79.2 (CH), 79.0 (CH), 78.9 (CH), 77.7 (CH), 77.4 (CH), 77.3 (CH), 73.9 (CH), 72.7
(CH2), 72.6 (CH2), 72.3 (CH), 71.6 (CH2), 70.4 (CH2), 68.0 (CH2), 67.9 (CH2), 67.1
(CH2), 67.0 (CH2), 59.1 (CH3), 59.0 (CH3), 57.8 (CH3), 57.1 (CH3), 56.0 (CH3), 55.1
(CH3), 47.6 (CH2), 46.7 (CH2), 43.3 (C), 36.4 (CH2), 36.1 (CH2), 27.3 (CH3), 26.5
(CH3), 19.7 (CH3), 19.3 (CH3), 19.2 (CH3), 18.8 (CH2), -0.8 (3 CH3) ppm
5.6.3 Synthesis of alcohol 77
OSEMOBOM
OMEM
ROPMB
OMEM
OMeOMOMOMe
O
O
R =
R =
Na(s-Bu)3BH
Et2O, -96°C
O
OH
I 72% total yield
d.r. 17:1
68% isolated yield
77
76
To a solution of 76 (2.30 g; 1.84 mmol) in Et2O (184 mL) at −96 ◦C (CH2Cl2, liq. N2) was
added Na(s-Bu)3BH (4.59 mL; 1m in THF) dropwise. After stirring for 1.5 h, TLC seemed
to indicate total consumption of 76, after which the reaction was quenched with EtOAc
(20 mL) and poured into a sat. NH4Cl sol. (300 mL) and EtOAc (130 mL), the organic phase
separated and the water phase extracted with EtOAc (2× 300 mL). The combined organic
phases were dried over MgSO4 and concentrated in vacuo. As LC-MS analysis showed
only 23.5 % conversion, the reaction was set up again under similar conditions except the
temperature now was held at −78 ◦C. After 2 h stirring at −78 ◦C, work-up was repeated
as described above and LC-MS analysis now showed + 99 % conversion. Purification by
flash chromatography (pentane/acetone 85/15 → 78/22) provided 77 (1.57 g; 68 % yield;
d.r. 17:1; 72 % yield on both diastereomers) as a clear oil.
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Name: (1Z,3S,5R,7S,9R,10R,11R,13R,15R,16S,17S )-7-benzyloxymethoxy-1-iodo-
17,18-O-isopropylidene-11,15-dimethoxy-3-(4-methoxy-benzyloxy)-10,16-di-(2-
methoxy-ethoxymethoxy)-13-methoxymethoxy-2,8,8-trimethyl-9-(2-trimethylsilyl-
ethoxymethoxy)-octadec-1-en-5-ol (77)
Formula: C58H99IO19Si
M.M.: 1255.39 g/mol
Rf: 0.26 (pentane/acetone 8/2)
IR: ν = 3504, 2935, 2887, 2822, 1612, 1584, 1514, 1454, 1369, 1303, 1248, 1207, 1173,
1153, 1098, 1068, 1022, 936, 919, 858, 834, 735, 699 cm-1
HRMS (m/z): calcd: 1272.5933, found: 1272.5907 [M + NH4
+]
[α]D = + 39.8 (c = 1.19 in CHCl3)
[α]365 = + 136.6
1H NMR (500 MHz, benzene-d6): δ = 7.41 (d, J=7.3 Hz, 2 H), 7.21 (t, J=7.5 Hz, 2 H),
7.18 (d, J=8.9 Hz, 2 H), 7.09 (t, J=7.3 Hz, 1 H), 6.80 (d, J=8.7 Hz, 2 H), 5.68 (d,
J=1.2 Hz, 1 H), 5.19 (d, J=6.4 Hz, 1 H), 5.15 (d, J=6.6 Hz, 1 H), 5.12 (d, J=6.6
Hz, 1 H), 5.08 (d, J=6.7 Hz, 1 H), 5.08 (d, J=6.7 Hz, 1 H), 4.94 (d, J=6.7 Hz, 1 H),
4.94 (d, J=6.7 Hz, 1 H), 4.80 (d, J=6.4 Hz, 1 H), 4.83 (d, J=6.7 Hz, 1 H), 4.82 (d,
J=12.2 Hz, 1 H), 4.69 (dd, J=9.6, 4.1 Hz, 1 H), 4.72 (d, J=12.8 Hz, 1 H), 4.66 (d,
J=6.6 Hz, 1 H), 4.49 - 4.54 (m, 1 H), 4.31 - 4.38 (m, 2 H), 4.24 (d, J=11.3 Hz, 1 H),
4.21 - 4.30 (m, 2 H), 4.00 - 4.13 (m, 3 H), 4.08 (d, J=11.1 Hz, 1 H), 3.93 (dd, J=7.2,
4.2 Hz, 1 H), 3.88 (t, J=8.4 Hz, 1 H), 3.81 (d, J=7.0 Hz, 1 H), 3.59 - 3.80 (m, 6 H),
3.46 (s, 3 H), 3.38 - 3.54 (m, 4 H), 3.31 (s, 3 H), 3.30 (s, 3 H), 3.26 (s, 3 H), 3.17 (s,
3 H), 3.17 (s, 3 H), 2.03 - 2.27 (m, 3 H), 1.91 (dt, J=14.2, 9.3 Hz, 1 H), 1.80 (ddd,
J=14.0, 9.5, 4.0 Hz, 1 H), 1.61 - 1.76 (m, 2 H), 1.58 (d, J=1.2 Hz, 3 H), 1.45 - 1.52
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(m, 1 H), 1.44 (s, 3 H), 1.36 (s, 3 H), 1.23 (s, 3 H), 1.23 (s, 3 H), 1.04 - 1.10 (m, 2
H), 0.03 (s, 9 H) ppm
APT (126 MHz, benzene-d6): δ = 160.3 (C), 146.7 (C), 139.4 (C), 130.6 (C), 130.2 (2
CH), 129.0 (2 CH), 128.3 (2 CH), 128.0 (CH), 114.6 (2 CH), 108.8 (C), 97.9 (CH2),
97.0 (CH2), 96.8 (CH2), 96.6 (CH2), 96.0 (CH2), 83.3 (CH), 80.8 (CH), 80.7 (CH),
79.1 (CH), 78.9 (CH), 77.7 (CH), 77.4 (CH), 77.4 (CH), 73.8 (CH), 72.8 (CH2), 72.7
(CH2), 72.1 (CH), 71.0 (CH2), 70.7 (CH2), 68.0 (CH2), 67.9 (CH2), 67.4 (CH), 67.0
(CH2), 66.8 (CH2), 59.1 (CH3), 59.1 (CH3), 57.9 (CH3), 56.9 (CH3), 56.0 (CH3), 55.1
(CH3), 44.0 (C), 41.5 (CH2), 39.9 (CH2), 36.3 (CH2), 35.9 (CH2), 27.3 (CH3), 26.5
(CH3), 20.8 (CH3), 19.7 (CH3), 18.9 (CH3), 18.7 (CH2), -0.9 (3 CH3) ppm
OSEMOBOM
OMEM
OHOPMB
OMEM
OMeOMOMOMe
O
OI
Name: (1Z,3S,5S,7S,9R,10R,11R,13R,15R,16S,17S )-7-benzyloxymethoxy-1-iodo-
17,18-O-isopropylidene-11,15-dimethoxy-3-(4-methoxy-benzyloxy)-10,16-di-(2-
methoxy-ethoxymethoxy)-13-methoxymethoxy-2,8,8-trimethyl-9-(2-trimethylsilyl-
ethoxymethoxy)-octadec-1-en-5-ol (79)
Formula: C58H99IO19Si
M.M.: 1255.39 g/mol
Rf: 0.21 (pentane/acetone 8/2)
IR: ν = 3494, 2935, 2886, 2822, 1612, 1587, 1514, 1454, 1369, 1328, 1303, 1279, 1247,
1204, 1173, 1153, 1100, 1024, 936, 920, 858, 836, 817, 738, 698, 664 cm-1
HRMS (m/z): calcd: 1272.5933, found: 1272.5888 [M + NH4
+]
[α]D = + 36.4 (c = 1.26 in CHCl3)
[α]365 = + 120.0
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1H NMR (500 MHz, benzene-d6): δ = 7.35 (d, J=7.2 Hz, 2 H), 7.24 (d, J=8.5 Hz, 2 H),
7.19 (t, J=7.6 Hz, 2 H), 7.08 (t, J=7.3 Hz, 1 H), 6.80 (d, J=8.5 Hz, 2 H), 5.75 (d,
J=1.1 Hz, 1 H), 5.27 (d, J=6.6 Hz, 1 H), 5.06 (d, J=6.6 Hz, 1 H), 5.07 (d, J=6.7
Hz, 1 H), 5.01 (d, J=6.6 Hz, 1 H), 5.01 (d, J=6.6 Hz, 1 H), 4.94 (d, J=6.3 Hz, 1
H), 4.92 (d, J=6.3 Hz, 1 H), 4.88 - 4.96 (m, 1 H), 4.82 (d, J=6.7 Hz, 1 H), 4.75 (d,
J=12.4 Hz, 1 H), 4.74 (d, J=6.7 Hz, 1 H), 4.58 (d, J=12.2 Hz, 1 H), 4.60 (d, J=6.6
Hz, 1 H), 4.37 - 4.44 (m, 1 H), 4.12 - 4.36 (m, 4 H), 4.33 (d, J=11.1 Hz, 1 H), 4.27
(d, J=11.3 Hz, 1 H), 3.96 - 4.10 (m, 3 H), 3.82 - 3.95 (m, 3 H), 3.71 - 3.81 (m, 2 H),
3.52 - 3.71 (m, 4 H), 3.36 - 3.51 (m, 4 H), 3.39 (s, 3 H), 3.31 (s, 3 H), 3.28 (s, 3 H),
3.25 (s, 3 H), 3.17 (s, 3 H), 3.16 (s, 3 H), 2.00 - 2.23 (m, 3 H), 1.72 - 1.99 (m, 4 H),
1.66 (d, J=1.2 Hz, 3 H), 1.40 - 1.57 (m, 1 H), 1.44 (s, 3 H), 1.35 (s, 3 H), 1.10 (s, 3
H), 1.11 (s, 3 H), 1.01 - 1.16 (m, 2 H), 0.04 (s, 9 H) ppm
APT (126 MHz, benzene-d6): δ = 160.1 (C), 147.6 (C), 138.9 (C), 131.3 (C), 130.1 (2
CH), 129.0 (2 CH), 114.4 (2 CH), 108.8 (C), 97.5 (CH2), 97.3 (CH2), 96.6 (CH2),
96.6 (CH2), 95.9 (CH2), 83.1 (CH), 81.3 (CH), 80.6 (CH), 79.2 (CH), 79.0 (CH), 77.6
(CH), 77.3 (CH), 76.5 (CH), 73.8 (CH), 72.7 (CH2), 72.6 (CH2), 72.2 (CH), 71.2
(CH2), 70.7 (CH2), 68.6 (CH), 68.0 (CH2), 67.9 (CH2), 67.0 (CH2), 66.9 (CH2), 59.1
(CH3), 59.1 (CH3), 57.9 (CH3), 57.2 (CH3), 56.0 (CH3), 55.1 (CH3), 44.3 (C), 42.2
(CH2), 40.6 (CH2), 36.3 (CH2), 36.1 (CH2), 27.3 (CH3), 26.5 (CH3), 19.5 (CH3), 19.3
(CH3), 18.9 (CH3), 18.7 (CH2), -0.9 (3 CH3) ppm
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5.6.4 Synthesis of methyl ether 78
Me3OBF4
Proton-sponge®
MS 4Å, CH2Cl2, rt
R = H
R = Me
OSEMOBOM
OMEM
OROPMB
OMEM
OMeOMOMOMe
O
OI
94%
77
78
To a solution of 77 (1.42 g; 1.13 mmol) in CH2Cl2 (34 mL) at rt were added molecular sieves
(452 mg; 4 A˚; powdered; activated). After stirring for 40 min, Proton-sponge R© (1.70 g;
7.92 mmol) and Me3OBF4 (1.00 g; 6.79 mmol) were added. After stirring for 3 h, the yellow-
orange suspension was filtered over a fritted funnel and the filtrate (+ 250 mL CH2Cl2)
washed with a 1mCuSO4 sol. (2× 250 mL). The water phases were back-extracted with
CH2Cl2 (3× 250 mL), the combined organic phases dried over MgSO4 and concentrated
in vacuo. Purification by flash chromatography (hexane/acetone 9/1 → 8/2) provided 78
(1.35 g; 94 % yield) as a clear oil.
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Name: (1Z,3S,5R,7S,9R,10R,11R,13R,15R,16S,17S )-7-benzyloxymethoxy-1-iodo-
17,18-O-isopropylidene-5,11,15-trimethoxy-3-(4-methoxy-benzyloxy)-10,16-di-(2-
methoxy-ethoxymethoxy)-13-methoxymethoxy-2,8,8-trimethyl-9-(2-trimethylsilyl-
ethoxymethoxy)-octadec-1-ene (78)
Formula: C59H101IO19Si
M.M.: 1269.41 g/mol
Rf: 0.22 (hexane/acetone 8/2)
IR: ν = 2930, 2884, 2817, 1612, 1584, 1514, 1454, 1369, 1300, 1279, 1247, 1204, 1153,
1093, 1022, 936, 920, 858, 835, 748, 698, 664 cm-1
HRMS (m/z): calcd: 1286.6089, found: 1286.6092 [M + NH4
+]
[α]D = + 33.0 (c = 1.02 in CHCl3)
[α]365 = + 115.3
1H NMR (500 MHz, benzene-d6): δ = 7.41 (d, J=7.2 Hz, 2 H), 7.27 (d, J=8.7 Hz, 2 H),
7.19 (t, J=7.6 Hz, 2 H), 7.09 (t, J=7.3 Hz, 1 H), 6.83 (d, J=8.5 Hz, 2 H), 5.70 (d,
J=1.2 Hz, 1 H), 5.14 (d, J=6.4 Hz, 1 H), 5.14 (d, J=6.4 Hz, 1 H), 5.07 (d, J=6.4
Hz, 1 H), 5.08 (d, J=7.0 Hz, 1 H), 5.06 (d, J=6.1 Hz, 1 H), 4.99 (d, J=6.4 Hz, 1 H),
4.97 (d, J=6.7 Hz, 1 H), 4.84 (d, J=12.4 Hz, 1 H), 4.84 (d, J=6.4 Hz, 1 H), 4.78 (d,
J=6.7 Hz, 1 H), 4.74 (d, J=12.4 Hz, 1 H), 4.57 - 4.67 (m, 2 H), 4.51 (d, J=6.3 Hz, 1
H), 4.32 (d, J=11.3 Hz, 1 H), 4.30 - 4.39 (m, 1 H), 4.22 (d, J=11.1 Hz, 1 H), 4.18 -
4.28 (m, 2 H), 3.97 - 4.12 (m, 3 H), 3.93 (dd, J=7.3, 4.3 Hz, 1 H), 3.87 - 3.91 (m, 2
H), 3.85 (d, J=6.6 Hz, 1 H), 3.78 (ddd, J=10.7, 6.0, 4.3 Hz, 2 H), 3.59 - 3.73 (m, 4
H), 3.43 (s, 3 H), 3.40 - 3.53 (m, 4 H), 3.32 (s, 3 H), 3.31 (s, 3 H), 3.28 (s, 3 H), 3.26
(s, 3 H), 3.17 (s, 3 H), 3.17 (s, 3 H), 2.05 - 2.27 (m, 4 H), 1.89 - 2.04 (m, 2 H), 1.82
(ddd, J=14.1, 9.4, 4.7 Hz, 1 H), 1.64 (d, J=1.4 Hz, 3 H), 1.50 (ddd, J=14.0, 8.2, 2.7
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Hz, 1 H), 1.44 (s, 3 H), 1.36 (s, 3 H), 1.25 (s, 6 H), 1.02 - 1.09 (m, 2 H), 0.04 ppm
(s, 9 H) ppm
APT (126 MHz, benzene-d6): δ = 160.1 (C), 147.5 (C), 139.4 (C), 131.2 (C), 130.1 (2
CH), 128.9 (2 CH), 128.0 (CH), 114.5 (2 CH), 108.8 (C), 97.8 (CH2), 97.3 (CH2),
96.9 (CH2), 96.6 (CH2), 96.1 (CH2), 81.8 (CH), 81.1 (CH), 80.3 (CH), 79.8 (CH),
79.2 (CH), 77.7 (CH), 77.4 (CH), 76.7 (CH), 75.5 (CH), 74.0 (CH), 72.8 (CH2), 72.7
(CH2), 72.5 (CH), 71.0 (CH2), 70.6 (CH2), 68.0 (2 CH2), 67.0 (CH2), 66.6 (CH2),
59.1 (CH3), 59.0 (CH3), 57.9 (CH3), 56.9 (CH3), 56.1 (CH3), 56.0 (CH3), 55.1 (CH3),
44.1 (C), 37.8 (CH2), 37.5 (CH2), 36.5 (CH2), 36.1 (CH2), 27.3 (CH3), 26.5 (CH3),
20.8 (CH3), 19.8 (CH3), 19.0 (CH3), 18.7 (CH2), -0.8 (3 CH3) ppm
5.6.5 Synthesis of alcohol 80
TBAF
HMPA
MS 4Å
R = SEM
R = H
OROBOM
OMEM
OMeOPMB
OMEM
OMeOMOMOMe
O
OI
80
78
To a solution of 78 (1.09 g; 860µmol) in HMPA (16.7 mL) at rt were added molecular
sieves (1.03 g; 4 A˚; powdered; activated). After stirring for 45 min, TBAF (3.87 mL; 1m
in THF) was added dropwise, resulting in a purple-black solution. After 30 min at rt and
10 min at 50 ◦C, a lot of side-product (82) seemed to be forming, after which the reaction
was cooled again to rt, an extra amount of molecular sieves was added, stirring continued
for 10 min at rt, followed by reaction overnight at 50 ◦C. After 16 h at 50 ◦C, TLC showed
total consumption of 78 and an improvement on the 80:82 ratio, after which work-up
and purification followed by direct flash chromatography (hexane/acetone 9/1 → 8/2),
providing 80 (382 mg; 39 % yield) as a clear oil.
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5.6 Coupling of C - 43 and D - 64; Synthesis of the C1−C17 fragment (22)
OHOBOM
OMEM
OMeOPMB
OMEM
OMeOMOMOMe
O
OI
Name: (1Z,3S,5R,7S,9R,10S,11R,13R,15R,16S,17S )-7-benzyloxymethoxy-1-iodo-17,18-
O-isopropylidene-5,11,15-trimethoxy-3-(4-methoxy-benzyloxy)-10,16-di-(2-methoxy-
ethoxymethoxy)-13-methoxymethoxy-2,8,8-trimethyl-octadec-1-en-9-ol (80)
Formula: C53H87IO18
M.M.: 1139.15 g/mol
Rf: 0.26 (pentane/acetone 3/1)
IR: ν = 3504, 2929, 2884, 2827, 1612, 1584, 1514, 1454, 1369, 1300, 1247, 1212, 1148,
1092, 1023, 918, 851, 820, 739, 700 cm-1
HRMS (m/z): calcd: 1156.5276, found: 1156.5231 [M + NH4
+]
[α]D = − 11.3 (c = 1.03 in CHCl3)
[α]365 = − 21.4
1H NMR (500 MHz, benzene-d6): δ = 7.40 (d, J=7.3 Hz, 2 H), 7.28 (d, J=8.5 Hz, 2 H),
7.18 (t, J=7.5 Hz, 2 H), 7.08 (t, J=7.3 Hz, 1 H), 6.82 (d, J=8.5 Hz, 2 H), 5.70 (d,
J=1.2 Hz, 1 H), 5.24 (d, J=6.4 Hz, 1 H), 5.06 (d, J=6.6 Hz, 1 H), 5.06 (d, J=6.6
Hz, 1 H), 5.02 (d, J=6.4 Hz, 1 H), 4.85 (d, J=12.2 Hz, 1 H), 4.81 (d, J=6.4 Hz, 1
H), 4.82 (d, J=6.7 Hz, 1 H), 4.74 (d, J=6.7 Hz, 1 H), 4.67 (d, J=11.9 Hz, 1 H), 4.64
- 4.70 (m, 1 H), 4.59 (d, J=6.7 Hz, 1 H), 4.33 (d, J=11.0 Hz, 1 H), 4.29 - 4.40 (m,
2 H), 4.24 (d, J=11.1 Hz, 1 H), 4.19 - 4.22 (m, 1 H), 4.12 - 4.19 (m, 1 H), 4.04 (dd,
J=8.5, 6.2 Hz, 1 H), 3.91 - 3.97 (m, 1 H), 3.82 - 3.91 (m, 3 H), 3.76 (ddd, J=10.6,
6.1, 4.1 Hz, 1 H), 3.57 - 3.70 (m, 5 H), 3.38 - 3.46 (m, 2 H), 3.31 - 3.36 (m, 2 H), 3.34
(s, 3 H), 3.31 (s, 3 H), 3.29 (s, 3 H), 3.28 (s, 3 H), 3.22 (s, 3 H), 3.16 (s, 3 H), 3.12
(s, 3 H), 1.90 - 2.20 (m, 6 H), 1.80 (ddd, J=14.1, 9.4, 4.1 Hz, 1 H), 1.64 (d, J=1.2
Hz, 3 H), 1.54 (ddd, J=13.9, 7.8, 2.3 Hz, 1 H), 1.44 (s, 3 H), 1.35 (s, 3 H), 1.15 (s, 3
H), 1.09 (s, 3 H) ppm
APT (126 MHz, benzene-d6): δ = 160.1 (C), 147.6 (C), 139.5 (C), 131.2 (C), 130.1 (2
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CH), 128.9 (2 CH), 128.5 (2 CH), 127.9 (CH), 114.4 (2 CH), 108.9 (C), 97.5 (CH2),
96.8 (CH2), 96.7 (CH2), 96.5 (CH2), 83.7 (CH), 81.2 (CH), 80.3 (CH), 79.2 (CH),
77.6 (CH), 77.6 (CH), 76.7 (CH), 75.6 (CH), 73.8 (CH), 73.2 (CH), 72.6 (2 CH2),
72.5 (CH), 71.0 (CH2), 70.7 (CH2), 68.9 (CH2), 68.1 (CH2), 67.0 (CH2), 59.1 (2
CH3), 57.8 (CH3), 57.7 (CH3), 56.5 (CH3), 56.0 (CH3), 55.1 (CH3), 43.5 (C), 37.7
(CH2), 37.6 (CH2), 36.3 (2 CH2), 27.3 (CH3), 26.5 (CH3), 19.1 (CH3), 19.1 (CH3),
18.6 (CH3) ppm
5.6.6 Synthesis of ketone 81
ROBOM
OMEM
OMeOPMB
OMEM
OMeOMOMOMe
O
O
R =
R =
DMP 
CH2Cl2, 0°CO
OHI
87%
80
81
To a solution of 80 (366 mg; 321µmol) in CH2Cl2 (9.64 mL) at 0
◦C was added Dess-Martin
periodinane (273 mg; 643µmol). After stirring for 5 h at 0 ◦C, the reaction was quenched
with a sat. NaHCO3 sol. (5 mL), a sat. Na2S2O3 sol. (5 mL) and CH2Cl2 (5 mL), followed
by 15 min stirring at rt, after which the reaction mixture was poured into a sat. NaHCO3
sol. (10 mL), a sat. Na2S2O3 sol. (10 mL) and CH2Cl2 (15 mL), the organic phase separated
and the water phase extracted with CH2Cl2 (3× 30 mL). The combined organic phases
were dried over MgSO4 and concentrated in vacuo. Purification by flash chromatography
(hexane/acetone 9/1 → 8/2) provided 81 (319 mg; 87 % yield) as a clear oil.
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OOBOM
OMEM
OMeOPMB
OMEM
OMeOMOMOMe
O
OI
Name: (1Z,3S,5R,7S,10R,11R,13S,15R,16S,17S )-7-benzyloxymethoxy-1-iodo-17,18-O-
isopropylidene-5,11,15-trimethoxy-3-(4-methoxy-benzyloxy)-10,16-di-(2-methoxy-
ethoxymethoxy)-13-methoxymethoxy-2,8,8-trimethyl-octadec-1-en-9-one (81)
Formula: C53H85IO18
M.M.: 1137.14 g/mol
Rf: 0.25 (pentane/acetone 3/1)
IR: ν = 2977, 2930, 2884, 2817, 1708, 1612, 1584, 1514, 1454, 1368, 1300, 1282, 1247,
1207, 1171, 1150, 1091, 1024, 982, 920, 851, 822, 739, 699 cm-1
HRMS (m/z): calcd: 1154.5119, found: 1154.5129 [M + NH4
+]
[α]D = − 18.1 (c = 1.06 in CHCl3)
[α]365 = − 141.5
1H NMR (500 MHz, benzene-d6): δ = 7.40 (d, J=7.2 Hz, 2 H), 7.27 (d, J=8.5 Hz, 2 H),
7.18 (t, J=7.5 Hz, 2 H), 7.09 (t, J=7.5 Hz, 1 H), 6.83 (d, J=8.5 Hz, 2 H), 5.70 (d,
J=1.4 Hz, 1 H), 5.26 (d, J=1.8 Hz, 1 H), 5.03 (d, J=6.5 Hz, 1 H), 5.01 (d, J=6.3
Hz, 1 H), 4.95 (d, J=6.7 Hz, 1 H), 4.85 (d, J=6.9 Hz, 1 H), 4.79 (d, J=6.7 Hz, 1 H),
4.76 (d, J=12.1 Hz, 1 H), 4.76 (d, J=6.9 Hz, 1 H), 4.72 (d, J=6.7 Hz, 1 H), 4.67 (d,
J=12.2 Hz, 1 H), 4.63 (dd, J=9.8, 2.9 Hz, 1 H), 4.57 (d, J=6.6 Hz, 1 H), 4.52 (d,
J=8.1 Hz, 1 H), 4.28 - 4.35 (m, 1 H), 4.31 (d, J=11.0 Hz, 1 H), 4.23 (d, J=11.3 Hz,
1 H), 4.17 - 4.25 (m, 1 H), 4.10 (d, J=10.5 Hz, 1 H), 4.02 (dd, J=8.5, 6.2 Hz, 1 H),
3.87 - 3.94 (m, 1 H), 3.80 - 3.87 (m, 3 H), 3.77 (ddd, J=10.9, 5.8, 3.9 Hz, 1 H), 3.67
(ddd, J=10.9, 5.8, 3.9 Hz, 1 H), 3.52 - 3.61 (m, 2 H), 3.42 - 3.48 (m, 2 H), 3.40 (s, 3
H), 3.31 - 3.36 (m, 2 H), 3.31 (s, 3 H), 3.28 (s, 3 H), 3.28 (s, 3 H), 3.19 (s, 3 H), 3.18
(s, 3 H), 3.10 (s, 3 H), 2.27 (ddd, J=14.9, 10.7, 1.7 Hz, 1 H), 2.01 - 2.11 (m, 2 H),
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1.75 - 1.99 (m, 4 H), 1.62 (d, J=1.2 Hz, 3 H), 1.51 (ddd, J=14.2, 8.0, 2.7 Hz, 1 H),
1.43 (s, 3 H), 1.42 (s, 3 H), 1.35 (s, 3 H), 1.34 (s, 3 H) ppm
APT (126 MHz, benzene-d6): δ = 212.0 (CH2), 160.1 (CH2), 147.4 (CH2), 139.3 (CH2),
131.2 (CH2), 130.1 (2 CH2), 128.9 (2 CH2), 128.0 (CH2), 114.4 (2 CH2), 108.8 (CH2),
97.5 (CH2), 96.6 (CH2), 96.5 (CH2), 95.4 (CH2), 82.6 (CH2), 80.3 (CH2), 79.0 (CH2),
77.7 (CH2), 77.7 (CH2), 77.6 (2 CH2), 76.8 (CH2), 75.3 (CH2), 73.4 (CH2), 72.6
(CH2), 72.5 (CH2), 71.0 (CH2), 70.7 (CH2), 68.1 (CH2), 67.9 (CH2), 67.0 (CH2), 59.0
(CH2), 59.0 (CH2), 57.8 (CH2), 57.2 (CH2), 56.4 (CH2), 56.0 (CH2), 55.1 (CH2), 53.2
(CH2), 38.1 (CH2), 37.4 (CH2), 36.4 (CH2), 35.7 (CH2), 27.3 (CH2), 26.6 (CH2), 22.6
(CH2), 20.9 (CH2), 19.0 (CH2) ppm
5.6.7 Synthesis of triol 84
OOBOM
OMEM
OMeOPMB
OMEM
OMeOMOMOMe
O
O CAN
ACN, H2O, 0°C
45%
OOBOM
OMEM
OMeOH
OMEM
OMeOMOMOMe
OH
OH
I
I
84
81
To a solution of 81 (300 mg; 264µmol) in ACN (3.96 mL) and H2O (3.96 mL) at 0
◦C
was added CAN ((NH4)2Ce(NO3)6) (723 mg; 1.32 mmol). After stirring for 22 h at 0
◦C,
the reaction mixture was poured into a sat. NaHCO3 sol. (40 mL) and EtOAc (40 mL),
the organic phase separated and the water phase extracted with EtOAc (3× 45 mL). The
combined organic phases were dried over MgSO4 and concentrated in vacuo. Purification
by flash chromatography (hexane/acetone 8/2→ 4/6) provided 84 (115 mg; 45 % yield) as
a clear oil.
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OOBOM
OMEM
OMeOH
OMEM
OMeOMOMOMe
OH
OHI
Name: (1Z,3S,5R,7S,10R,11R,13S,15R,16R,17S )-7-benzyloxymethoxy-3,17,18-trihydroxy-
1-iodo-5,11,15-trimethoxy-10,16-di-(2-methoxy-ethoxymethoxy)-13-methoxymethoxy-
2,8,8-trimethyl-octadec-1-en-9-one (84)
Formula: C42H73IO17
M.M.: 976.92 g/mol
Rf: 0.08 (pentane/acetone 65/35)
IR: ν = 3456, 2930, 2889, 2822, 1706, 1454, 1385, 1367, 1282, 1197, 1093, 1022, 918, 847,
814, 794, 739, 699 cm-1
HRMS (m/z): calcd: 994.4231, found: 994.4227 [M + NH4
+]
[α]D = − 13.4 (c = 0.96 in CHCl3)
[α]365 = − 176.4
1H NMR (500 MHz, benzene-d6): δ = 7.42 (d, J=7.5 Hz, 2 H), 7.20 (t, J=7.6 Hz, 2 H),
7.10 (t, J=7.3 Hz, 1 H), 5.49 (s, 1 H), 5.36 (s, 1 H), 4.94 (d, J=7.2 Hz, 1 H), 4.93 (d,
J=6.6 Hz, 1 H), 4.87 (d, J=6.7 Hz, 1 H), 4.81 (d, J=11.1 Hz, 1 H), 4.76 (d, J=7.6
Hz, 1 H), 4.76 (d, J=11.3 Hz, 1 H), 4.68 (d, J=6.1 Hz, 1 H), 4.67 (d, J=6.0 Hz, 1
H), 4.61 (d, J=11.4 Hz, 1 H), 4.63 (d, J=5.8 Hz, 1 H), 4.57 (d, J=6.6 Hz, 1 H), 4.30
(d, J=8.9 Hz, 1 H), 4.10 - 4.21 (m, 1 H), 4.13 (d, J=10.7 Hz, 1 H), 3.92 - 3.99 (m, 1
H), 3.70 - 3.91 (m, 5 H), 3.61 (dt, J=8.2, 4.2 Hz, 1 H), 3.46 - 3.57 (m, 2 H), 3.36 -
3.45 (m, 1 H), 3.43 (s, 3 H), 3.26 (s, 6 H), 3.23 - 3.34 (m, 4 H), 3.21 (s, 3 H), 3.09 (s,
3 H), 3.06 (s, 3 H), 2.22 - 2.34 (m, 1 H), 1.95 - 2.06 (m, 2 H), 1.82 - 1.95 (m, 4 H),
1.73 (s, 3 H), 1.54 (dd, J=13.5, 6.9 Hz, 1 H), 1.39 (s, 3 H), 1.39 (s, 3 H) ppm
APT (126 MHz, benzene-d6): δ = 212.0 (C), 150.6 (C), 139.0 (C), 129.0 (2 CH), 128.4
(2 CH), 97.8 (CH2), 97.4 (CH2), 96.6 (CH2), 95.0 (CH2), 83.7 (CH), 80.7 (CH), 79.1
(CH), 77.8 (CH), 77.6 (CH), 76.3 (CH), 73.5 (CH), 73.3 (CH), 72.6 (CH), 72.3 (2
CH2), 71.7 (CH), 70.7 (CH2), 68.3 (CH2), 67.6 (CH2), 64.3 (CH2), 59.0 (CH3), 58.8
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(CH3), 58.0 (CH3), 57.1 (CH3), 56.6 (CH3), 56.0 (CH3), 53.3 (C), 38.6 (CH2), 37.9
(CH2), 36.7 (CH2), 35.8 (CH2), 22.4 (CH3), 21.4 (CH3), 19.3 (CH3) ppm
5.6.8 Synthesis of aldehyde 85
OOBOM
OMEM
OMeOH
OMEM
OMeOMOMOMe
OH
OH
NaIO4
acetone, H2O
OOBOM
OMEM
OMeOH
OMEM
OMeOMOMOMe O
I
I
84
85
To a solution of 84 (95.8 g; 98.1µmol) in acetone (981µL) and H2O (981µL) at rt was
added NaIO4 (62.9 mg; 294µmol). After stirring for 23 min at rt, EtOAc (2 mL) and a sat.
Na2S2O3 sol. (4 mL) were added and stirring continued for 6 min, after which the reaction
mixture was poured into H2O (10 mL) and EtOAc (15 mL), the organic phase separated
and the water phase extracted with EtOAc (3× 15 mL). The combined organic phases
were dried over MgSO4 and concentrated in vacuo. Crude 85 (98.1µmol) was obtained
quantitatively as a clear oil and was used as such in subsequent reactions.
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OOBOM
OMEM
OMeOH
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OMeOMOMOMe OI
Name: (2S,3R,5S,7R,8R,11S,13R,15S,16Z )-11-benzyloxymethoxy-15-hydroxy-17-iodo-
3,7,13-trimethoxy-2,8-di-(2-methoxy-ethoxymethoxy)-5-methoxymethoxy-10,10,16-
trimethyl-heptadec-16-enal (85)
Formula: C41H69IO16
M.M.: 944.88 g/mol
Rf: 0.38 (pentane/acetone 6/4)
IR: ν = 3473, 2926, 2889, 2822, 1731, 1707, 1454, 1367, 1282, 1243, 1199, 1092, 1023, 917,
849, 739, 699, 675 cm-1
HRMS (m/z): calcd: 962.3969, found: 962.3948 [M + NH4
+]
[α]D = − 29.2 (c = 0.83 in CHCl3)
[α]365 = − 225.6
1H NMR (500 MHz, benzene-d6): δ = 9.73 (d, J=1.4 Hz, 1 H), 7.41 (d, J=7.0 Hz, 2 H),
7.19 (t, J=7.6 Hz, 2 H), 7.09 (t, J=7.5 Hz, 1 H), 5.48 (d, J=1.1 Hz, 1 H), 5.35 (d,
J=2.0 Hz, 1 H), 4.92 (d, J=6.7 Hz, 1 H), 4.93 (d, J=7.0 Hz, 1 H), 4.86 (d, J=6.9
Hz, 1 H), 4.78 - 4.83 (m, 1 H), 4.75 (d, J=7.3 Hz, 1 H), 4.75 (d, J=11.9 Hz, 1 H),
4.66 (d, J=6.7 Hz, 1 H), 4.59 (d, J=6.6 Hz, 1 H), 4.61 (d, J=12.1 Hz, 1 H), 4.54 (d,
J=6.6 Hz, 1 H), 4.55 (d, J=6.6 Hz, 1 H), 4.27 - 4.33 (m, 1 H), 4.04 - 4.14 (m, 2 H),
3.99 (dd, J=4.0, 1.4 Hz, 1 H), 3.74 - 3.92 (m, 3 H), 3.45 - 3.58 (m, 3 H), 3.39 (s, 3
H), 3.22 - 3.33 (m, 4 H), 3.25 (s, 3 H), 3.23 (s, 3 H), 3.19 (s, 3 H), 3.08 (s, 3 H), 3.06
(s, 3 H), 2.25 (ddd, J=15.0, 10.4, 2.7 Hz, 1 H), 1.82 - 2.05 (m, 6 H), 1.72 (d, J=1.4
Hz, 3 H), 1.53 (ddd, J=14.2, 7.3, 2.1 Hz, 1 H), 1.38 (s, 3 H), 1.37 (s, 3 H) ppm
APT (126 MHz, benzene-d6): δ = 211.9 (C), 202.5 (CH), 150.5 (C), 138.9 (C), 129.0 (2
CH), 128.4 (2 CH), 128.3 (CH), 97.7 (CH2), 96.6 (2 CH2), 95.0 (CH2), 83.7 (CH),
83.6 (CH), 79.0 (CH), 77.7 (CH), 77.5 (CH), 76.3 (CH), 73.3 (CH), 73.2 (CH), 72.6
(CH), 72.4 (CH2), 72.3 (CH2), 70.7 (CH2), 68.3 (CH2), 67.6 (CH2), 59.0 (CH3), 58.8
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(CH3), 58.2 (CH3), 57.0 (CH3), 56.6 (CH3), 56.0 (CH3), 53.3 (C), 38.6 (CH2), 37.9
(CH2), 36.8 (CH2), 35.7 (CH2), 22.4 (CH3), 21.5 (CH3), 19.3 (CH3) ppm
5.6.9 Synthesis of seco-acid 24
NaClO2, NaH2PO4
2-Me-2-butene
t-BuOH, H2O, rt
OOBOM
OMEM
OMeOH
R
OMEM
OMeOMOMOMe
R = OH
R = HOI
quant.
24
85
To a solution of 85 (crude; 98.1µmol) in t-BuOH (1.37 mL) and 2-Me-2-butene (589µL) at
rt was added a solution of NaClO2 (35.5 mg; 392µmol) and NaH2PO4 (47.1 mg; 392µmol)
in H2O (349µL) dropwise. After stirring for 2 h at rt, the reaction mixture was poured
into a sat. NH4Cl sol. (15 mL) and EtOAc (15 mL), the organic phase separated and the
water phase extracted with EtOAc (4× 15 mL). The combined organic phases were dried
over MgSO4 and concentrated in vacuo. Crude 24 (98.1µmol) was obtained quantitatively
as a clear oil and was used as such in subsequent reactions.
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OOBOM
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Name: (2S,3R,5R,7R,8R,11S,13R,15S,16Z )-11-benzyloxymethoxy-15-hydroxy-17-iodo-
3,7,13-trimethoxy-2,8-di-(2-methoxy-ethoxymethoxy)-5-methoxymethoxy-10,10,16-
trimethyl-9-oxo-heptadec-16-enoic acid (24)
Formula: C41H69IO17
M.M.: 960.88 g/mol
Rf: 0.22 (pentane/acetone/AcOH 5.8/4/0.2)
IR: ν = 3457, 2928, 2889, 2822, 1737, 1707, 1454, 1380, 1367, 1279, 1243, 1199, 1171,
1091, 1023, 918, 848, 796, 751, 699, 667 cm-1
HRMS (m/z): calcd: 959.3507, found: 959.3469 [M - H+]
[α]D = − 30.9 (c = 0.59 in CHCl3)
[α]365 = − 215.7
1H NMR (500 MHz, benzene-d6): δ = 7.42 (d, J=7.5 Hz, 2 H), 7.20 (t, J=7.6 Hz, 2 H),
7.07 - 7.13 (m, J=7.3, 7.3 Hz, 1 H), 5.49 (d, J=1.1 Hz, 1 H), 5.34 (d, J=2.0 Hz,
1 H), 4.93 (d, J=6.9 Hz, 1 H), 4.93 (d, J=6.9 Hz, 1 H), 4.87 (d, J=6.9 Hz, 1 H),
4.82 (dd, J=10.7, 1.7 Hz, 1 H), 4.76 (d, J=6.9 Hz, 1 H), 4.76 (d, J=12.4 Hz, 1 H),
4.75 (d, J=5.3 Hz, 1 H), 4.64 (d, J=6.7 Hz, 1 H), 4.61 (d, J=12.2 Hz, 1 H), 4.60 (d,
J=5.2 Hz, 1 H), 4.58 (d, J=6.6 Hz, 1 H), 4.27 - 4.33 (m, 2 H), 4.11 - 4.18 (m, 1 H),
4.09 (d, J=10.2 Hz, 1 H), 3.91 - 3.97 (m, 1 H), 3.81 - 3.91 (m, 2 H), 3.46 - 3.62 (m,
3 H), 3.40 (s, 3 H), 3.23 - 3.35 (m, 4 H), 3.32 (s, 3 H), 3.27 (s, 3 H), 3.26 (s, 3 H),
3.10 (s, 3 H), 3.07 (s, 3 H), 2.26 (ddd, J=14.9, 10.5, 2.3 Hz, 1 H), 1.84 - 2.13 (m, 6
H), 1.73 (d, J=1.4 Hz, 3 H), 1.50 - 1.57 (m, 1 H), 1.39 (s, 3 H), 1.37 (s, 3 H) ppm
APT (126 MHz, benzene-d6): δ = 212.1 (C), 150.5 (C), 138.9 (C), 129.0 (2 CH), 128.5
(2 CH), 97.7 (CH2), 96.8 (CH2), 96.6 (CH2), 95.0 (CH2), 83.7 (CH), 79.1 (CH), 78.2
(CH), 77.8 (CH), 77.6 (CH), 76.3 (CH), 73.3 (CH), 73.3 (CH), 72.7 (CH), 72.3 (2
CH2), 70.7 (CH2), 68.8 (CH2), 67.6 (CH2), 58.9 (CH3), 58.8 (CH3), 58.5 (CH3), 57.1
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(CH3), 56.6 (CH3), 56.1 (CH3), 53.3 (C), 38.6 (CH2), 37.9 (CH2), 37.0 (CH2), 35.9
(CH2), 22.4 (CH3), 21.5 (CH3), 19.3 (CH3) ppm
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5.6 Coupling of C - 43 and D - 64; Synthesis of the C1−C17 fragment (22)
5.6.10 Synthesis of macrolactone 22
O
O
O
OMEM
OMe
MeO
OBOM
OMEM
OMe
OMOM
I
i)
 TCB-Cl, DIPEA, THF, rt 
ii)
 DMAP, toluene, 40°C
OOBOM
OMEM
OMeOH
OMEM
OMeOMOMOMe O
OH
I
diolide
(56%)
(22%)
OOBOM
OMEM
OMeO
OMEM
OMeOMOMOMe
O
I
O OBOM
MEMO
OMe O
OMEM
OMe OMOM OMe
O
I
+
24
22
87
To a solution of 24 (crude; 98.1µmol) in THF (1.96 mL) at rt were added DIPEA (171µL;
981µmol) and 2,4,6-trichlorobenzoyl chloride (76.6µL; 490µmol). After stirring for 4 h
at rt, the reaction mixture was diluted with toluene (24.5 mL) and added over 3 h to a
solution of DMAP (300 mg; 2.45 mmol) in toluene (58.9 mL) at 40 ◦C, resulting in a white,
turbid solution. After another 16 h of stirring at 40 ◦C, the reaction was quenched with
MeOH (3.0 mL) and the resulting clear reaction mixture was poured into a sat. NH4Cl
sol. (200 mL) and EtOAc (100 mL), the organic phase separated and the water phase ex-
tracted with EtOAc (3× 200 mL). The combined organic phases were dried over MgSO4
and concentrated in vacuo. Purification by flash chromatography (hexane/acetone 8/2 →
6/4) provided 22 (51.4 mg; 56 % yield) and diolide 87 (20.7 mg; 22 % yield) as a clear oil.
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Name: (3S,4R,6R,8R,9R,12S,14R,16S )-12-benzyloxymethoxy-16-((Z )-(2-iodo-1-methyl-
vinyl))-4,8,14-trimethoxy-3,9-di-(2-methoxy-ethoxymethoxy)-6-methoxymethoxy-
11,11-dimethyl-oxacyclohexadecane-2,10-dione (22)
Formula: C41H67IO16
M.M.: 942.87 g/mol
Rf: 0.37 (pentane/acetone 65/35)
IR: ν = 2930, 2889, 2822, 1755, 1735, 1708, 1685, 1454, 1380, 1367, 1282, 1248, 1199,
1150, 1091, 1023, 915, 848, 804, 750, 698, 665 cm-1
HRMS (m/z): calcd: 960.3812, found: 960.3795 [M + NH4
+]
[α]D = − 25.6 (c = 1.21 in CHCl3)
[α]365 = − 121.8
1H NMR (500 MHz, benzene-d6): δ = 7.32 (d, J=7.5 Hz, 2 H), 7.19 (t, J=7.6 Hz, 2 H),
7.10 (t, J=7.3 Hz, 1 H), 5.90 (dd, J=10.3, 2.5 Hz, 1 H), 5.63 (d, J=0.8 Hz, 1 H), 4.97
(d, J=1.4 Hz, 1 H), 4.76 - 4.83 (m, 5 H), 4.75 (d, J=6.9 Hz, 1 H), 4.68 (d, J=6.9 Hz,
1 H), 4.66 (d, J=6.7 Hz, 1 H), 4.61 (d, J=12.1 Hz, 1 H), 4.54 (d, J=5.0 Hz, 1 H),
4.54 (d, J=11.9 Hz, 1 H), 4.26 - 4.34 (m, 1 H), 4.05 (dd, J=9.5, 1.4 Hz, 1 H), 3.90
(d, J=8.4 Hz, 1 H), 3.71 - 3.84 (m, 3 H), 3.68 (ddd, J=10.8, 6.3, 3.8 Hz, 1 H), 3.57
- 3.64 (m, 2 H), 3.43 (s, 3 H), 3.41 (s, 3 H), 3.30 (s, 3 H), 3.28 - 3.34 (m, 4 H), 3.26
(s, 3 H), 3.10 (s, 3 H), 3.10 (s, 3 H), 2.36 (ddd, J=15.1, 5.3, 2.3 Hz, 1 H), 2.22 (ddd,
J=14.3, 8.5, 4.9 Hz, 1 H), 2.14 - 2.19 (m, 1 H), 1.99 - 2.05 (m, 1 H), 1.83 - 1.99 (m,
3 H), 1.75 (ddd, J=15.0, 10.5, 1.2 Hz, 1 H), 1.60 (d, J=1.4 Hz, 3 H), 1.40 (s, 3 H),
1.39 (s, 3 H) ppm
APT (126 MHz, benzene-d6): δ = 211.0 (C), 169.7 (C), 146.0 (C), 138.8 (C), 129.0 (2
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5.6 Coupling of C - 43 and D - 64; Synthesis of the C1−C17 fragment (22)
CH), 128.3 (CH), 128.3 (2 CH), 98.1 (CH2), 96.1 (CH2), 95.8 (CH2), 95.4 (CH2),
82.6 (CH), 80.7 (CH), 79.2 (CH), 78.7 (CH), 77.9 (CH), 76.7 (CH), 75.3 (CH), 74.6
(CH), 72.4 (2 CH2), 71.7 (CH), 70.6 (CH2), 68.5 (CH2), 68.1 (CH2), 59.0 (CH3), 59.0
(CH3), 58.1 (CH3), 57.5 (CH3), 57.3 (CH3), 55.8 (CH3), 54.2 (C), 40.2 (CH2), 34.9
(CH2), 34.4 (CH2), 32.8 (CH2), 24.4 (CH3), 19.9 (CH3), 19.6 (CH3) ppm
OOBOM
OMEM
OMeO
OMEM
OMeOMOMOMe
O
I
O OBOM
MEMO
OMe O
OMEM
OMe OMOM OMe
O
I
Name: diolide (87)
Formula: C82H134I2O32
M.M.: 1885.73 g/mol
Rf: 0.30 (pentane/acetone 65/35)
ESI-MS (m/z): 1902.6 [M + NH4
+]
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NMR analysis Precursor 22 was analysed by 1D and 2D NMR techniques, including
1H, APT, HSQC and HMBC. Next follow the 1H and APT spectra with assignment of the
proton and carbon resonances, the numbering according to following scheme. Also included
are the HMBC spectra showing the correlation between CH-15 and Cq-1, providing proof
of the macrocyclization.
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5.6 Coupling of C - 43 and D - 64; Synthesis of the C1−C17 fragment (22)
5.6.11 Synthesis of diol 90
OSEMOH
OMEM
ROPMB
OMEM
OMeOMOMOMe
O
O
Me4NBH(OAc)3 
ACN, AcOH, -35°C
R =
R =
O
OH
I
98%
75
90
A solution of Me4NBH(OAc)3 (585 mg; 2.22 mmol) in ACN (2.22 mL) and AcOH (2.22 mL)
was stirred at rt for 30 min, after which it was cooled to −35 ◦C. Next, a solution of 76
(252 mg; 222µmol) in ACN (4.44 mL) was added dropwise and stirring continued at −35 ◦C
for 23 h, after which a sat. Rochelle salt sol. (15 mL) was added and the reaction mixture
poured into a sat. NaHCO3 sol. (75 mL) and CH2Cl2 (75 mL), the organic phase separated
and the water phase extracted with CH2Cl2 (2× 75 mL). The combined organic phases
were washed with a sat. NaHCO3 sol. (50 mL), dried over MgSO4 and concentrated in
vacuo. Purification by flash chromatography (hexane/acetone 3/1) provided 90 (247 mg;
98 % yield) as a clear oil.
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Name: (1Z,3S,5R,7R,9R,10R,11R,13R,15R,16S,17S )-1-iodo-17,18-O-isopropylidene-
11,15-dimethoxy-3-(4-methoxy-benzyloxy)-10,16-di-(2-methoxy-ethoxymethoxy)-13-
methoxymethoxy-2,8,8-trimethyl-9-(2-trimethylsilyl-ethoxymethoxy)-octadec-1-ene-
5,7-diol (90)
Formula: C50H91IO18Si
M.M.: 1135.24 g/mol
Rf: 0.28 (hexane/acetone 3/1)
IR: ν = 3478, 2935, 2887, 2822, 1612, 1584, 1513, 1464, 1370, 1300, 1282, 1247, 1210,
1173, 1150, 1096, 1070, 1023, 936, 919, 858, 835, 768, 694, 665 cm-1
HRMS (m/z): calcd: 1152.5358, found: 1152.5341 [M + NH4
+]
[α]D = + 48.8 (c = 0.96 in CHCl3)
[α]365 = + 155.6
1H NMR (500 MHz, benzene-d6): δ = 7.25 (d, J=8.7 Hz, 2 H), 6.82 (d, J=8.7 Hz, 2 H),
5.74 (d, J=1.3 Hz, 1 H), 5.09 (d, J=6.6 Hz, 1 H), 4.99 (d, J=6.6 Hz, 1 H), 4.98 (d,
J=6.6 Hz, 1 H), 4.90 (d, J=6.8 Hz, 1 H), 4.83 - 4.88 (m, 1 H), 4.84 (d, J=6.8 Hz, 1
H), 4.81 (d, J=6.5 Hz, 1 H), 4.74 (d, J=6.5 Hz, 1 H), 4.66 (d, J=6.5 Hz, 1 H), 4.57
(dd, J=6.6, 2.0 Hz, 1 H), 4.32 - 4.44 (m, 2 H), 4.35 (d, J=11.2 Hz, 1 H), 4.21 (d,
J=11.3 Hz, 1 H), 4.17 - 4.26 (m, 2 H), 4.06 (dd, J=8.5, 6.1 Hz, 1 H), 3.84 - 3.97 (m,
4 H), 3.74 - 3.82 (m, 3 H), 3.62 - 3.73 (m, 3 H), 3.60 (dd, J=9.3, 2.2 Hz, 1 H), 3.39 -
3.47 (m, 4 H), 3.46 (s, 3 H), 3.33 (s, 3 H), 3.30 (s, 3 H), 3.26 (s, 3 H), 3.18 (s, 3 H),
3.17 (s, 3 H), 2.09 - 2.19 (m, 3 H), 1.80 - 1.90 (m, 2 H), 1.53 - 1.74 (m, 3 H), 1.65 (d,
J=1.4 Hz, 3 H), 1.44 (s, 3 H), 1.36 (s, 3 H), 1.24 (s, 3 H), 1.01 (s, 3 H), 0.96 - 1.03
(m, 2 H), 0.03 (s, 9 H) ppm
APT (126 MHz, benzene-d6): δ = 160.2 (C), 147.6 (C), 131.1 (C), 130.2 (2 CH), 114.5
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(2 CH), 108.9 (C), 96.7 (CH2), 96.6 (2 CH2), 96.5 (CH2), 81.4 (CH), 80.6 (CH),
80.2 (CH), 79.1 (CH), 77.7 (CH), 77.5 (CH), 76.6 (CH), 74.1 (CH), 73.6 (CH), 72.7
(CH2), 72.6 (CH2), 72.3 (CH), 71.1 (CH2), 68.0 (2 CH2), 67.0 (CH2), 66.7 (CH2),
66.5 (CH), 59.1 (CH3), 59.1 (CH3), 57.8 (CH3), 57.5 (CH3), 56.0 (CH3), 55.1 (CH3),
42.9 (C), 41.3 (CH2), 38.9 (CH2), 36.3 (CH2), 36.1 (CH2), 27.3 (CH3), 26.5 (CH3),
21.5 (CH3), 19.3 (CH3), 19.1 (CH3), 18.7 (CH2), -0.9 (3 CH3) ppm
5.6.12 Synthesis of methyl ether 91
Me3OBF4
Proton-sponge®
MS 4Å, CH2Cl2, -40°C
OSEMOH
OMEM
OROPMB
OMEM
OMeOMOMOMe
O
O
R = Me
R = HI
34%
91
90
To a solution of 90 (172 mg; 152µmol) in CH2Cl2 (3.80 mL) at rt were added molecu-
lar sieves (61 mg; 4 A˚; powdered; activated). After stirring for 30 min at rt, the reaction
mixture was cooled to −40 ◦C and Proton-sponge R© (586 mg; 2.74 mmol) and Me3OBF4
(337 mg; 2.28 mmol) were added. After stirring for 65 h at −40 ◦C, the yellow-orange
suspension was filtered over a fritted funnel and the filtrate (+ 40 mL CH2Cl2) washed
with a 1mCuSO4 sol. (2× 40 mL). The water phases were back-extracted with CH2Cl2
(3× 40 mL), the combined organic phases dried over MgSO4 and concentrated in vacuo.
Purification by flash chromatography (Et2O) provided recovered starting material 90
(77.0 mg; 45 %), target material 91 (49.7 mg; 28 %) and a mixture of target material and
the permethylated product (32.5 mg; 19 %). The recovered starting material was reacted
again according to similar conditions and work-up as above. Further purification by sequen-
tial flash chromatography (Et2O and hexane/acetone 85/15) provided recovered starting
material 90 (54.1 mg; 31 %), target material 91 (59.0 mg; 34 %) and a mixture of target
material and the permethylated product (39.4 mg; 23 %).
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OSEMOH
OMEM
OMeOPMB
OMEM
OMeOMOMOMe
O
OI
Name: (1Z,3S,5R,7R,9R,10R,11R,13R,15R,16S,17S )-1-iodo-17,18-O-isopropylidene-
5,11,15-trimethoxy-3-(4-methoxy-benzyloxy)-10,16-di-(2-methoxy-ethoxymethoxy)-
13-methoxymethoxy-2,8,8-trimethyl-9-(2-trimethylsilyl-ethoxymethoxy)-octadec-1-
en-7-ol (91)
Formula: C51H93IO18Si
M.M.: 1149.26 g/mol
Rf: 0.32 (Et2O)
IR: ν = 3509, 2928, 2884, 2822, 1612, 1584, 1514, 1463, 1454, 1369, 1303, 1282, 1247,
1210, 1173, 1150, 1095, 1062, 1024, 936, 919, 858, 835, 711, 693, 659 cm-1
HRMS (m/z): calcd: 1166.5514, found: 1166.5478 [M + NH4
+]
[α]D = + 26.8 (c = 1.33 in CHCl3)
[α]365 = + 86.1
1H NMR (500 MHz, benzene-d6): δ = 7.25 - 7.30 (m, 2 H), 6.82 - 6.87 (m, 2 H), 5.74 (d,
J=1.2 Hz, 1 H), 5.10 (d, J=6.7 Hz, 1 H), 5.06 (d, J=6.7 Hz, 1 H), 5.01 (d, J=6.6
Hz, 1 H), 4.91 (d, J=6.6 Hz, 1 H), 4.85 (d, J=6.7 Hz, 1 H), 4.85 (d, J=6.6 Hz, 1
H), 4.79 (d, J=6.6 Hz, 1 H), 4.70 (d, J=6.6 Hz, 1 H), 4.66 - 4.71 (m, 1 H), 4.57 (dd,
J=6.6, 1.8 Hz, 1 H), 4.36 (d, J=11.3 Hz, 1 H), 4.33 - 4.40 (m, 1 H), 4.23 - 4.28 (m,
1 H), 4.21 (d, J=11.3 Hz, 1 H), 4.12 (d, J=9.9 Hz, 1 H), 4.02 - 4.09 (m, 2 H), 3.94
(dd, J=7.3, 4.1 Hz, 1 H), 3.86 - 3.93 (m, 2 H), 3.59 - 3.86 (m, 8 H), 3.51 (s, 3 H),
3.42 - 3.50 (m, 4 H), 3.34 (s, 3 H), 3.33 (s, 3 H), 3.27 (s, 3 H), 3.21 (s, 3 H), 3.18 (s,
3 H), 3.17 (s, 3 H), 2.11 - 2.23 (m, 3 H), 1.73 - 1.89 (m, 4 H), 1.64 (d, J=1.4 Hz, 3
H), 1.52 - 1.60 (m, 1 H), 1.44 (s, 3 H), 1.36 (s, 3 H), 1.27 (s, 3 H), 1.05 (s, 3 H), 0.95
- 1.02 (m, 2 H), 0.02 (s, 9 H) ppm
APT (126 MHz, benzene-d6): δ = 160.2 (C), 147.4 (C), 131.2 (C), 130.2 (2 CH), 114.4
(2 CH), 108.8 (C), 96.6 (2 CH2), 96.6 (CH2), 96.1 (CH2), 81.2 (CH), 80.4 (CH), 79.3
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(CH), 79.2 (CH), 77.8 (CH), 77.5 (CH), 77.0 (CH), 77.0 (CH), 73.9 (CH), 72.9 (CH),
72.7 (CH2), 72.7 (CH2), 72.1 (CH), 70.9 (CH2), 68.0 (CH2), 67.9 (CH2), 67.0 (CH2),
66.7 (CH2), 59.1 (CH3), 59.1 (CH3), 57.8 (CH3), 57.4 (CH3), 57.3 (CH3), 56.1 (CH3),
55.2 (CH3), 43.1 (C), 38.7 (CH2), 36.4 (CH2), 36.0 (CH2), 35.4 (CH2), 27.3 (CH3),
26.5 (CH3), 20.6 (CH3), 19.4 (CH3), 19.0 (CH3), 18.7 (CH2), -0.9 (3 CH3) ppm
5.6.13 Synthesis of diol 92
OROH
OMEM
OMeOPMB
OMEM
OMeOMOMOMe
O
O
R = H
R = SEM
TBAF, HMPA 
MS 4Å, 80°C
I
54%
91
92
To a solution of 91 (31.5 mg; 27.4µmol) in HMPA (274µL) at rt were added molecular
sieves (4 A˚; powdered; activated). After stirring for 15 min, TBAF (137µL; 1m in THF)
was added dropwise, resulting in a brown-black solution, which was heated to 80 ◦C. After
6 h at 80 ◦C, an extra amount of molecular sieves and TBAF (55.0µL; 1m in THF) were
added and stirring continued at 80 ◦C. After an extra 16.5 h, TLC showed total consump-
tion of 91, after which work-up and purification followed by direct flash chromatography
(hexane/acetone 9/1 → 8/2), providing 92 (15.0 mg; 54 % yield) as a clear oil.
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OHOH
OMEM
OMeOPMB
OMEM
OMeOMOMOMe
O
OI
Name: (1Z,3S,5R,7R,9R,10S,11R,13R,15R,16S,17S )-1-iodo-17,18-O-isopropylidene-
5,11,15-trimethoxy-3-(4-methoxy-benzyloxy)-10,16-di-(2-methoxy-ethoxymethoxy)-
13-methoxymethoxy-2,8,8-trimethyl-octadec-1-ene-7,9-diol (92)
Formula: C45H79IO17
M.M.: 1019.00 g/mol
Rf: 0.16 (hexane/acetone 7/3)
IR: ν = 3494, 2930, 2884, 2827, 1612, 1584, 1513, 1455, 1369, 1247, 1210, 1176, 1150,
1092, 1025, 917, 851, 822, 716, 680, 641 cm-1
HRMS (m/z): calcd: 1041.4254, found: 1041.4261 [M + Na+]
[α]D = + 1.9 (c = 0.50 in CHCl3)
[α]365 = + 17.9
1H NMR (500 MHz, benzene-d6): δ = 7.30 (d, J=8.7 Hz, 2 H), 6.83 (d, J=8.7 Hz, 2 H),
5.75 (d, J=1.4 Hz, 1 H), 5.08 (d, J=6.7 Hz, 1 H), 4.95 (d, J=6.4 Hz, 1 H), 4.82 (d,
J=6.7 Hz, 1 H), 4.80 (d, J=6.4 Hz, 1 H), 4.71 - 4.76 (m, 1 H), 4.73 (d, J=6.7 Hz, 1
H), 4.61 (d, J=6.7 Hz, 1 H), 4.32 - 4.40 (m, 1 H), 4.38 (d, J=11.1 Hz, 1 H), 4.22 -
4.28 (m, 1 H), 4.26 (d, J=11.4 Hz, 1 H), 4.20 (d, J=10.5 Hz, 1 H), 4.12 - 4.17 (m, 1
H), 4.06 (dd, J=8.4, 6.1 Hz, 1 H), 3.99 (d, J=1.1 Hz, 1 H), 3.85 - 3.95 (m, 3 H), 3.74
- 3.81 (m, 2 H), 3.58 - 3.72 (m, 6 H), 3.42 (dt, J=5.8, 4.1 Hz, 2 H), 3.30 - 3.36 (m,
2 H), 3.34 (s, 3 H), 3.31 (s, 3 H), 3.29 (s, 3 H), 3.27 (s, 3 H), 3.22 (s, 3 H), 3.17 (s,
3 H), 3.12 (s, 3 H), 2.12 (ddd, J=14.3, 7.4, 2.9 Hz, 1 H), 1.98 - 2.04 (m, 2 H), 1.90
(ddd, J=14.0, 9.3, 4.6 Hz, 1 H), 1.75 - 1.87 (m, 3 H), 1.69 (ddd, J=13.7, 6.4, 1.1 Hz,
1 H), 1.64 (d, J=1.4 Hz, 3 H), 1.45 (s, 3 H), 1.36 (s, 3 H), 1.22 (s, 3 H), 0.94 (s, 3
H) ppm
APT (126 MHz, benzene-d6): δ = 160.2 (C), 147.6 (C), 131.4 (C), 130.2 (2 CH), 114.4
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(2 CH), 108.9 (C), 96.9 (CH2), 96.8 (CH2), 96.5 (CH2), 83.1 (CH), 80.5 (CH), 79.2
(CH), 77.6 (CH), 77.6 (CH), 76.9 (2 CH), 76.3 (CH), 74.6 (CH), 74.4 (CH), 73.7
(CH), 72.6 (CH2), 72.6 (CH2), 70.9 (CH2), 69.0 (CH2), 68.0 (CH2), 67.0 (CH2), 59.1
(2 CH3), 58.0 (CH3), 57.8 (CH3), 57.7 (CH3), 56.0 (CH3), 55.1 (CH3), 42.2 (C), 39.0
(CH2), 36.4 (CH2), 36.3 (CH2), 36.2 (CH2), 27.3 (CH3), 26.5 (CH3), 21.0 (CH3), 19.1
(CH3), 17.4 (CH3) ppm
5.6.14 Synthesis of acetonide 93
OHOH
OMEM
OMeOPMB
OMEM
OMeOMOMOMe
O
O
CSA, DMP, rt
87%
OO
OMEM
OMeOPMB
OMEM
OMeOMOMOMe
O
O
I
I
93
92
To a solution of 92 (10.6 mg; 10.4µmol) in DMP (156µL) at rt was added a solution of
CSA (483µg) in DMP (104µL). After stirring for 4.5 h, an extra amount of CSA (483µg)
in DMP (104µL) was added and stirring continued at rt. After a total stirring of 5.5 h, the
reaction mixture was poured into a sat. NaHCO3 sol. (4 mL) and EtOAc (4 mL), the organic
phase separated and the water phase extracted with EtOAc (3× 4 mL). The combined
organic phases were dried over MgSO4 and concentrated in vacuo. Purification by flash
chromatography (hexane/acetone 9/1→ 75/25) provided 93 (9.6 mg; 87 % yield) as a clear
oil.
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OO
OMEM
OMeOPMB
OMEM
OMeOMOMOMe
O
OI
Name: (1Z,3S,5S,7R,9R,10R,11R,13R,15R,16S,17S )-1-iodo-7,9-O :17,18-O-
bis(isopropylidene)-5,11,15-trimethoxy-3-(4-methoxy-benzyloxy)-10,16-di-(2-
methoxy-ethoxymethoxy)-13-methoxymethoxy-2,8,8-trimethyl-octadec-1-ene (93)
Formula: C48H83IO17
M.M.: 1059.07 g/mol
Rf: 0.31 (hexane/acetone 7/3)
IR: ν = 2977, 2934, 2884, 2822, 1612, 1584, 1514, 1455, 1378, 1303, 1247, 1200, 1155,
1091, 1028, 919, 851, 820, 716, 681 cm-1
HRMS (m/z): calcd: 1076.5013, found: 1076.4997 [M + NH4
+]
[α]D = + 27.3 (c = 0.32 in CHCl3)
[α]365 = + 93.4
1H NMR (500 MHz, benzene-d6): δ = 7.31 (d, J=8.7 Hz, 2 H), 6.84 (d, J=8.7 Hz, 2 H),
5.75 (d, J=1.3 Hz, 1 H), 5.09 (d, J=6.8 Hz, 1 H), 5.05 (d, J=6.5 Hz, 1 H), 4.98 (d,
J=6.5 Hz, 1 H), 4.83 (d, J=6.8 Hz, 1 H), 4.76 (d, J=6.6 Hz, 1 H), 4.72 (dd, J=9.6,
3.5 Hz, 1 H), 4.64 (d, J=6.6 Hz, 1 H), 4.36 (d, J=11.3 Hz, 1 H), 4.33 - 4.42 (m, 1
H), 4.29 (dd, J=3.3, 1.6 Hz, 1 H), 4.26 (d, J=11.5 Hz, 1 H), 4.19 - 4.25 (m, 1 H),
4.07 (dd, J=8.4, 6.1 Hz, 1 H), 3.83 - 3.95 (m, 4 H), 3.73 - 3.83 (m, 3 H), 3.58 - 3.69
(m, 4 H), 3.41 - 3.46 (m, 4 H), 3.37 (s, 3 H), 3.36 (s, 3 H), 3.30 (s, 3 H), 3.27 (s, 3
H), 3.23 (s, 3 H), 3.17 (s, 3 H), 3.15 (s, 3 H), 2.06 - 2.19 (m, 3 H), 1.90 (ddd, J=14.0,
9.5, 4.1 Hz, 1 H), 1.82 (ddd, J=14.2, 9.6, 4.7 Hz, 1 H), 1.61 - 1.71 (m, 3 H), 1.63 (d,
J=1.3 Hz, 3 H), 1.54 (s, 3 H), 1.51 (s, 3 H), 1.45 (s, 3 H), 1.36 (s, 3 H), 1.27 (s, 3
H), 0.85 (s, 3 H) ppm
APT (126 MHz, benzene-d6): δ = 160.2 (C), 147.6 (C), 131.4 (C), 130.2 (2 CH), 114.4 (2
CH), 108.9 (C), 99.3 (C), 96.7 (CH2), 96.5 (CH2), 96.5 (CH2), 82.9 (CH), 80.7 (CH),
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79.3 (CH), 78.6 (CH), 77.7 (CH), 77.6 (CH), 76.8 (CH), 75.9 (CH), 75.8 (CH), 73.8
(CH), 73.1 (CH), 72.7 (CH2), 72.7 (CH2), 70.9 (CH2), 68.5 (CH2), 68.1 (CH2), 67.0
(CH2), 59.0 (2 CH3), 58.0 (CH3), 57.9 (CH3), 57.4 (CH3), 56.0 (CH3), 55.1 (CH3),
39.8 (CH2), 37.1 (CH2), 36.7 (C), 36.6 (CH2), 36.3 (CH2), 30.9 (CH3), 27.3 (CH3),
26.5 (CH3), 21.2 (CH3), 19.6 (CH3), 19.1 (CH3), 14.5 (CH3) ppm
5.6.15 Synthesis of PMP acetal 96
OBOM
OMEM
OHOPMB
OMEM
OMeOMOMOMe
O
O DDQ, CH2Cl2   
pH 7 buffer, rt
90%
OBOM
OMEM
OO
OMEM
OMeOMOMOMe
O
O
I
I
OSEM
OSEM
PMP__
77
96
To a solution of 77 (42.6 mg; 33.9µmol) in CH2Cl2 (340µL) and pH 7 phosphate buffer
(34µL) at rt was added DDQ (9.2 mg; 40.7µmol), which resulted in a green-black solution.
After stirring for 40 min at rt, an extra amount of DDQ was added, stirring continued
for 23 min, after which the reaction mixture was poured into a pH 7 phosphate buffer
(40 mL), brine (10 mL) and EtOAc (50 mL), the organic phase separated and the water
phase extracted with EtOAc (2× 50 mL). The combined organic phases were dried over
MgSO4 and concentrated in vacuo. Purification by flash chromatography (hexane/acetone
9/1 → 84/16) provided 96 (38.1 mg; 90 % yield) as a clear oil.
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OBOM
OMEM
OO
OMEM
OMeOMOMOMe
O
OI OSEM
PMP__
Name: (1Z,3S,5R,7S,9R,10R,11R,13R,15R,16S,17S )-7-benzyloxymethoxy-1-iodo-17,18-
O-isopropylidene-11,15-dimethoxy-3,5-O-(4-methoxy-benzylidene)-10,16-di-(2-
methoxy-ethoxymethoxy)-13-methoxymethoxy-2,8,8-trimethyl-9-(2-trimethylsilyl-
ethoxymethoxy)-octadec-1-ene (96)
Formula: C58H97IO19Si
M.M.: 1153.37 g/mol
Rf: 0.33 (hexane/EtOAc 4/6)
IR: ν = 3488, 2929, 2884, 2822, 1616, 1589, 1518, 1454, 1368, 1334, 1303, 1285, 1248,
1204, 1173, 1150, 1102, 1024, 936, 919, 858, 834, 775, 738, 698, 664 cm-1
HRMS (m/z): calcd: 1270.5776, found: 1270.5743 [M + NH4
+]
[α]D = + 32.5 (c = 1.15 in CHCl3)
[α]365 = + 122.5
1H NMR (500 MHz, benzene-d6): δ = 7.52 (d, J=8.9 Hz, 2 H), 7.46 (d, J=7.2 Hz, 2
H), 7.25 (t, J=7.7 Hz, 2 H), 7.10 (t, J=7.5 Hz, 1 H), 6.81 (d, J=8.9 Hz, 2 H), 5.58
(d, J=0.9 Hz, 1 H), 5.43 (s, 1 H), 5.10 (d, J=6.9 Hz, 1 H), 5.09 (d, J=6.9 Hz, 1 H),
5.07 (d, J=7.2 Hz, 1 H), 5.01 (d, J=6.7 Hz, 1 H), 5.01 (d, J=6.4 Hz, 1 H), 4.94 (d,
J=6.4 Hz, 1 H), 4.90 (d, J=6.7 Hz, 1 H), 4.79 - 4.87 (m, 1 H), 4.85 (d, J=12.2 Hz,
1 H), 4.83 (d, J=6.7 Hz, 1 H), 4.83 (d, J=6.7 Hz, 1 H), 4.66 (d, J=12.1 Hz, 1 H),
4.65 (d, J=6.7 Hz, 1 H), 4.41 - 4.47 (m, 1 H), 4.28 - 4.38 (m, 2 H), 4.16 - 4.26 (m, 2
H), 4.00 - 4.07 (m, 2 H), 3.85 - 3.95 (m, 3 H), 3.62 - 3.80 (m, 5 H), 3.60 (dd, J=9.3,
2.3 Hz, 1 H), 3.56 (d, J=9.5 Hz, 1 H), 3.40 - 3.48 (m, 4 H), 3.33 (s, 3 H), 3.31 (s, 3
H), 3.29 (s, 3 H), 3.26 (s, 3 H), 3.17 (s, 3 H), 3.16 (s, 3 H), 2.03 - 2.22 (m, 3 H), 1.77
- 1.86 (m, 2 H), 1.75 (d, J=1.4 Hz, 3 H), 1.63 - 1.71 (m, 1 H), 1.45 - 1.52 (m, 2 H),
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1.44 (s, 3 H), 1.35 (s, 3 H), 1.21 (s, 6 H), 0.93 (ddd, J=14.3, 9.6, 7.0 Hz, 1 H), 0.84
(ddd, J=14.2, 9.2, 5.8 Hz, 1 H), 0.00 (s, 9 H) ppm
APT (126 MHz, benzene-d6): δ = 160.7 (C), 147.7 (C), 139.1 (C), 132.3 (C), 129.2 (2
CH), 128.4 (4 CH), 128.3 (CH), 114.0 (2 CH2), 108.8 (C), 101.1 (CH), 98.1 (CH2),
97.1 (CH2), 97.0 (CH2), 96.6 (CH2), 95.9 (CH2), 82.0 (CH), 81.1 (CH), 81.1 (CH),
79.2 (CH), 79.0 (CH), 77.7 (CH), 77.3 (CH), 74.0 (2 CH), 73.8 (CH), 72.7 (CH2),
72.7 (CH2), 72.3 (CH), 70.8 (CH2), 68.0 (CH2), 68.0 (CH2), 67.0 (CH2), 66.6 (CH2),
59.0 (2 CH3), 57.8 (CH3), 56.9 (CH3), 56.0 (CH3), 55.1 (CH3), 43.9 (C), 38.4 (CH2),
36.6 (CH2), 36.1 (CH2), 34.4 (CH2), 27.3 (CH3), 26.5 (CH3), 20.7 (CH3), 20.1 (CH3),
19.7 (CH3), 18.4 (CH2), -0.8 (3 CH3) ppm
5.6.16 Synthesis of diol 95
OSEMOBOM
OMEM
OHOR
OMEM
OMeOMOMOMe
O
O
R = H
R = PMB
CAN             
ACN, H2O, 0°C
I
77%
79
95
To a solution of 79 (28.0 mg; 22.3µmol) in ACN (223µL) and H2O (446µL) at 0
◦C was
added CAN ((NH4)2Ce(NO3)6) (48.9 mg; 89.2µmol). After stirring for 6 h at 0
◦C, the
reaction mixture was poured into a sat. NaHCO3 sol. (10 mL) and CH2Cl2 (10 mL), the
organic phase separated and the water phase extracted with CH2Cl2 (3× 10 mL). The
combined organic phases were dried over MgSO4 and concentrated in vacuo. Purification
by flash chromatography (hexane/acetone 9/1 → 8/2) provided 95 (19.6 mg; 77 % yield)
as a clear oil.
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OSEMOBOM
OMEM
OHOH
OMEM
OMeOMOMOMe
O
OI
Name: (1Z,3S,5S,7S,9R,10R,11R,13R,15R,16S,17S )-7-benzyloxymethoxy-1-iodo-
17,18-O-isopropylidene-11,15-dimethoxy-10,16-di-(2-methoxy-ethoxymethoxy)-13-
methoxymethoxy-2,8,8-trimethyl-9-(2-trimethylsilyl-ethoxymethoxy)-octadec-1-en-
3,5-diol (95)
Formula: C50H91IO18Si
M.M.: 1135.24 g/mol
Rf: 0.11 (hexane/acetone 8/2)
IR: ν = 3473, 2923, 2884, 2817, 1721, 1605, 1454, 1369, 1248, 1199, 1150, 1097, 1022, 920,
856, 836, 768, 739, 697, 665 cm-1
HRMS (m/z): calcd: 1152.5358, found: 1152.5349 [M + NH4
+]
[α]D = + 20.7 (c = 0.49 in CHCl3)
[α]365 = + 55.9
1H NMR (500 MHz, benzene-d6): δ = 7.30 (d, J=7.9 Hz, 2 H), 7.18 (t, J=7.2 Hz, 2 H),
7.07 (t, J=7.5 Hz, 1 H), 5.55 (t, J=1.1 Hz, 1 H), 5.24 (d, J=6.6 Hz, 1 H), 5.10 (d,
J=9.5 Hz, 1 H), 5.08 (d, J=6.7 Hz, 1 H), 5.05 (d, J=6.7 Hz, 1 H), 5.00 (d, J=6.6
Hz, 1 H), 4.96 (d, J=6.6 Hz, 1 H), 4.93 (d, J=6.6 Hz, 1 H), 4.90 (d, J=6.7 Hz, 1
H), 4.83 (d, J=6.7 Hz, 1 H), 4.75 (d, J=6.7 Hz, 1 H), 4.67 (d, J=12.1 Hz, 1 H), 4.61
(d, J=6.6 Hz, 1 H), 4.48 (d, J=12.2 Hz, 1 H), 4.40 (dd, J=6.8, 1.1 Hz, 1 H), 4.31 -
4.37 (m, 1 H), 4.18 - 4.25 (m, 2 H), 4.13 - 4.17 (m, 1 H), 4.01 - 4.08 (m, 2 H), 3.85
- 4.01 (m, 3 H), 3.79 (d, J=6.9 Hz, 1 H), 3.72 - 3.78 (m, 2 H), 3.69 (td, J=5.4, 3.8
Hz, 1 H), 3.62 - 3.67 (m, 1 H), 3.52 - 3.60 (m, 2 H), 3.48 (dt, J=5.5, 4.7 Hz, 2 H),
3.42 (td, J=5.6, 4.0 Hz, 2 H), 3.40 (s, 3 H), 3.29 (s, 3 H), 3.26 (s, 3 H), 3.17 (s, 3 H),
3.16 (s, 3 H), 2.09 - 2.21 (m, 2 H), 1.94 - 2.09 (m, 3 H), 1.88 (ddd, J=13.8, 9.8, 3.5
Hz, 1 H), 1.77 (d, J=1.5 Hz, 3 H), 1.79 (ddd, J=13.3, 9.2, 3.7 Hz, 1 H), 1.54 - 1.60
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(m, 1 H), 1.45 (s, 3 H), 1.36 (s, 3 H), 1.11 (s, 3 H), 1.10 (s, 3 H), 1.02 - 1.07 (m, 2
H), 0.02 (s, 9 H) ppm
APT (126 MHz, benzene-d6): δ = 150.5 (C), 138.3 (C), 129.1 (2 CH), 128.5 (2 CH), 108.9
(C), 98.0 (CH2), 97.2 (CH2), 96.6 (2 CH2), 95.9 (CH2), 84.6 (CH), 81.2 (CH), 79.2
(2 CH), 77.6 (CH), 77.3 (CH), 74.2 (CH), 73.8 (CH), 72.9 (CH), 72.8 (CH2), 72.6
(CH2), 72.3 (CH), 70.8 (CH2), 70.5 (CH), 68.1 (CH2), 68.0 (CH2), 67.0 (CH2), 66.8
(CH2), 59.1 (CH3), 59.1 (CH3), 57.9 (CH3), 57.3 (CH3), 56.0 (CH3), 44.4 (C), 41.9
(CH2), 39.7 (CH2), 36.3 (CH2), 36.1 (CH2), 27.3 (CH3), 26.5 (CH3), 19.9 (CH3), 19.8
(CH3), 19.1 (CH3), 18.8 (CH2), -0.9 (3 CH3) ppm
5.6.17 Synthesis of acetonide 99
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95%
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OSEM
CSA, DMP, rt
95
99
To a solution of 95 (15.5 mg; 13.7µmol) in DMP (137µL) at rt was added a solution of CSA
(634µg) in DMP (137µL). After stirring for 1.5 h, the reaction mixture was poured into
a sat. NaHCO3 sol. (4 mL) and EtOAc (4 mL), the organic phase separated and the water
phase extracted with EtOAc (3× 4 mL). The combined organic phases were dried over
MgSO4 and concentrated in vacuo. Purification by flash chromatography (hexane/acetone
9/1 → 7/3) provided 99 (15.3 mg; 95 % yield) as a clear oil.
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Name: (1Z,3S,5S,7S,9R,10R,11R,13R,15R,16S,17S )-7-benzyloxymethoxy-1-iodo-
3,5-O :17,18-O-bis(isopropylidene)-11,15-dimethoxy-10,16-di-(2-methoxy-
ethoxymethoxy)-13-methoxymethoxy-2,8,8-trimethyl-9-(2-trimethylsilyl-
ethoxymethoxy)-octadec-1-ene (99)
Formula: C53H95IO18Si
M.M.: 1175.30 g/mol
Rf: 0.24 (hexane/acetone 8/2)
IR: ν = 2977, 2930, 2888, 2822, 1454, 1378, 1370, 1287, 1248, 1223, 1153, 1101, 1075,
1025, 936, 920, 858, 836, 796, 736, 698 cm-1
HRMS (m/z): calcd: 1192.5671, found: 1192.5675 [M + NH4
+]
[α]D = + 4.6 (c = 0.47 in CHCl3)
[α]365 = + 5.4
1H NMR (500 MHz, benzene-d6): δ = 7.40 (d, J=7.6 Hz, 2 H), 7.20 (t, J=7.6 Hz, 2
H), 7.10 (t, J=7.5 Hz, 1 H), 5.56 (d, J=1.4 Hz, 1 H), 5.17 (d, J=6.7 Hz, 1 H), 5.13
(dd, J=9.8, 6.3 Hz, 1 H), 5.07 (d, J=6.7 Hz, 1 H), 5.07 (d, J=6.7 Hz, 1 H), 5.04 (d,
J=6.9 Hz, 1 H), 5.00 (d, J=6.3 Hz, 1 H), 4.95 (d, J=6.3 Hz, 1 H), 4.92 (d, J=6.7
Hz, 1 H), 4.84 (d, J=12.5 Hz, 1 H), 4.82 (d, J=6.9 Hz, 1 H), 4.75 (d, J=6.7 Hz, 1
H), 4.66 (d, J=12.4 Hz, 1 H), 4.60 (d, J=6.7 Hz, 1 H), 4.38 - 4.44 (m, 1 H), 4.29 -
4.38 (m, 2 H), 4.15 - 4.24 (m, 1 H), 3.99 - 4.10 (m, 2 H), 3.96 (dd, J=8.2, 2.7 Hz, 1
H), 3.86 - 3.94 (m, 3 H), 3.84 (d, J=7.2 Hz, 1 H), 3.71 - 3.79 (m, 2 H), 3.68 (ddd,
J=10.7, 5.6, 4.0 Hz, 1 H), 3.52 - 3.65 (m, 2 H), 3.55 (d, J=10.1 Hz, 1 H), 3.49 (td,
J=6.0, 4.1 Hz, 2 H), 3.42 (td, J=5.5, 3.8 Hz, 2 H), 3.39 (s, 3 H), 3.29 (s, 3 H), 3.25
(s, 3 H), 3.18 (s, 3 H), 3.16 (s, 3 H), 2.00 - 2.22 (m, 4 H), 1.88 - 2.00 (m, 2 H), 1.76
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- 1.87 (m, 2 H), 1.75 (d, J=1.4 Hz, 3 H), 1.47 (s, 3 H), 1.44 (s, 3 H), 1.39 (s, 3 H),
1.35 (s, 3 H), 1.09 (s, 3 H), 1.08 (s, 3 H), 0.95 - 1.03 (m, 2 H), 0.03 (s, 9 H) ppm
APT (126 MHz, benzene-d6): δ = 147.9 (C), 139.2 (C), 128.9 (2 CH), 128.0 (CH), 108.9
(C), 101.1 (C), 97.2 (CH2), 97.1 (CH2), 96.6 (2 CH2), 95.8 (CH2), 81.5 (CH), 81.2
(CH), 79.2 (CH), 78.8 (CH), 77.6 (CH), 77.3 (CH), 73.9 (CH), 73.9 (CH), 72.8 (CH2),
72.7 (CH2), 72.3 (CH), 72.0 (CH), 70.7 (CH2), 68.0 (CH2), 67.9 (CH2), 67.0 (CH2),
66.7 (CH2), 65.9 (CH), 59.1 (CH3), 59.1 (CH3), 57.9 (CH3), 57.3 (CH3), 56.1 (CH3),
44.1 (C), 38.8 (CH2), 36.4 (CH2), 36.2 (CH2), 35.4 (CH2), 27.3 (CH3), 26.5 (CH3),
25.7 (CH3), 25.4 (CH3), 20.1 (CH3), 19.5 (CH3), 19.0 (CH3), 18.7 (CH2), -0.8 (3 CH3)
ppm
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6.1 Doel en strategie
Het doel van deze doctoraatsthesis was om de structuur-activiteitsrelatie van de zijketen
van peloruside A te verkennen, een veelbelovend macrocyclisch lacton met microtubuli-
stabiliserende activiteit, dat aangewend kan worden in de strijd tegen kanker. Daarom werd
het ontwerp en de synthese van peloruside A en twee reeksen zijketen-analogen voorgesteld,
die toegankelijk zijn via een Stille en Suzuki koppelingstrategie (Schema 6.1).
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Schema 6.1. Stille en Suzuki koppelingstrategie
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Schema 6.2. Retrosynthetische benadering
Beide strategiee¨n vereisen de synthese van een voldoende hoeveelheid van vinyljodide pre-
cursor 22. De voorgestelde retrosynthetische benadering (Schema 6.2) bestaat eerst uit
de opening van het macrolacton om het acyclische C1−C17 seco-zuur 24 te bekomen,
gevolgd door een uiterst convergente asymmetrische aldolkoppelingstrategie. De eerste
aldoldontkoppeling tussen C11 en C12 levert Bouwsteen C (het C12−C17 fragment), dat
vanuit propargyl alcohol kan gemaakt worden, en Bouwsteen D (het C1−C11 fragment).
Deze laatste kan verder ontkoppeld worden tussen C6 en C7 in Bouwsteen A (het C1−C6
fragment) en Bouwsteen B (het C7−C11 fragment), die resp. vanuit L-ascorbinezuur en
neopentylglycol kunnen gemaakt worden. Syntheseroutes om elke bouwsteen te bekomen
werden ontwikkeld tijdens de doctoraatsthesis van Gert Smans68, maar elke route had
zijn tekortkomingen en/of praktische belemmeringen, wat hun efficie¨nte en grootschalige
bereiding verhinderde.
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Tijdens deze doctoraatsthesis werden daarom drie doelen nagestreefd:
• optimalisatie van de gekende syntheseroutes68 van Bouwsteen A, B, C en D, de teko-
rtkomingen aanpakken en daarbij een praktische en opschaalbare multigram proce-
dure ontwikkelen e´n een voldoende hoeveelheid van Bouwsteen C en D bekomen
• de aldolkoppeling van Bouwsteen C en D e´n de synthese van een voldoende hoeveel-
heid van vinyljodide precursor 22
• het ontwerp en de synthese van peloruside A en de zijketen-analogen, volgens de Stille
en Suzuki koppelingstrategie
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6.2 Synthese, optimalisatie en opschalen van Bouw-
steen A, B, C en D
Bouwsteen A
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O
O
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O
OMEM
OMeOO
O
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OHO
79%
i)
 K2CO3,H2O2, H2O, kt
ii)
 EtBr, ACN, reflux
90%
MEM-Cl, DIPEA
CH2Cl2, reflux
98%
DIBAL-H
Et2O, kt
93%
(COCl)2, DMSO, Et3N
CH2Cl2, -78°C
96%
L-proline, (S)-BINOL
aceton, kt
94% totaal rendement
d.r. 16:1
89% geïsoleerd rendement
Me3OBF4
Proton-sponge®
MS 4Å, CH2Cl2, kt
89%
L-ascorbinezuur 25 26
27 28
29 30 A - 31
Schema 6.3. Synthese van Bouwsteen A (A - 31)
De synthese van Bouwsteen A (A - 31) begon vanuit L-ascorbinezuur. Na bescherming van
het eindstandige vicinale diol als acetonide (25), volgde de oxidatieve splitsing en ethy-
lering, wat α-hydroxy ester 26 opleverde, dat beschermd werd als MEM ether. Daarna
volgde de tweestaps reductie-oxidatie van ester 27 naar aldehyde 29, dat een organokat-
alytische asymmetrische aldolkoppeling onderging met L-proline, (S )-BINOL en aceton als
het nucleofiel. Methylering van hydroxyketon 30 onder Meerwein condities leverde A - 31
in 7 stappen. Hierbij konden we de originele syntheseroute68 op een significante manier
verbeteren, waarbij het totaalrendement toenam van 21 % (80 % gemiddeld rendement per
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stap) naar 49 % (90 % gemiddeld rendement per stap), in hetzelfde aantal lineaire stappen.
Daarenboven voorzag deze synthese de grootschalige bereiding van A - 31.
Bouwsteen A (A - 31) bevat drie stereocentra waarvan de configuratie moest bewezen
worden (Schema 6.4). C1 en C2 zijn afkomstig van het chiral pool beginmateriaal L-
ascorbinezuur en de configuratie werd aangenomen zoals voorgesteld. C3 werd ingevoerd
in de organokatalytische aldolkoppeling met L-proline en de absolute configuratie werd
bevestigd met het Mosher protocol. Daarvoor werd hydroxyketon 30 gederivatiseerd in de
overeenkomstige (S )- en (R)-MTPA esters. Door de chemische shift verschillen (∆δ = δS−
δR) van de L1 en L2 groep protonen te vergelijken, konden de L1 en L2 groep ondubbelzinnig
toegekend worden en werd daardoor de absolute configuratie van C3 bevestigd.
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Schema 6.4. Stereochemiebewijs van C3 via het Mosher protocol
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Bouwsteen B
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Schema 6.5. Synthese van Bouwsteen B (B - 39)
Voor de synthese van Bouwsteen B (B - 39) was er reeds een hogerendements- (90 % gemid-
deld rendement per stap) maar lange procedure (8 stappen) beschikbaar van Smans68,
vertrekkende vanuit (R)-pantolacton. Deze keer konden slechts minimale verbeteringen
voorgesteld worden aan de synthese op zich. Daarom werd een nieuwe, kortere en meer
efficie¨nte syntheseroute voorgesteld, die vertrok vanuit neopentylglycol. Na een tweestaps
monobenzylering werd alcohol 55 geoxideerd onder Swern condities, wat aldehyde 56
opleverde in een zo goed als kwantitatief rendement na 3 stappen. Daarna volgde een
asymmetrische alkoxyallylboratie, die een MEM monobeschermd diol invoerde met matige
enantioselectiviteit, waarna de overblijvende hydroxylgroep (58) werd beschermd als SEM
ether. Uiteindelijk bracht de one-pot tweestaps oxidatieve splitsing van de eindstandige
alkeengroep van 38, aldehyde B - 39 op in 6 stappen. In vergelijking met de originele route
van Smans68, werd een nieuwe en meer convergente benadering toegepast, die de synthese
verbeterde van 8 stappen (49 % totaalrendement; 91 % gemiddeld rendement per stap)
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naar 6 stappen (54 % totaalrendement, 90 % gemiddeld rendement per stap, 78 % e.e.), op
een manier die de grootschalige bereiding van B - 39 toeliet in een minimale hoeveelheid
tijd.
Bouwsteen B (B - 39) bevat twee stereocentra, C8 en C9, waarvan de configuratie moest
bewezen worden (Schema 6.6). Aangezien B - 39 reeds gemaakt werd door Smans68 via
een andere syntheseroute, bewezen we de relatieve stereochemie door de spectrale data van
38 en B - 39 te vergelijken met deze die gemaakt werden door Smans68, wat ons toeliet
om te bevestigen dat onze verbindingen diastereomerisch identiek zijn aan deze bekomen
door Smans68.
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Schema 6.6. Stereochemiebewijs van C8
Smans68 bewees de stereochemie door het C8 stereocentrum te correleren met het C9 stere-
ocentrum, dat afgeleid kon worden van het natuurlijke (R)-pantolacton dat hij als be-
ginmateriaal had gebruikt. Na ontscherming van de SEM ether van 37 werd syn-diol 59
bekomen, dat beschermd werd als trans-acetonide 60. De stereochemie werd nu bepaald
met behulp van de 3JH,H NMR koppelingsconstanten van de waterstofatomen op C8 en C9,
die gerelateerd zijn aan de dihedrale torsiehoeken via de Karplus vergelijking. Via molec-
ulaire modelling werd een dihedrale hoek van 169◦ voorspeld voor trans-acetonide 60,
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wat met de Karplus vergelijking vertaalt naar een koppelingsconstante van 8-9 Hz. Voor
cis-acetonide 61 werd een dihedrale hoek van 39◦ voorspeld, wat met de Karplus vergeli-
jking vertaalt naar een koppelingscontsante van 4-6 Hz. Voor het acetonide afkomstig van
37 werd een 3JH,H koppelingsconstante van 8.16 Hz gemeten, wat de trans-relatie van 60
bevestigde en dus de syn-stereochemie van het afgeleide diol 59, wat op zijn beurt de
stereochemie van C8 bevestigde.
In tegenstelling tot de synthese van Smans68, werden in onze synthese de twee stereocentra
op C8 en C9 ingevoerd in een enkele stap, wat leidt tot de vorming van twee enantiomeren
(78 % e.e.). Om aan te tonen dat het hoofd enantiomeer hetzelfde en verwachte enan-
tiomeer was, hebben we de optische draaiing van 38 vergeleken met deze van de veron-
derstelde zelfde verbinding van Smans68. Aangezien wij een optische draaiing verkregen
van [α]D =− 28.6 en [α]365 =− 91.5 en Smans een optische draaiing verkreeg van resp.
[α]D =− 31.9 en [α]365 =− 100.4, kunnen we ondubbelzinnig besluiten dat het hoofd enan-
tiomeer dat we verkregen hebben in onze synthese, hetzelfde en verwachte enantiomeer
is.
Bouwsteen D
De synthese van Bouwsteen D (D - 64) begon met de aldolkoppeling van Bouwsteen A
(A - 31) en Bouwsteen B (B - 39), wat hydroxyketon 45 opleverde, gevolgd door methy-
lering onder Meerwein condities, wat 46 opleverde. Daarna volgde de diastereoselectieve
reductie van het keton met NaEt3BH en bescherming van het secundaire alcohol (47) als
een MOM ether (62). Tenslotte werd de benzyl ether selectief verwijderd door middel van
hydrogenolyse, gevolgd door oxidatie van het bekomen primaire alcohol (63), wat aldehyde
D - 64 opleverde in 6 stappen. In vergelijking met de originele route van Smans68, werd
een MEM beschermgroep vervangen door een MOM beschermgroep en werden enkele in-
dividuele stappen verder geoptimaliseerd. Dit verbeterde de synthese, startend van A - 31
en B - 39, op een significante manier, waarbij het totaalrendement toenam van 31 % (82 %
gemiddeld rendement per stap) tot 50 % (89 % gemiddeld rendement per stap), in het-
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Schema 6.7. Synthese van Bouwsteen D (D - 64)
zelfde aantal lineaire stappen. Bovendien liet deze route de grootschalige bereiding toe
van D - 64, klaar voor de koppeling met C - 43 en verdere synthese richting vinyljodide
precursor 22.
Bouwsteen D bevat twee nieuwe stereocentra, C7 en C5, die respectievelijk werden in-
gevoerd in de asymmetrische aldolkoppeling en de diastereoselectieve ketonreductie. Eerst
werd de relatieve stereorelatie tussen C5 en C7 bepaald, gevolgd door de relatie tussen
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C7 en het gekende C9 stereocentrum. Om dit te kunnen doen werden de zuurstofrijke
stereocentra omgezet in conformationeel rigide cyclische acetonides, wat toeliet om hun
relatie aan te tonen via 13C NMR spectroscopie (Schema 6.8).
Vertrekkend vanuit aldolproduct 45 werd het keton eerst gereduceerd op een niet-
diastereoselectieve manier naar zowel 5,7-syn-diol 65 en 5,7-anti-diol 66 (nog te
bevestigen), die vervolgens werden omgezet in hun overeenkomstige cyclische acetonides
5,7-cis/trans-acetonide 67/68. Door vergelijking van de bekomen 13C chemische shifts
van de acetaal methyl groepen kon de configuratie van beide 5,7-diolen worden bevestigd.
De stereochemisch bevestigde 5,7-diolen werden vervolgens gepermethyleerd naar
de overeenkomstige 5,7-dimethoxy verbindingen en ook 47 werd gemethyleerd naar
5-O-methyl-47. Vergelijking van de NMR spectra toonde ondubbelzinnig aan dat
5,7-anti-dimethoxy 70 (gemaakt uit 5,7-anti-diol 66) en 5-O-methyl-47 (gemaakt
uit 47) identiek waren, wat de 5,7-anti -relatie van 47 bevestigde.
Om de absolute stereochemie van C5 en C7 te bepalen werd de relatie tussen C7 en
het gekende C9 stereocentrum bepaald. Ditmaal werd 5,7-anti-diol 66 omgezet in
7,9-trans-acetonide 72. Door het opnemen van de 13C chemische shifts van de acetaal
methyl groepen kon de 7,9-anti -relatie van 5,7-anti-diol 66 en 7,9-trans-acetonide 72
bevestigd worden. Aangezien de configuratie van C9 als (R) gekend staat, werd door C5
aan C7 te correleren en C7 aan C9, de absolute stereochemie van C5 en C7 bewezen.
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Schema 6.8. Stereochemiebewijs van C5 en C7
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OH
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-20°C -> -10°C
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Schema 6.9. Synthese van Bouwsteen C (C - 43)
De synthese van Bouwsteen C (C - 43) begon vanuit propargyl alcohol. Eerst leverde
een anti -carbometalatie reactie de regio- en stereoselectieve invoering van een jodide en
methyl groep tot (Z )-jodomethylpropenol 40 op. Daarna volgde de MnO2 oxidatie van
allyl alcohol 40 tot het vluchtige en reactieve allyl aldehyde 41, wat onmiddellijk een
organokatalytische asymmetrische aldolkoppeling onderging met D-proline en aceton als
nucleofiel. Hydroxyketon 42 werd dan beschermd als PMB ether met versgemaakt PMB-
trichlooracetimidaat 44, wat C - 43 opbracht in 4 stappen. Hierbij waren we in staat om
de originele synthese op een significante manier te verbeteren, waarbij het totaalrendement
toenam van 36 % (78 % gemiddeld rendement per stap, 97 % e.e.) tot 53 % (85 % gemiddeld
rendement per stap, 99 % e.e.), in hetzelfde aantal lineaire stappen. Bovendien voorzag deze
synthese de grootschalige bereiding van C - 43.
16
15
OPMB O
17
I
C - 43
Bouwsteen C (C - 43) bevat e´e´n stereocentrum op C15 en een trigesubstitueerde dubbele
binding met Z configuratie op C16−C17. De structuur en absolute configuratie van C - 43
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kon bevestigd worden door X-straal diffractie van een kristal van zijn hydroxyketon pre-
cursor 42.
6.3 Synthese van vinyljodide precursor 22
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Schema 6.10. Synthese van vinyljodide precursor 22
De laatste rechte lijn van de synthese richting 22 begon met de asymmetrische aldolkop-
peling van Bouwsteen C (C - 43) en Bouwsteen D (D - 64), gevolgd door bescherming van
het secundaire alcohol (74) als een BOM ether (76). De volgende stap was de diastereose-
lectieve reductie van het keton met Na(s-Bu)3BH, waarbij het laatste stereocentrum (77)
werd ingevoerd en deze hydroxylgroep werd gemethyleerd onder Meerwein condities, wat
verbinding 78 opleverde.
Vanaf dit punt konden we beginnen met de noodzakelijke selectieve ontschermingen en func-
tionele groep transformaties (Schema 6.11). Eerst kwam de selectieve ontscherming van
SEM ether 78 tot secundair alcohol 80, gevolgd door oxidatie met Dess-Martin periodinaan
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Schema 6.11. Synthese van vinyljodide precursor 22
tot keton 81. Daarna volgde de dubbele ontscherming van de PMB ether en het acetonide
tot triol 84, gevolgd door oxidatieve splitsing van het vicinale diol tot aldehyde 85 met
NaIO4 en verdere oxidatie tot seco-zuur 24 onder Pinnick oxidatie condities. Uiteindelijk
onderging dit seco-zuur macrolactonisatie met behulp van het Yamaguchi macrolactonisatie
protocol, wat vinyljodide precursor 22 opleverde, maar ook een significante hoeveelheid di-
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olide 87, in 10 stappen vanuit Bouwsteen C (C - 43) en Bouwsteen D (D - 64). Ondanks
dat de meeste stappen goede rendementen opleveren zijn er nog steeds verbeteringen nodig
en hoogstwaarschijnlijk ook mogelijk voor de ontscherming van de SEM ether, de PMB
ether, het acetonide en ook bij de macrolactonisatie, waar vorming van het diolide verme-
den moet worden. Beginnend van C - 43 en D - 64 kon vinyljodide precursor 22 bekomen
worden in 10 stappen (3.8 % totaalrendement; 72 % gemiddeld rendement per stap). De
langste lineaire sequentie om 22 te bekomen (vanuit L-ascorbinezuur) bestaat uit 23
stappen (0.93 % totaalrendement, 82 % gemiddeld rendement per stap).
Vinyljodide precursor 22 bevat twee nieuwe stereocentra, C11 en C13, die werden ingevoerd
in de asymmetrische aldolkoppeling en de diastereoselectieve ketonreductie. Deze werden
gecorreleerd aan reeds gekende stereocentra door omzetting in conformationeel rigide cyclis-
che acetonides, waarvan hun relatie werd bewezen met behulp van 13C NMR spectroscopie
(Schema 6.12).
Om de relatie te bepalen tussen de C9 en C11 stereocentra hebben we het verondersteld
ongewenste aldolproduct 75, dat de enige verbinding was die we initieel konden bekomen
als een enkel diastereomeer in een voldoende hoeveelheid, omgezet in het overeenkomstige
acetonide 93. De 13C chemische shifts van de acetaal methyl groepen bevestigden dat de
C9 en C11 stereocentra zich in een syn-relatie bevonden, wat bewees dat 75 ook effectief
het ongewenste diastereomeer was.
Om de relatie te bepalen tussen de C13 en C15 stereocentra werd 76 gereduceerd op een
niet-diastereoselectieve manier met DIBAL-H in CH2Cl2 en het bekomen 77 en 79 wer-
den gescheiden. Het verondersteld gewenste diastereomeer 77 werd omgezet tot het PMP
acetaal 96 met DDQ. Dit cyclische 13,15-cis PMP acetaal zal een stoel-conformatie aan-
nemen, wat leidt tot drie axiale waterstoffen die nabij genoeg zijn om te bepalen via een
NMR NOESY meting. Het axiale acetaal waterstof toonde sterke NOEs met beide water-
stoffen op C13 en C15, wat enkel mogelijk is met het 13,15-cis PMP acetaal en dus zijn
configuratie aantoont. Als extra bewijs werd het verondersteld ongewenste diastereomeer
79 ontschermd met CAN in ACN/H2O en vervolgens omgezet in acetonide 99 met CSA
in DMP. De 13C chemische shifts van de acetaal methyl groepen bevestigden de 13,15-
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Schema 6.12. Stereochemiebewijs van C11 en C13
anti -relatie van 79. Op deze manier konden zowel het gewenste 77 als het ongewenste 79
stereochemisch bewezen worden.
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6.4 Richting peloruside A en zijketen-analogen
Spijtig genoeg, wegens enkele onverwachte nevenreacties in het laatste deel van de to-
taalsynthese van 22, bleven we achter met niet-geoptimaliseerde lage rendementen in de
ontscherming van de SEM ether, de PMB ether en het acetonide. Ook het Yamaguchi
macrolactonisatie protocol moet verder aangepast worden om de vorming van diolide 87
te vermijden. Dit resulteerde in slechts een minieme hoeveelheid 22, wat het niet haalbaar
maakte om de verdere synthese richting zowel peloruside A en de twee reeksen zijketen-
analogen volgens de Stille en Suzuki koppelingstrategie aan te vatten. Er zijn echter wel nog
grote hoeveelheden van C - 43 en D - 64 aanwezig, die aangewend kunnen worden in verder
onderzoek om de laatste stappen van de totaalsynthese te optimaliseren en daarmee een
voldoende hoeveelheid 22 te bekomen. Dit zou de synthese van peloruside A en zijketen-
analogen moeten mogelijk maken, zoals hierna verder uitgewerkt.
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Schema 6.13. Voorgestelde analogen via de Stille koppelingstrategie
Volgens onze Stille koppelingstrategie (Schema 6.13) kan een eerste reeks zijketens in-
gevoerd worden, allen met alkenyl of (hetero)aryl groepen, met behulp van de overeenkom-
stige stannaan verbindingen. Deze zijn ofwel commercieel beschikbaar of kunnen worden
gesynthetiseerd, gebaseerd op of a.d.h.v. gekende literatuur procedures. De voorgestelde
analogen hebben als doel om de invloed van de elektronische en sterische eigenschapen van
de zijketen op de biologische activiteit te verkennen, door verschillende heteroatomen en
sterische omgevingen in te brengen.
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Schema 6.14. Voorgestelde analogen via de Suzuki koppelingstrategie
Volgens onze Suzuki koppelingstrategie (Schema 6.14) kan, naast de synthese van peloru-
side A, een tweede en strategische reeks zijketens ingevoerd worden. De voorgestelde analo-
gen hebben vooral als doel om de invloed van het primaire zijketenalcohol te verkennen,
dat van belang blijkt voor de activiteit van peloruside.
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List of compounds
This list contains all the compounds that could be isolated during the synthesis. This
includes their molecular structure, compound number and page reference of their experi-
mental procedure.
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Abbreviations
ACN : acetonitrile
APT : Attached Proton Test
ADMET : absorption/administration, distribution, metabolism, excretion and toxicity
(R/S)-BINOL : (R/S )-1,1’-bi-2-naphthol
Bn : benzyl
BOM : benzyloxymethyl
CAN : cerium(IV) ammonium nitrate; (NH4)2Ce(NO3)6
CSA : camphor-10-sulfonic acid
Cy : cyclohexyl
DAIB : (diacetoxyiodo)benzene
DDQ : 2,3-dichloro-5,6-dicyano-1,4-benzoquinone
d.e. : diastereomeric excess
d.r. : diastereomeric ratio
DIBAL-H : diisobutylaluminium hydride
(+/−)-DIP-Cl : (+/−)-diisopinocampheyl chloroborane
DIPEA : N,N -diisopropylethylamine
DMAP : 4-dimethylaminopyridine
DMP : Dess-Martin periodinane (oxidation reagent); 2,2-dimethoxypropane (solvent)
DMPU : 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H )-pyrimidinone
DMSO : dimethylsulfoxide
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Abbreviations
∆Ea : activation energy difference
e.e. : enantiomeric excess
EI-MS : electron ionization - mass spectrometry
EOM : ethoxymethyl
eq. : equivalent(s)
ESI-MS : electrospray ionization - mass spectrometry
HATR : horizontal attenuated total reflectance
HDX-MS : hydrogen/deuterium exchange - mass spectrometry
HMPA : hexamethylphosphoramide
HPLC : high-performance liquid chromatography
HR FAB-MS : high resolution fast-atom bombardment mass spectrometry
HRMS : high resolution mass spectrometry
IC50 : half maximal inhibitory concentration
ICC : Iterative Cross-Coupling
Ipc : isopinocampheyl
IR : infrared (spectroscopy)
k : reaction rate constant
LC-MS : liquid chromatography - mass spectrometry
MDA : microtubule destabilizing agent
MDR : multidrug resistance
MEM : 2-methoxy-ethoxymethyl
MHz : megahertz
MIDA : N -methyliminodiacetic acid
M.M. : molar mass
MOM : methoxymethyl
MS : mass spectrometry
MS 4 A˚ : molecular sieves 4 A˚
MSA : microtubule stabilizing agent
MTPA : α-methoxy-α-trifluoromethylphenylacetate
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Abbreviations
NMMO : N -methylmorpholine N -oxide
NMR : nuclear magnetic resonance
NOE(SY) : Nuclear Overhauser Effect (Spectroscopy)
OTf : triflate; trifluoromethanesulfonate
Pa : acetal type protecting group
P-gp : P-glycoprotein
Ph : phenyl
PIDA : pinene-derived iminodiacetic acid
PKC : protein kinase C
PMB : p-methoxybenzyl
PMP : p-methoxyphenyl
ppm : parts per million
Proton-sponge R© : 1,8-bis(dimethylamino)naphthalene
QSAR : quantitative structure-activity relationship
quant. : quantitative
R : universal gas constant
Rf : ratio-to-front
rt : room temperature
SAR : structure-activity relationship
SEM : 2-trimethylsilyl-ethoxymethyl
SM : starting material
STD-NMR : saturation-transfer difference NMR
T : temperature
Tb : boiling temperature
TBAF : tetra-n-butylammonium fluoride
TBAI : tetra-n-butylammonium iodide
TCB-Cl : 2,4,6-trichlorobenzoyl chloride
TEMPO : (2,2,6,6-tetramethylpiperidin-1-yl)oxy
THF : tetrahydrofuran
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Abbreviations
TLC : thin layer chromatography
TS : transition state
UV : ultraviolet
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